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Abstract  
Epithelial cells adhere to each other and are connected via a series of junctions. 
Tight junctions (TJs) are a specific type of junction consisting of heteromeric 
protein complexes that are linked to the actin cytoskeleton and are important in 
regulating paracellular permeability and cell polarity. RhoGTPases are small 
molecular switch proteins that are important regulators of the cytoskeleton and 
modulators of gene expression. RhoGTPases have thus been identified as 
being major signalling components associated with TJs. However little is known 
about how RhoGTPases are regulated to control junction formation and gene 
expression in corneal epithelial cells. I used a siRNA screening approach 
combined with functional assays to identify components of RhoGTPase 
signalling that affect the assembly of junctions and gene expression in Human 
corneal epithelial cells (HCE). I identified and validated several candidates that 
regulate junction assembly. One of these candidates was p114RhoGEF, a 
novel TJ localised guanine nucleotide exchange factor (GEF) important for the 
assembly of functional TJs. p114RhoGEF is a widely expressed and I 
discovered its depletion effects junction formation and morphogenesis in three 
dimensional culture systems in different epithelial cell types. p114RhoGEF is 
required for activation of RhoA at cell-cell junctions and junctional actinomyosin 
activity, p114RhoGEF is present in a complex containing Myosin II-A, the RhoA 
effector Rock II and the junctional adaptor protein Cingulin; indicating 
p114RhoGEF is a component of a junction associated RhoA-signalling module. 
p114RhoGEF, thus regulates spatial activation of RhoA at cell-cell junctions 
and organisation of the junctional cytoskeleton. p114RhoGEF may also have a 
role in cell migration, as depletion in HCE cells, caused cells to migrate at a 
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slower rate during wound healing assays. I have also started to explore the 
function of a putative p114RhoGEF ortholog, cg10188 in Drosophila 
melanogaster. Preliminary experiments have identified cg10188 to be important 
in larval development.   
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Introduction 
 
(Parts of this introduction were published as a review article titled ‘Rho  
signalling and Tight junction functions’, see reference 4) 
 
Overview 
In multicellular organisms, epithelia consist of specialized cells that form 
selective barriers controlling the passage of water, ions and other small 
molecules between different body compartments and the external environment. 
This requires cells to be polarized, that is, to form distinct membrane domains. 
An apical side, for facing the lumen of a body cavity or the outside environment 
and a basal side, adjacent to the underlying tissue. For instance, the epithelial 
cells lining the intestinal lumen are at the interface between the internal and 
external environments regulating the absorption of nutrients and water, as well 
as ion homeostasis. In addition, these cells provide a protective barrier against 
commensal and pathogenic microorganisms. Epithelial cells have to adhere 
tightly to each other to form sheets and are connected to each other via a series 
of intercellular junctions (Figure 1.0). Gap junctions are one class of junction, 
these are communicating junctions that form intercellular pores between 
adjacent cells and allow the selective passage of small molecules up to 1kDa. 
They are composed of twelve connexin subunits, of which six subunits known 
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as a connexon, are contributed from each adjacent cell 8. Three other classes of 
epithelial junctional complex exist, Tight junctions (TJs), Adherens junctions 
(AJs) and Desmosomes, known collectively as the epithelial junctional complex 
9, 10. 
 
These structures consist of heteromeric protein complexes and are linked to 
different cytoskeletal elements. They mediate cell-cell adhesion to different 
extents, and play crucial roles in the biogenesis and maintenance of epithelial 
barriers In epithelial cells, the distribution of TJs and AJs is generally spatially 
well defined: TJs are typically located at the apical end of the basolateral 
membrane, where they form an apical ring, while AJs and desmosomes are 
located more within the basolateral membrane 9.  In contrast, the distribution of 
junctional complexes in endothelial cells is less defined, with TJs and AJs being 
more intertwined with each other 11, 12. TJs and AJs are both linked 
intracellularly to the actin cytoskeleton, which is often seen to co-localize with 
junctions to form a “belt like” ring of filaments encircling the perimeter of the cell, 
sometimes referred to as “perijunctional actin”. In contrast, desmosomes are 
linked to intermediate filaments of the keratin family and function to confer 
structural strength to epithelia enabling them to resist pressure, shear stress 
and friction 13 14. In epithelia desmosomes appear to be located more basally 
than TJ and AJ and are distributed along the lateral membrane of adjacent 
cells. Hemidesmosomes are a special class of junction related to Desmosomes 
and form along the basal membrane. They are involved in attachment of 
epithelia to laminin, an extracellular matrix protein of basement membranes 14. 
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At the electron microscopic level, (Figure 1.1) AJs are present at sites where 
the two opposing membranes of neighbouring cells are separated by a gap of 
about 20nm along which the neighbouring plasma membranes appear very 
parallel over a distance of 0.2-0.5µm 7. Using deep etching electron microscopy 
to observe structures within the inter cellular space in this parallel region, AJs 
were found to be connected to each other by numerous cylinder-like 
projections, that are thought to be multimeric structures containing the 
transmembrane components of AJs known as Cadherins and nectins (see 
molecular composition of AJ). TJs at the resolution of transmission electron 
microscopy (TEM), appear as sites where there is close apposition of adjacent 
plasma membranes between neighbouring cells 9 (Figure 1.1). In freeze fracture 
replicas, these close contact sites are seen as networks of intracellular strands 
that encircle the cells below the apical surface 15-17 (Figure 1.1). TJs can 
mediate adhesion, but primarily act as dynamic barriers that selectively regulate 
the diffusion of water, ions and other small molecules through the paracellular 
space between neighboring cells. They also function to maintain cell polarity, by 
acting as a molecular barrier, thus restricting the diffusion of apical and 
basolateral membrane components.  The functional role for AJs is somewhat 
similar to desmosomes as its name implies they are crucial for the initiation and 
maintenance of intercellular adhesion. The initiation of adhesion, developmental 
cell movements, tissue biogenesis and wound repair all require dynamic 
changes in cell adhesion, AJ complexes provide the strength to maintain stable 
cell-cell associations in response to external stress caused by tissue 
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morphogenesis or body movement, thus contributing to embryogenesis and 
tissue homeostasis.  
 
Aside from the adhesive properties and the classical gate and fence functions, 
intercellular junctions have emerged to act as dynamic heteromeric signalling 
complexes. 18 19. The signalling at junctions is bi-directional, such that signals 
are transmitted from the cell interior to forming or existing junctions, to regulate 
their assembly and function, while junctions coordinately receive and transmit 
information back to the cell interior to regulate gene expression and subsequent 
cellular behaviour like proliferation and differentiation. Multiple TJ and AJ 
components interact with the actin cytoskeleton. These interactions are known 
to be important to regulate the permeability properties of TJs, mediate the 
strength of adhesive contacts of AJs and for processes that require junctional 
reorganization during the initiation of cell-cell adhesion and assembly of 
junctions. Many studies have implicated both actinomyosin contractility and 
actin dynamics, such as filament polymerization and turnover, as being 
important mechanisms in the formation, maintenance and regulation of the 
permeability properties of junctions 20-27.   Junctions also recruit signalling 
proteins that regulate gene expression and, subsequently, proliferation and 
differentiation.  
In this introduction, I will first provide a comprehensive overview of the 
molecular composition of junctions. Introduce small molecular switch proteins 
known as RhoGTPases that function as important cytoskeletal regulators and 
modulators of gene expression. I will then discuss how they are regulated and 
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have recently emerged as being major signalling components associated with 
junctions.  
 
 
 
 
 
 
 
 
 
 
Figure 1.0 Epithelial intercellular junctions. Schematic  representation  of  a  polarized  absorptive  epithelial  cell  illustrating  different  types  of intercellular  junction.  Gap  junctions  are  a  type  of  intercellular  junction  and  form  small  pores  between two  adjacent  cells  and  allow  the  selective  passage  of  small  molecules  up  to  1kDa.  Tight  junctions, Adherens  junctions  and  Desmosomes  form  what  is  known  collectively  as  the  epithelial  junctional complex. All these types of junction consist of heteromeric protein complexes having similar architecture of  transmembrane  proteins  that  are  linked  to  a  cytoplasmic  plaque  of  diverse  adaptor  and  signaling proteins.   Tight junctions(TJ) are the most apical of this complex whereas Adherenes junctions (AJ) and Desmosomes  are  located  more  basally  along  the  lateral  membrane.  Desmosomes  and  AJs  function primarily in cell‐cell adhesion, whereas TJ are known to regulate Paracellular permeability. Both TJs and AJs are linked to the actin cytoskeleton, whereas Desmosomes are linked to Intemediate filaments of the Keratin  class.  Hemidesmosomes  are  structures  similar  to  Desmosomes  being  linked  to  Intermediate filaments but, Cell‐extracellular matrix adhesions. Diagram from 3 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Figure 1. 1 Structure of the Epithelial Junctional Complex. 
A  Transmission electron micrograph  (TEM) of Kidney epithelial  cells  the apical  junctional  complex, Tight junctions (TJ) can be seen at sites of close opposition in between opposing plasma membranes of neighbouring cells Desmosomes (D) appear in regions located more basaolateral to the apical TJs 2. 
B  freeze  fracture  replica  of  intestinal  epithelial  cells  showing  transmembrane based TJ  strands.  5  C TEM  image  of  apical  junctional  complex  in  intestinal  cells  showing  the  microvilli  (MV)  and  the position  of  ZO  (zonula  Occludins  /  TJ)  Zonula  Adherenes  (ZA/AJ)  ,  Desmosomes  (DM).  The  arrow marks the site of AJ where the two adjacent plasma membranes of neighbouring cells run very parallel 7D Quick‐freeze, deep‐etch image of the AJ between intestinal epithelial cells. White arrow shows the presence of rod‐like bridging structures extending between adjacent cells 7 
 A    C 
B 
 D 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Molecular composition of Tight junctions   
At the molecular level, TJs consist of multimeric protein complexes, 
having a similar architectural principle as other cell-cell adhesion complexes 7, 
28, 29. The TJ complex is composed of integral membrane proteins linked to a 
network of adaptor proteins that form a cytoplasmic plaque (Table 1.0). The 
transmembrane proteins are known to mediate cell-cell adhesion as well as to 
form the paracellular barrier.  The adaptors of the cytoplasmic plaque act as 
linkers between transmembrane proteins and the cytoskeleton, and as 
scaffolds, to recruit different types of signalling proteins. The transmembrane 
proteins of the TJ are often grouped according to the number of times they span 
the plasma membrane. There are single pass membrane proteins such as 
JAMs (junction adhesion molecules) 30-32 and CAR, (Coxsackievirus-adenovirus 
receptor) 33; three pass membrane proteins such as BVES (blood 
vessel/epicardial substance) 34; and four pass membrane domains such as the 
claudins (24 family members) 17, 35, Occludin 36, 37, tricellulin, a protein enriched 
at cell-cell contact points between three adjacent cells 38 and the recently 
identified MarvelD3 39. While most of the transmembrane proteins seem to have 
at least some adhesive abilities, it is the tetraspan membrane proteins that 
seem to be more directly linked to epithelial barrier functions 17, 40, 41. 
The claudins are thought to be the major components of tight junction 
strands and seem to underlie the different barrier properties of different types of 
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epithelia due to the tissue-specific expression of different claudins 42, 43. Aside 
from being a structural components of the junctional barrier, Claudins are 
responsible for the ion selectivity of the paracellular pathway, a function that is 
thought to involve the formation of ion-selective pores or channels. 35, 41, 44-
46However, the molecular structure of these ion-selective pores remains 
unclear. The role of Occludin in barrier permeability is controversial due to the 
discrepancy between the Occludin mouse knockout model and the many in vitro 
studies. While the Occludin knockout mouse model exhibited complex 
phenotypic defects in a range of epithelia, TJs themselves did not appear to be 
affected morphologically, and, as far as examined, the barrier function of the 
intestinal epithelium was normal 47, 48. However, data from cells in culture 
suggest an important role for Occludin in the permeability properties of TJs 37, 
49. For example, overexpression studies of Occludin in MDCK cells resulted in 
raised transepithelial electrical resistance (TER), a measure of the 
instantaneous ionic conductivity properties of an epithelial layer, but also to 
increased size-selective paracellular tracer permeability, a measure of slow 
diffusion across junctions 50. The observation that dominant negative Occludin 
constructs inhibit paracellular tracer permeability suggests that Occludin 
promotes permeability 37. The exact mechanisms behind these observations 
remain unclear, but these and similar observations suggest that ion 
conductance and tracer permeation are mediated by distinct molecular 
mechanisms that can be differentially regulated 37. When Occludin was 
depleted by RNA interference in MDCK cells, paracellular permeability was not 
effected, but a failure to activate the RhoGTPase RhoA in response to certain 
stimuli was observed 51.  Moreover, a recent study demonstrated Occludin 
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regulates barrier function in response to pro inflammatory cytokines. Stimulation 
of MDCK II cells with a combination of pro inflammatory cytokines52, TNFα and 
INFγ resulted in increased TER and decreased paracellular permeability. 
Knockdown of Occludin attenuated the barrier alterations induced by these 
cytokines, suggesting Occludin contributes to regulating epithelial barrier 
functions of epithelial cells in response to inflammatory stimuli.    
   
Many of the transmembrane proteins interact with proteins in the cytoplasmic 
plaque via PDZ(PSD/DlgA/ZO-1)-binding domains present in their cytosolic 
domains and PDZ domains found on components of the plaque such as ZO-1, 
ZO-2, and ZO-3 53-55 ; PAR-3 and PAR-656; Pals1 57 and PATJ58, MUPP159 and 
the MAGI proteins 60 . However there are several adaptor proteins that do not 
contain PDZ domains. Examples are JACOP/ paraCingulin 61, 62 and Cingulin, a 
protein known to interact with junctional membrane proteins; ZO-1, -2 and -3; as 
well as F-actin, Myosin II and GEF-H1, a junction associated activator of the 
RhoGTPases 63, 64.  
Scaffolding proteins also mediate interactions with filamentous actin, thus 
linking the TJ to the actin cytoskeleton, and recruit many different types of 
signalling proteins to the TJ. These include various protein kinases such as 
different isoforms of protein kinase C (PKC); protein and lipid phosphatases; 
small monomeric G proteins such as Rho, Rab and Ras GTPases and their 
regulators; as well as heterotrimeric GTPases 2, 28, 65. In addition, transcription 
factors are also recruited to junctions via scaffolding proteins, which is thought 
to be important for the regulation of gene expression 66.  
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The ZO proteins are classic examples of scaffolding proteins of TJs. ZO-1, 2 
and 3 have three PDZ binding domains and a single SH3 and GuK domain. The 
ZO proteins have been shown to interact directly by in vitro binding assays with 
the C terminal domain of Claudins 1-8 through their PDZ1 domains 67. The ZO-
proteins also interact in vitro with Occludin. This interaction is mediated 
between the GuK domain and region in the centre of the C terminal domain of 
Occludin 68.  
 
The C-terminal region of ZO-1 69 and ZO-3 70 are known to bind f-actin in co-
sedimentation assays, whereas ZO-2 does not 69, 71. ZO-1 can also 
homodimerise and can bind ZO-2 and 3 but, ZO-2 and 3 can not form a 
complex with each other 71. They also bind α-Catenin, a component of AJs that 
binds actin filaments 72. This interaction between the ZO proteins is thought to 
provide “fine tuning” of components in junctions to allow different types of 
scaffold structures permitting, different types of connections to the actin 
cytoskeleton provide a linking scaffold for signalling crosstalk between 
components of AJs and TJs.  
ZO-1 has been implicated in controlling epithelial cell proliferation and 
differentiation. One line of evidence comes from experiments where truncated 
forms of ZO-1 were expressed in MDCK cells and resulted in partial 
dedifferentiation. 73 ZO-1 and ZO-2 expression can be altered in certain types of 
tumours74, 75,  suggesting a functional link in the suppression of factors that 
promote proliferation. For example in colorectal cells, ZO-1 expression is down 
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regulated where the AJ component β-Catenin is overexpressed.76 β-Catenin is 
involved in Wingless/Wnt growth factor signalling and regulates transcription by 
association with the T cell factor (TCF)/Lef transcription factor. β-Catenin 
signalling is often deregulated in many cancers, leading to activation of β-
Catenin, therefore β-Catenin promotes proliferation 77, 78. It seems that β-
Catenin signalling inactivates the growth suppressive function of ZO-1. An 
involvement of ZO-1 in nuclear processes has also been suggested, based on 
reports that show it localised to the nucleus. However this localisation is 
somewhat controversial, as different laboratories disagree about the nuclear 
localisation of ZO-1 79 80, 81 ZO-1 is known to affect the transcription of several 
genes 82, 83, however this does not require nuclear localisation of ZO-1, but 
sequestration of a transcriptional repressor protein known as ZONAB 80. 
 
 ZONAB is a protein that is an interesting example of a class of protein termed 
NACos (localise to nucleus and adhesion complexes) 82. This type of protein 
has a dual localisation and provides TJs with a means to directly regulate gene 
expression and subsequently cellular behaviour, such as proliferation. ZONAB 
is a Y box transcription factor that binds to the SH3 domain of ZO-180. ZONAB 
localises to the nucleus where it acts as a transcriptional repressor of the Erb-2 
gene and renal differentiation markers 80 and can stimulate transcription of 
cyclinD1 and PCNA  genes 83, which is important in proliferation. ZONAB is 
known to bind sequences containing inverted CCAAT boxes from several 
different promoters in vitro 80. In MDCK (Madin-Darby canine kidney) cells, 
ZONAB is expressed at high levels during proliferation and is present at TJs 
 25 
and the nucleus. It becomes down-regulated in mature monolayers, and is no 
longer present in the nucleus 82. Experiments in MDCK cells where ZO-1 was 
over-expressed reduced the nuclear accumulation of ZONAB and inhibited 
proliferation. This suggested that TJs modulate epithelial proliferation through 
the sequestration of ZONAB by ZO-182. Further evidence to support the role of 
ZONAB in proliferation was shown by its ability to directly interact with CDK4, a 
G1/S phase regulator. CDK4 was shown to localise to junctions and the 
nucleus. The nuclear accumulation of CDK4, like ZONAB can also be inhibited 
by over-expression of ZO-182. Several promoters of genes that are G1/S phase 
regulators have ZONAB binding sites. Cyclin D1 and PCNA (proliferating cell 
nuclear antigen) and have been demonstrated to be up-regulated in ZONAB 
over-expressing cells 83. This evidence demonstrates nuclear accumulation of 
ZONAB is linked to the regulation cell cycle genes and is a good example of 
how TJs, can by direct mechanisms regulate gene expression. TJs can thus be 
seen as actin-bound, multimeric protein complexes that interconnect 
neighbouring cells that receive and send signals and thereby regulate epithelial 
barrier functions, as well as epithelial proliferation and differentiation. 
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Protein   Interacting partners  
  
Tight junctions     
     
Transmembrane proteins tetraspan    
Occludin  
ZO‐1,2,3 JAM‐A, Cingulin, MarvelD3,YES,PI3K,ERK1,casenin 
kinase 1ε 
   PP1,PP2A,itch,F‐actin 
Claudins  ZO‐1,2,3,PATJ, MUPP‐1,PATJ,WNK4,OAP1,EphA2 
     
MavelD3  Tricellulin84 
     
Tricellulin   ZO‐1, MavelD3 
Transmembrane proteins single span    
JAM, CAR,  Occludin, ZO‐1,Cingulin, PAR3,MUPP‐1, AF6/afadin 
     
ESAM,CLMP  reovirus,adenovirus,coxsackievirus 
     
BVES  ZO‐1 34 
     
CRB3 (crumbs homologue 3)  Pals1, PatJ and PAR6  
Cytoplasmic adaptor proteins    
ZO‐1 
Occludin, Claudins, JAMs,BVES, ZO‐1, 2, 3, 
Cingulin,Tuba,Apg2, f‐actin  
   α‐Catenin,α‐actinin,Afadin,shroom2, connexins 
     
ZO‐2 
Occludin, claudins, ZO‐1, F‐actin, Cingulin, α‐Catenin, f‐
actin,hScrib, 
   connexin 43,SAFB,Jun,fos,Myc,Csk,AP1 
     
ZO‐3  
Occludin,claudins,ZO‐1,Cingulin,PATJ,Afadin,p120Catenin,f‐
actin 
     
MAGI‐1  PTEN.JAMs,synaptopodin,MASCOT,α‐actinin, Rap GEF2 
     
MAGI‐2  PTEN,β1‐adrenergic receptor 
     
MUPP‐1  Claudins, JAMs, CAR 
     
PATJ  Pals1, CRB3,PATJ,ZO‐3,JEAP,angiomotin 
     
Pals1  PATJ,CRB3,PAR6,Lin7,MPP4 
     
PAR‐6 
CRB3,PAR3, aPKC, Cdc42,Rac1,Pals1,smurf,Ect2,TGF‐β 
receptors 
     
PAR‐3  PAR‐6,Tiam‐1,aPKC,Cdc42,Rac‐1,14‐3‐3proteins 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JEAP   PATJ 
     
Cingulin   ZO‐1, ‐2, ‐3, JAM, F‐actin, Myosin II,GEF‐H1 
     
paraCingulin (JACOP)   GEF‐H1, Tiam‐1, f‐actin 
     
Shroom2  ZO‐1,MyosinVIIa 
   
Amot  Rich‐1,Pals‐1, PatJ, Par‐3 85 
   
Signalling proteins     
aPKC  Occludin PAR3. PAR6,Cdc42,  
     
GEF‐H1   Cingulin, ZONAB, RhoA 
     
CDK4  ZONAB,D‐type cyclins 
     
G proteins  ZO‐1 Gα12 
     
PTEN  MAGI‐1,2,3,PAR3 
     
PP1  Occludin 
     
PP2A  Occludin 
   
Rich1   Amot 85 
   
Tuba   ZO‐1, Cdc4286 
     
YES  Occludin 
     
Rab 3b  Noc2,plgR,calmodulin 
     
Rab13  Protein kinase A, MICAL‐L2 
     
WNK4  Claudins 
Transcriptional regulators    
ZONAB   ZO‐1, GEF‐H1, CDK4, symplekin  
     
Symplekin  ZONAB, poly adenylation factor CstF,HSF1 
     
AP‐1  ZO‐2  
     
HuASH1  Unknown 
 
Table 1.0 Molecular components of Tight junctions.  Shown above is list of different classes of protein (Transmembrane, Adaptor, Signalling and transcriptional regulator) that  are  associated with  the  TJ  complex.  Interaction  partners  are  also  listed  for  particular  proteins.  This  is  by  no means a complete comprehensive list, as many more novel TJ proteins and new associations between them yet to be discovered. Table adapted from 2  6 where additional information has been added the reference is indicated. 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Molecular composition Adherens junctions   
AJs are adhesive junctions in epithelial cells. The main adhesion receptors in 
these junctions are Cadherin family proteins (Table 1.1). E-Cadherin is a 
member of the Cadherin super-family expressed in most epithelial tissues 87. E-
Cadherin is the most understood of all the Cadherins due to its prominent role 
as a tumour suppressor and regulator of morphogenesis 19. E-Cadherin, like all 
Cadherin proteins, is a single pass transmembrane glycoprotein. It is the 
extracellular domain of E-Cadherin that forms homotypical interactions with E-
Cadherins in neighbouring cells. This interaction is calcium dependent, as 
calcium is required for the correct comformational organisation of the 
extracellular domain.88 Interactions between the cytoplasmic domain of E-
Cadherin and other proteins, namely the Catenins, recruit signalling 
components that are important for linkage to and regulation of the local actin 
cytoskeleton and also the control of gene transcription. The cytoplasmic domain 
of E-Cadherin binds directly to Catenin family members β-Catenin and p120 
Catenin 89 90. α-Catenin is known to directly bind to β-Catenin to form a dimmer, 
resulting in the formation of a Cadherin-Catenin complex. α-Catenin is 
indispensable for Cadherin-mediated adhesion; absence of α-Catenin disrupts 
the formation of AJs and the association of the Cadherin-Catenin complex with 
actin filaments is prevented. α-Catenin binds bundles of actin filaments and 
actin interacting proteins such as ZO-1, α-actinin, vinculin, ZO-1, formin 1, 
afadin and Eplin 72, 91-93.  
 
 29 
It was thought on the basis of several observations that the α-β-Catenin dimer 
links the Cadherin complex to the actin filaments and so physically connects the 
AJ to the actin cytoskeleton, and thus represents a structural  component of the 
assembly, maintenance and function of the AJ complex 94. However this model 
is somewhat controversial, and some studies suggest that α-Catenin is not 
directly involved in the linkage between the E-Cadherin/β-Catenin complex and 
actin filaments because experiments show that binding of α-Catenin to actin 
and β-Catenin in vitro is mutually exclusive 95, 96. Alternative models of how E-
Cadherin complexes are linked to the actin cytoskeleton suggest other β-
Catenin binding proteins 97 or other unknown α-Catenin/actin binding proteins. 
However a recent study showed that when force was applied to α-Catenin 
generated from the spatial activation of actinomyosin contraction at the 
basalolateral membrane, only the stretched region of α-Catenin was able to 
recruit vinculin, an actin binding protein, resulting in linkage to the actin 
cytoskeleton and AJ development 98.  This study may offer an alternative 
explanation for the mutually exclusive binding of α-Catenin to actin and β-
Catenin in vitro as this could be a reflection of the technical difficulties of 
isolating this complex just because it does not bind in vitro does not mean it 
never occurs. Indeed, it is possible that when force is applied to α-Catenin it 
may change its structure to reveal a masked actin binding site when α-Catenin 
is bound to the E-Cadherin/β-Catenin complex. 
  
Nectins are another class of transmembrane protein associated with AJs 99, 100. 
The interactions between Nectin proteins unlike Cadherins is calcium 
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independent. The cytoplasmic domain of Nectins associates with Afadin, 101 
which is known to bind to f-actin 102 and also weakly to α-Catenin 101. It is 
thought that via this link Nectin complexes are linked to the actin cytoskeleton. 
However it still remains unclear how Nectin complexes are physically 
associated with Cadherins. It is probably mediated via Afadin/ α-Catenin 
interactions, as Afadin and α-Catenin are known to be essential for this 
interaction 101, 103, but may involve other unknown intermediate adaptor proteins. 
  
β-Catenin is a multifunctional protein, that is a key component of AJs. β-Catenin 
is able to interact with multiple binding partners that function in cell-cell 
adhesion and also translocates to the nucleus, where it can associate with 
LEF/TCF transcription factors, important for proliferation 104 105. The tumour 
suppressive function of E-Cadherin is partly due to its sequestration of β-
Catenin at cell-cell adhesion sites 77. Overexpression of β-Catenin is also often 
seen in many cancers 77, 106 78 and is generally thought to promote 
proliferation.107 It is not fully understood how different cellular pools of β-Catenin 
are regulated and communicate with each other. The Wnt/wingless growth 
factor signalling pathway is one of the main regulators of β-Catenin 107. Wnt 
signalling regulates the activity of glycogen synthase 3β(GSK3β), which in turn 
controls the phospholyation state of β-Catenin. Phospholyated β-Catenin is 
present in a complex with adenomatous polyposis coli protein (APC) and axin 
resulting in ubiquitination and subsequent targeting of β-Catenin to the 
proteasome for degradation 108. In the absence of Wnt signalling β-Catenin 
remains phospholyated and therefore degraded in the cytoplasm. In the 
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presence of Wnt, GSK3β is inactivated and β-Catenin remains 
dephosphorylated resulting in an inhibition of degradation, translocation to the 
nucleus and activation of gene transcription mediated by LEF/TCF 109, 110. 
Protein   Interacting partners  
   
Adherens junctions     
     
Transmembrane proteins    
Cadherins   Cadherin, β‐Catenin, p120‐Catenin,Hakai,RapGEF1 (C3G)  
     
Nectin  Nectin, afadin, PAR‐3 
     
Vezatin  Myosin VIIA, Cadherin–Catenin complex 
Cytoplasmic adaptor proteins    
     
α‐Catenin  β‐Catenin, F‐actin, ZO‐1, Ena‐VASP, formin‐1,  
   afadin, Zyxin, Spectrin, α‐actinin, vinculin, Eplin  
     
β‐Catenin 
α‐Catenin, p120‐Catenin, Lin‐7, IQGAP, fascin, PI3‐
kinase,RapGEF6 
     
p120‐Catenin  E‐Cadherin, β‐Catenin, VAV‐2 (Rho‐GEF),p190RhoGAP,RhoA 
     
     
Afadin  Nectin, α‐Catenin, F‐actin, ZO‐1, Ponsin, profilin, Bcr, c‐Src 
     
Eplin   F‐actin, α‐Catenin 
    
 
 
Table 1. 1 Molecular components of Adherens junctions.  Shown  above  is  list  of  different  classes  of  protein  (Transmembrane,  or  adaptor)  that  are associated  with  the  AJ  complexes.  Shown  also  are  interaction  partners  of  particular  AJ components . Table adapted from 2  6. 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AJs aside from regulating β-Catenin mediated transcriptional responses can 
also regulate the activity of the transcription factor NF-κB. NF-κB regulates 
genes involved in cell growth and survival 111 112, 113, pro-inflammatory immune 
responses 114 as well as genes important for Epithelial to Mesenchymal 
Transition (EMT) 115. 
 
NF-κB is a structurally conserved family of transcription factors that exist as 
dimeric complexes. Each monomeric subunit of the dimer contains a N-terminal 
300 amino acid sequence termed the Rel homology domain, which contains 
sequences important for dimerisation, nuclear localization and DNA binding 114.  
There are five NF-κB monomeric subunits in mammals; these are p65 a.k.a 
RelA, c-Rel, RelB, p50 and p52. NF-κB subunits bind DNA target sites upon 
homo or hetrodimerisation with each other to form transcriptionally active 
complexes that have varying activities depending on subunit composition 116 . 
NF-κB complexes are normally sequestered as transcriptionally inactive 
complexes in the cytoplasm by association of an inhibitory binding protein IkBα 
that prevents NF-κB from translocaling to the nucleus 116. In general activation 
of the canonical pathway involving p65/p50 and c-Rel/p50 NF-κB complexes is 
preceded by activation of the IKK complex that phospholyates the inhibitory 
binding protein IkB resulting in its degradation and thus permitting NF-κB to 
translocate to the nucleus where it mediates transcription of target genes 116.  
 
 33 
Many studies have implicated NF-κB transcriptional activity to be required for 
the maintenance and invasive phenotypes of cancers 115, 117 118.  NF-κB is 
known to activate several developmentally important transcription factors such 
as snail, slug, twist, ZEB1 and 2 that are important for promoting EMT by 
promoting the expression of genes important for maintaining a mesenchymal 
phenotype such as vimentin fibronectin and metalloproteinases115, while 
repressing epithelial phenotype associated genes such as E-Cadherin 119, 
occuldin and claudins 120. The snail family of transcription factors is known to 
regulate EMT during developmental processes as well as to participate in 
tumour progression. Snail is a direct repressor of E-Cadherin gene transcription 
119.  
 
A recent study observed the p65 subunit of NF-κB in association with a complex 
formed by E-Cadherin/ α,β and p120 Catenins 121. This E-Cadherin-Catenin-
p65 complex was disrupted when AJs were perturbed by K-ras overexpression 
or E-Cadherin depletion by siRNAs. Furthermore stimulation of basal and TNFα 
stimulated NF-κB transcriptional activity was also observed when E-Cadherin 
was depleted, suggesting that E-Cadherin, in a manner analogous to E-
Cadherin-β-Catenin interactions, represses NF-κB activation possibly by 
sequestering it at AJ complexes and thereby suppresses transcription of Snail 
and other transcription factors important for promoting EMT.  
 
p120 Catenin is a component of AJ showing structural similarities to β-Catenin. 
p120 like β-Catenin can also bind to E-Cadherin and plays a role in cell-cell 
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adhesion122. Like β Catenin, p120 Catenin can function as a transcriptional 
regulator, but instead of regulating LEF-1 it is known to regulate another 
transcription factor called Kaiso that is known to repress transcription of β-
Catenin target genes  123.  
Studies in a mouse model where p120 Catenin is conditionally knocked out in 
the epidermis revealed links between p120 Catenin and the regulation of NF-κB 
signalling in cell proliferation and inflammatory responses 124. In this study p120 
null neonatal epidermis showed no overt disruption in paracellular permeability 
and adhesion, however older mice started to display epidermal hyperplasia and 
chronic inflammation. p120 Catenin null epidermal cells were shown to have 
elevated levels of active NF-κB causing expression of NF-κB target genes such 
as pro-inflammatory cytokines that were responsible for the inflammation and 
epidermal hyperplasia  observed in older mice. Interestingly the role of p120 
Catenin in NF-κB regulation was not dependent upon its function in 
maintenance of Cadherin-mediated adhesion, but appeared to function to 
activate NF-κB via the regulation of RhoGTPases.  P120 is known to be a 
negative regulator of the RhoGTPase RhoA, and hence provides an important 
link between NF-κB signalling and RhoGTPase regulation.   
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Assembly of apical cell­cell Junctions   
Assembly of AJ and TJs has been studied in different experimental systems 
most extensively in MDCK cells. In this model system it has been determined 
that junctions assemble in a sequential stepwise manner. Calcium dependent, 
E-Cadherin mediated cell adhesion is the initial cue that triggers assembly of all 
junctions 125 126. After E-Cadherin engagement the next step seems to be the 
formation of primordial junctions that contain components from AJ and TJ. 
Changes in cell morphology and organization of the actin cytoskeleton result in 
the final step of maturation and polarized cells with distinct AJ and TJs.   
De novo junction assembly has also been studied using in vivo models during 
early development 127. The sequential recruitment of junctional proteins 
observed in cultured cells, correlates well with the development of functional 
intercellular junctions in the first epithelial structure to form in the mouse pre-
implantation embryo, the trophectoderm. The junctional complex of this 
epithelium forms as a result of the sequential recruitment of AJs and TJs 
proteins to cell-cell contacts. Starting with E-Cadherin engagement during 
compaction of the 8 cell embryo and ending in the recruitment of claudins to 
produce mature functional TJs in the 32 cell blastocyst 128. 
The initiation of cell-cell adhesion is mediated first by the touching of actin 
based protrusive membrane structures. MDCK cells, for example, form transient 
lamellipodia, to initiate contact129, 130.  Whereas keratinocytes use filopodia, to 
initiate cell-cell adhesion 131.  
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Initial plasma membrane contact from adjacent cells has been visualized in 
MDCK cells using GFP-tagged E-Cadherin 129. This study defined different 
sequential stages in cell-cell contact development. The first stage showed E-
Cadherin distribution changed from a diffuse pool of cell surface E-Cadherin 
into small punctate clusters upon touching of adjacent plasma membranes. 
These punta have been observed in different cell types and systems and 
represent a primodial junctional state, as they are known to contain other 
proteins associated with AJ and TJs such as Catenins, nectins JAM-A and ZO-1 
129, 131, 132. These initial punta are stablised by association of actin filaments. The 
actin cytoskeleton undergoes striking changes during junction formation. During 
this initial stage of contact, thin actin filaments can be observed branching out 
from the circumferential ring of actin. These filaments terminate at these 
punctuate E-cadherin containing complexes and are thought to stabilise them at 
the plasma membrane129, 131. 
 
In the second stage, circumferential actin filaments near cell-cell contact sites 
separate and the two ends of the cable swing outwards towards the perimeter 
of the contacts. As a result of these actin cytoskeletal changes, E-Cadherin 
punta spread out to the margins of the contact to form large E-Cadherin 
containing plaques. One might think of it as a zipper whereby changes in the 
actin cytoskeleton causes zipping up cell membranes from sites of punctate 
clustered E-Cadherin complexes into a continuous line that spans the contact 
surface between the two adjacent cells. This reorganisation results in the 
formation of the circumferential actin cables that circumscribes both cells and 
that are linked to the E-Cadherin plaques at the contact zone of neighbouring 
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cells. Actin polymerization has been suggested to provide the driving 
mechanical force for this zippering effect, which seals cell membranes together 
as contacts expand 131. A number of actin regulatory proteins that promote 
polymerisation, such as the Arp/2/3 complex133, formins134 and members of the 
Mena/VASP family 135, are all known to be recruited to sites of E-Cadherin 
contacts and are thought to be important regulators of this stage of junction 
assembly. The Arp/2/3 complex is known to promote actin nucleation and 
branched filament polymerization 136. Arp2/3 is known to be important for the 
formation of lamellipodia membrane protrusions. Lamellipodia are important for 
junction formation by permitting neighbouring cells to expand cell-cell contacts 
along the whole length of touching adjacent membranes 130. Arp2/3 activity can 
be inhibited by α-Catenin 96, through a mechanism whereby dimers of α-
Catenin bind to actin filaments resulting in a conformational change the three-
dimensional structure of the actin filaments. The change in filament structure is 
enough to prevent Arp2/3 binding, thus preventing filament branching and also 
protects actin filaments from cleavage from the actin depolymerising factor 
cofilin (Nelson, W.J 2010 unpublished). This protection of actin filaments by α-
Catenin might be important for limiting Arp2/3 activity and so lamellipodia 
formation to newly contacting membranes, while stabilising older contacts by 
developing stable un-branched actin filaments.  
 
The final stage of junction assembly is the maturation of this primordial 
junctional complex into polarized cells with distinct AJ and TJs. ZO-1 and JAM-
A are known to be present in primordial E-Cadherin based contacts and are the 
first TJ proteins to be present at the compaction stage of the 8 cell mouse 
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embryos 128 . The recruitment of additional TJ proteins then follows, including 
proteins that are components of polarity complexes, which establish apical 
/basal polarity, and the transmembrane proteins that are the constituents of TJ 
strands, such as Occludin and the Claudins.  
 
As junctions mature, there is an elongation of the lateral membrane. The actin 
cytoskeleton reorganizes to form a perijunctional actin ring. Circumferential 
actin filaments contract and bundle so that they tightly align with the apical 
junctional complex 129, 137, 138. Actinomyosin forces generated by Myosin II 
activity are required for this actin reorganization and cell shape changes. 
Inhibition of Myosin II ATPase activity does not prevent E-Cadherin contacts 
forming, but does prevent formation of the peri-junctional actin ring, TJ 
formation and cell polarization 137. Furthermore a recent study has highlighted 
the role for different isoforms of Myosin II having roles at different stages of 
junction assembly. 139. Myosin IIB can compensate functionally for Myosin IIA 
but not visa versa, suggesting a unique functional role for Myosin IIB. Myosin 
IIA seems to have an essential role in Cadherin clustering and in concentration 
of Cadherin complexes at forming AJs. In contrast to Myosin IIA, Myosin IIB has 
been proposed to function at later stages of junction formation by strengthening 
the perijunctional actin ring, thereby by enabling it to resist orthogonal forces 
produced when cells form a continuous epithelial sheet. Furthermore Myosin IIA 
and IIB junctional localization appear to be regulated by different signalling 
pathways. Myosin IIA is regulated RhoA/ Rock signalling pathway, and IIB by 
signalling from the GTPase Rap, suggesting they are parts of two distinct 
functional Myosin II signalling modules.  However it remains unknown how the 
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activity of these modules are coordinated in forming AJs. 
 
The regulation of the actin cytoskeletion dynamics and actinomyosin 
contractility is critical in the initiation and maturation of cell-cell junctions. The 
Rho family of small GTPases, are molecular switch proteins that are master 
regulators of the actin cytoskeleton. It is therefore not surprising that they have 
emerged as being crucial regulators in the assembly and maintenance of cell-
cell junctions. In these next sections I will discuss how Rho signalling is 
regulated and can be coordinated in a spatial and temporal manner by 
additional Rho regulatory factors and discuss their regulation in the assembly 
and function of junctions.  
RhoGTPases   
 The Ras super-family of small monomeric GTPases contains about 150 
members in mammals 140. This super family is further subdivided into five main 
sub families; Ras, Rho, Rab, Rap and Arf RhoGTPases. Like all Ras family 
members they are molecular switch proteins that employ a simple biochemical 
mechanism to control many complex cellular processes. The basis for this 
mechanism relies on the ability to cycle between On or active (guanosine-5'-
triphosphate (GTP) bound), or Off / inactive (guanosine-5'-biphosphate (GDP) 
bound) states. When GTP bound, considered the active state, the RhoGTPase 
undergoes a conformational change that allows it to interact with downstream 
effectors that are often kinases, phosphotases and lipases and so to transduce 
signals. The activation of RhoGTPases is often regulated by various cell surface 
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receptors, such as adhesion molecules, cytokine receptors, tyrosine kinases, as 
well as G-protein coupled receptors. 
 In mammals the Rho family of GTPases is comprised of 20 members 141. Most 
studies have focused on what is termed classically activated Rho proteins, 
these undergo the normal on /off cycle of activity and include Rac1-3, Cdc42 
and Rho A, B and C. However 8 members of the Rho family are considered 
atypical. These have lost their GTPase hydrolysis activity and remain 
predominantly GTP bound. Examples are RhoBTBs142 and Rnds 143. Atypical 
Rhos therefore are not regulated by GEFs or GAPs, but by other methods like 
gene expression, protein stability or phospholyation. RhoGTPases were first 
indentified as regulators of the actin cytoskeleton 144. They are also important 
regulators of gene transcription and contribute to mitogen activated protein 
kinase cascades and inflammatory signalling. They have been implicated in a 
diverse array of cellular processes such as cell-cell adhesion, migration, 
phagocytosis, cytokinesis, cellular morphogenesis, polarization, proliferation 
and cell survival. 145, 146 
 
Regulation of RhoGTPases   
Cycling between GDP and GTP bound states is tightly regulated by additional 
protein factors that can be divided into two families. GTPase activating proteins 
(GAPs) 147, which, enhance the slow intrinsic GTPase activity of the 
RhoGTPase and Guanine nucleotide exchange factors (GEFs) 148, which 
catalyse the exchange of GDP by GTP. GEFs are positive regulators and GAP 
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negative regulators of RhoGTPase signalling. The inactivation of the 
RhoGTPase by a GAP, is sometimes coupled with its extraction from 
membranes. Extraction is mediated by Guanine nucleotide dissociation 
inhibitors (GDIs) 149, 150, which are a third set of regulatory proteins that 
preferentially bind the inactive, GDP-bound RhoGTPase and prevent GDP 
dissociation. This is thought to keep the RhoGTPase in an inactive state in the 
cytosol and prevent delivery of RhoGTPases to membranes where they can 
become activated by interactions with GEFs. GDIs therefore act to keep 
RhoGTPases permanently inactive, by sequestering them in the cytosol. 
However the mechanism for release of the RhoGTPase from GDI is not yet fully 
understood but may be mediated by phospholyation of the GDI or the 
RhoGTPase by a number of different kinases. 
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Figure 1. 2 RhoGTPase regulatory cycle RhoGTPases cycle between inactive (GDP bound) and active (GTP bound) confirmations. Upon conversion from inactive to active states a conformational change occurs exposing structural features required for the recruitment  of  effector  proteins,  that  transmit  downstream  effects  (see  blue  box)..  Three  families  of protein  factors  regulate  the  activity  and  subcellular  localization  of  the  RhoGTPase.  GEFs  are  positive regulators of RhoGTPases by promoting  the exchange of GDP to GTP. GEFs exhibit  specificity  towards a particular RhoGTPase. Most contain domains that allow interactions with different scaffold proteins and or  phospholipids.  These  interactions  may  regulate  catalytic  exchange  activity  and/or  the  subcellular localization of GEFs.  Some  scaffold proteins  can also bind RhoGTPase effector proteins. Extracellular or intracellular stimuli may activate the GEF causing activation of the RhoGTPase permitting  it  to bind and activate  effector  proteins.    Some  GEFs  can  also  act  as  scaffolds  themselves.  Scaffolds,  thus  provide  a platform for recruitment of GEFs and effectors allowing efficient signal transduction and spatial activation of  Rho  signalling.  RhoGTPases  have  intrinsic  GTPase  activity  and  can  hydrolyse  GTP  to  GDP  leading  to inactivation.  GAPs  are  negative  regulators  of  RhoGTPases  by  enhancing  the  intrinsic  GTP  hydrolysis activity of  the RhoGTPase and thereby promote the transfer of  the RhoGTPase back to an  inactive state. GAPs also exhibit specificity towards a particular RhoGTPase and like GEFs have other domains that can interact with scaffolds (not shown above) permitting tight control of signal transduction pathways linking upstream  signalling  to  inactivation  of  specific  Rho  signaling  pathways.  RhoGTPases  are modified  post‐translationally by the addition of an isoprenyl (geranyl‐geranyl) lipid group to cystine of a CAAX motif at the C‐terminal region of the GTPase. Inactivation of a RhoGTPase is sometimes coupled with its extraction from a membrane.  GDIs  sequester  the RhoGTPases  in  their  inactive GDP bound  form  in  the  cytosol,  by masking the C‐terminal isoprenyl group preventing its localization to membranes.      
 43 
 
Guanine nucleotide exchange factors (GEFs)  
The first mammalian GEF to be identified was discovered as a cancer 
transforming gene from diffuse B-cell lymphoma cells and was assigned the 
name Dbl 151 152. Dbl contains a region of ~240 amino acids residues that has 
homology to cdc24 a GEF for cdc42 in yeast Saccharomyces cerevisiae 
implicated in cell polarity 153. Dbl was shown to be a GEF for human Cdc42 and 
subsequently this Dbl (DH) domain has been found in approximately 70 
proteins in humans, which constitute the Dbl family of RhoGEFs 148. Many of 
these RhoGEFs have oncogenic activity, which has aided in their identification. 
Invariably Dbl family GEFs have a DH domain and an adjacent C-terminal 
Pleckstrin Homology (PH) domain.  
The DH domain of ~ 200 amino acids is the minimal domain required for 
nucleotide exchange activity in vitro. There is low sequence homology between 
DH domains of different RhoGEFs, but structural studies on a number of GEFs 
Dbl, Dbs, Vav-1, Tiam-1 148 154 have revealed there is conserved tertiary 
structure. There is extensive contact in the interface between the DH domains 
of Dbl GEFs and RhoGTPases, structural and biochemical studies, demonstrate 
large variation of residues amongst different GEF:RhoGTPase complexes 
important for determining specificity of a GEF towards a specific RhoGTPase. 
An example of this was from a study where Rac1 was mutated at Trp-56 to Phe. 
This mutation prevented activation of Rac1 by Tiam-1, yet Rac1 could still 
efficiently be activated by ITSN-L another GEF that is normally a Cdc42-specific 
GEF 155. Similarly a single Leu-Ile mutation in the DH domain of the GEF Dbs 
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permitted it to have robust catalytic exchange activity for of Rac1, which is not 
normally its substrate 156. 
 Crystal structures of DH domains bound to RhoGTPases have been used to 
discover the mechanism of nucleotide exchange, a process involving 
remodelling of the switch regions that alters the shape of the nucleotide binding 
pocket and directly occludes binding of a Mg2+ cofactor causing dissociation of 
the guanine nucleotide. This leaves the GTPase nucleotide pocket exposed and 
GTP binds, as its cellular concentration is normally greater than GDP 148.  
 
PH domains of Dbl GEFs are ~100 amino acids in length and are invariable 
located C-terminally to DH domains in GEFs.  Experimental evidence suggests 
different functional roles of PH domains in different GEFs.  The function of the 
PH domain in certain Dbl GEFs has been linked to a membrane targeting role, 
whereas in other GEFs the PH domain is thought to contribute to RhoGTPase 
activation by stimulating nucleotide exchange activity and determining 
specificity.   
 
Analysis of the structure of Dbs in complex with Cdc42 showed regions of the 
DH-associated PH domain that are required for effective activation of Cdc42 157. 
However, the structure of Tiam-1 in complex with Rac-1 shows PH domains are 
significantly removed from the bound GTPase 154, making it difficult to see how 
they could influence productive interactions required for GTPase activation. PH 
domains also have been discovered to regulate GEF activity by binding to 
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phospholipids. For example the exchange activity of P-Rex-1 and Vav1 
activators of Rac1 was stimulated in vitro by the addition of soluble 
PtnIns(3,4,5)P3, presumably by an allosteric regulation of GEF activity, whereas 
PtdIns(4,5)P2 inhibited Vav1 exchange activity 158. Experimental evidence also 
implicates the PH domain in targeting the GEF to membranes 159, 160. However, 
the PH domains of Dbl GEFs consistently bind phospholipids with low affinity 
and little specificity, implying that these interactions may be insufficient for 
targeting to membranes. Indeed membrane targeting of Dbs, Tiam-1, and Vav-1 
does not require the PH domain 160-162, but is mediated by other domains/motifs. 
Furthermore many other GEFs are not regulated by phospholipid binding, 
suggesting different functional roles for PH domains 163.  
The targeting of Dbl GEFs to specific subcellular sites may however be 
mediated by interactions of the PH domain with other proteins. For example, the 
PH domain of Dbl is known to interact directly with ezrin, a linker protein that 
mediates interactions between the plasma membrane and the actin 
cytoskeleton 164. The PH domain of GEF-H1 is known to mediate binding to the 
TJ adaptor protein Cingulin, resulting in the targeting and subsequent 
inactivation of GEF-H1 at TJs 64.  Undoubtedly, future work will discover more 
instances of Dbl GEF -PH- domain interactions with diverse sets of proteins that 
will link activation of Rho signalling to distinct cellular sites and signalling 
cascades. 
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Dock family GEFs  
A Second family of Guanine nucleotide exchange factors called the Dock180-
realted family of GEFs, also known as the CZH family has been indentified in 
invertebrates and mammals 165 166. They have been shown to be bona fide 
Guanine nucleotide exchange factors proteins, but are unrelated in their 
sequence homology to Dbl family GEFs, suggesting that they evolved from a 
different ancestral linage. Dock180 was the first member to be discovered as a 
binding partner of Crk, a protein involved in receptor tyrosine kinase signalling 
from focal adhesions 167.  Ced-5 the ortholog of Dock180 in the worm 
Caenorhabditis elegans was shown to be required for cell migration and 
phagocytosis 167 where as the fly Drosophila meloanogaster ortholog myoblast  
city was identified as a protein essential for myoblast fusion and dorsal closure 
168. Subsequent studies have identified 11 family members in mammals and 
most show preferential activation towards Rac 165. However, Dock 9, also 
known as Zizimin1 preferentially activates Cdc42 169.  They all lack the typical 
DH-PH module found in Dbl GEFs, but instead have two conserved Dock 
homology regions (DHR). The DHR2 region is responsible for nucleotide 
exchange activity.  In contrast to Dbl GEFs, the structure and catalytic 
mechanism of Dock180 GEFs has not been studied as extensively as Dbl 
GEFs. However structural studies of DOCK9 complexed with Cdc42 show 
regions in the DHR2 domain directly insert into Cdc42 nucleotide binding pocket 
and interfere with Mg2+ binding causing nucleotide dissociation 170. 
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The DHR1 domain of Dock180 GEFs is known to bind phospholipids analogous 
to PH domains in Dbl GEFs, that are required for membrane targeting. DHR1 
domains binds PtdIns(3,5)-bisphosphate and PtdIns(3,4,5)P3  in vitro and in 
cells. When the DHR1 in Dock180 was mutated this prevented Rac dependent 
cell elongation and cell migration even through GTP bound Rac loading was 
unaffected, suggesting an important difference between activation of Rac and 
the biological output of Rac signalling 171. Thus supporting a possible role for 
the DHR1 domain of Dock180 in Rac signalling by regulating the positioning of 
Rac signalling at sites of PtdIns(3,4,5)P3 production.  
 
Rho GTPase activating proteins   
RhoGTPase activating proteins (GAP) are considered to be negative regulators 
of RhoGTPases. Their mechanism of action is to enhance the intrinsic catalytic 
GTPase activity of the RhoGTPase, resulting in GTP hydrolysis to GDP and 
thus termination of Rho signalling. Approximately 70 proteins in the human 
genome contain a RhoGAP domain and to date over just half of these have 
been characterised 147. GAP proteins contain a conserved 150 amino acid 
RhoGAP domain that is essential for GAP activity.  RhoGAP domains form a 
structure containing 9 alpha helixes with a conserved arginine residue in a loop 
region 172. Studies where this arginine was mutated to alanine have been 
shown to prevent GAP activity, and structural analysis of RhoGAP domains in 
complex with RhoGTPases have revealed this residue to form part of the 
catalytic active site that promotes GTP hydrolysis by stablising a transition state 
intermediate of the GTP hydrolysis reaction 173. The interaction of a RhoGAPs 
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with GTPases is mediated by the RhoGAP domain. Structural studies revealed 
the RhoGAP domain interacts with the switch I and II regions of GTPases that 
undergo conformational shape changes upon GTP binding 172. RhoGAPs, like 
RhoGEFs, show specificity for particular RhoGTPases they interact with. 
Interactions between the RhoGAP and non-conserved regions in the 
RhoGTPase p-loop region contribute towards a GAP’s GTPase substrate 
specificity.   
Regulation of Rho signalling   
The number of GEFs and GAPs largely outnumbers the number of 
RhoGTPases as over 70 Rho GEFs and GAPs are encoded in the human 
genome 147, 148. There are a number of possible explanations for this 
observation. Firstly not all GEFs and GAPs are widely expressed, with some 
showing tissue specific expression and function. Secondly, specificity towards a 
particular RhoGTPase could be an explanation; however, in vitro binding 
assays have shown that some GEFs and GAPs regulate the activation state of 
multiple RhoGTPases.  Finally, apart from the conserved catalytic domains, 
GEFs and GAPs contain a diverse array of different types of protein domains 
allowing them to interact with phospholipids, signalling molecules such as 
heterotrimeric G-proteins, tyrosine kinases, adaptor/scaffolding proteins, or also 
act as scaffolding proteins themselves. All of these types of interactions enable 
GEFs and GAPs to be regulated in a variety of ways, modulating the spatial and 
temporal restricted control of Rho signalling pathways in response to diverse 
extracellular and intracellular stimuli. 
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Regulation of the catalytic activity of GEFs and GAPs can be controlled directly 
by post-translational modification such as phosphorylation or indirectly by 
protein-protein interactions. Many Dbl GEFs are constitutively activated as a 
result of deletion of domains important for inhibitory intramolecular binding to 
the DH domain 174 . Mutations resulting in N and C-terminal truncations of Dbl 
GEFs were discovered in many different cancers. These truncation mutants 
often have greater transforming oncogenic potential when overexpressed in 
cultured cells than of the full length forms.  
 
 A well characterised example of N-terminal domain regulation, is demonstrated 
by phosphorlyation of Vav-1 174 175.   The N-terminal region interacts with the 
DH domain to allosterically prevent access by RhoGTPases.  Phosphorlyation 
of Try174 within this N-terminal domain and of other proximal Try residues by 
various receptor-associated tyrosine kinases, such as Lck 176, opens the DH 
domain to GTPases by disrupting the inhibitory intramolecular binding of the N-
terminal region to the DH domain. However, although many RhoGEFs are 
phosphorlyated as a result of different stimuli, the consequences of 
phosphorylation are only beginning to be understood. For example, the Rho 
GEF Tiam-1 is phosphorlyated on several sites by Calcium/calmodulin-
dependent (CaM) kinase II, protein kinase C and Src with varying effects on 
stimulation or inhibition of GEF activity 177-179. Furthermore phosphorlyation at 
residue Thr 678 of the TJ associated RhoA-specific, GEF-H1 by the Erk-1/2 
kinase, has been demonstrated to enhance GEF-H1 exchange activity to 
towards RhoA 180. However, phosphorlyation of GEF-H1 at Ser 885 by other 
kinases, such as PAK1 and Aurora 181 182 and phosphorlyation at Ser959 by 
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CDK1 182 resulted in down regulation of GEF-H1 activity by ill-defined 
mechanisms. The RhoGAP CdGAP is also regulated by ERK-1/2 by 
phosphorlyation at Thr776 resulting in inactivation of its GAP activity in vitro 183. 
The post translational modification of GEFs and GAPs by phosphorlyation is 
clearly important in the regulation of Rho signalling, understanding the 
mechanism of how phosphorlyation modulates activity is a worthy aim for future 
investigations.   
    
Several Dbl family RhoGEFs are main points of convergence between 
signalling cascades originating from heterotrimeric G proteins and those that 
regulate RhoGTPases. p115RhoGEF, LARG, and PDZ-RhoGEF all contain a 
highly divergent regulator of G protein signalling (RGS) domain that is typically 
associated with enhancing the GTPase activity of Gα subunits 184, 185. Purified 
p115RhoGEF186 and LARG185, increase the rate of GTP hydrolysis of Gα12 and 
Gα13 to produce GDP bound and therefore inactive forms of these 
heterotrimeric G proteins. Furthermore, purified p115RhoGEF and LARG are 
known to act as exchange factors for RhoA. Their exchange activity can be 
stimulated by interaction with activated Gα12 and Gα13. p115RhoGEF and 
LARG therefore seem to act as downstream effectors of active GTP bound Gα 
subunits, while simultaneously acting as GAPs to terminate signalling from Gα 
subunits. Regulation between heterotrimeric G proteins and RhoGEF signalling 
initially seems antagonistic, but permits this system to have an inbuilt signal to 
noise control. Only signals that produce robust stimulation of GPCR and thus a 
high concentration of GTP bound Gα subunits would activate RhoGEF 
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signalling, as weaker or spurious signals that activated Gα subunits would be 
eliminated by the GAP activity of the bound RhoGEF.  
 
Coordination between signalling from heterotrimeric G proteins and 
RhoGTPases can also be regulated by the interaction of βγ subunits of 
heterotrimeric G proteins with Dbl family GEFs. For example the RhoGEF P-
Rex-1 activates Rac in response to a synergistic stimulation by βγ subunits 
PtdIns(3,4,5)P3. 187. Additionally, interaction of βγ subunits with the DH-PH 
domain of p114RhoGEF was demonstrated to enhance RhoA mediated SRE-
driven gene transcription 188.  
   
Regulation of GEFs and GAPs by subcellular sequestration    
Regulation of the subcellular localisation of GEFs and GAPs is often mediated 
by domains outside of their conserved catalytic domains. This provides a 
common means of restricting the spatial and temporal regulation of Rho 
signalling in response to different stimuli. For instance the RhoGEFs Net 1 and 
Ect2 both contain nuclear localization sequences that target them to the 
nucleus, where they are sequestered and prevented from interacting and 
activating their substrate RhoA 189, 190. Ect2 is known to be important in 
cytokinesis, and it is held inactive in the nucleus during interphase. When 
mitosis occurs the nuclear envelope breaks down and Ect2 is released where it 
associates with microtubules as well as to the cleavage furrow during 
subsequent different phases of cell division where it is thought to activate 
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RhoA190. GEF-H1 interacts directly with microtubules resulting in inhibition of its 
nucleotide exchange activity towards RhoA at the plasma membrane 191. The 
Dbl RhoGEF Tiam-1 is know to be recruited to cell-cell contacts through its 
association with the TJ adaptor protein Par3 via a N-terminal region of Tiam-
1192. In Par-3 depleted cells Tiam-1 activity is not restricted to this site and 
results in aberrant activation of Rac preventing cell-cell junctions from forming 
correctly 193.  Furthermore, the Cdc42 RhoGEF Tuba is localised to TJs by 
interaction between its C-terminal SH3 domain and the TJ adaptor protein ZO-1 
86. This localisation is presumably important for the spatially restricted activation 
of Cdc42 and the effector N-WASP, as depletion of Tuba effects TJ assembly 
via organization of the peri-junctional actin cytoskeleton. The Cdc42 GAP Rich-
1 is Iocalised to TJs by interaction with the TJ adaptor protein Amot, via coiled 
coil regions of Amot and the BAR domain of Rich-1. Amot/Rich 1 complex 
seems to function to modulate Cdc42 activity at TJs by regulating intracellular 
protein trafficking of polarity complex containing Pals1, PatJ and Par-3 85. Many 
RhoGEFs contain evolutionary conserved C-terminal PDZ binding motifs that 
enable them to interact with proteins containing PDZ domains, a common 
domain often found in adaptor proteins of the cytoplasmic plaque of junctional 
complexes 194.   For example, binding of the Cdc42 GEF βPIX to the polarity 
protein Scribble is mediated by the PDZ domains of Scribble. βPIX promotes 
regulated exocytosis by Cdc42 activation. Scribble is thought to mediate 
membrane localization of βPIX an essential requirement in this process 195.  
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GEFs can act as scaffolds to recruit RhoGTPases effectors proteins enabling 
them to provide a platform for efficient transduction of RhoGTPase signalling.  
GEFs, by binding the downstream RhoGTPase effectors are able to activate 
RhoGTPases and effectors in close proximity to each other, thus providing a 
mechanism for permitting efficient and spatially restricted control of Rho 
signalling. The interaction between active RhoGTPase effector and GEF can 
create in some instances a feed back loop to further enhance signals or 
suppress activating signals. For example, the GEF α-PIX has an important role 
in coordination the activation of Cdc42 with GPCR-mediated signals crucial to 
chemotaxis 196. Upon activation of chemoattractant receptors the βγ subunits of 
the stimulated heterotrimeric G protein binds to the Cdc42 effector protein p21 
activated kinase (PAK), which also associates with α-PIX. This results in an 
enhanced activation of Cdc42 by α-PIX. Active Cdc42 can then activate the 
highly concentrated local PAK. Essentially α-PIX is acting as a scaffold to 
coordinate signals from GPCRs with the activation of Cdc42 and subsequent 
downstream activation of high local concentrations of PAK.  This system may 
have inbuilt negative feed back, as activation of PAK has been demonstrated to 
inhibit binding to PIX isoforms α and β 197. The Cdc42 specific GEF, ITSN-L 
shows enhanced nucleotide exchange activity on binding to the SH3 domain of 
the Cdc42 effector (WisKott-Aldrich syndrome protein (WASP) 198. Activated 
GTP bound Cdc42 and ITSN-L probably functionally compete for binding to 
available amounts of WASP. With lower amounts of WASP available for binding 
to ITSN-L when Cdc42 is activated, an increase in the pool of basally repressed 
form of ITSN-L would occur, that would feed back to shut down levels of active 
Cdc42. Interestingly the Cdc42 specific GAP CdGAP also binds to ITSN-L 199 
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and may also play a role an additional control to tightly regulate WASP 
activation.  ITSN-L itself is therefore acting in a negative feed back loop to allow 
fine-tuning of Cdc42 activation. ITSN-L may also act as a scaffold to recruit 
protein factors that add an additional tight regulation of Cdc42 activation.   
In summary GEFs and GAPs permit RhoGTPase regulation to be linked to 
diverse types of upstream stimuli to allow for Rho signal specificity, to permit the 
coupling of upstream signals with the correct type of downstream effector to 
produce appropriate cellular responses. The examples discussed demonstrate 
RhoGEFs and GAPs can be activated in a variety of ways by direct 
phospholyation or by interaction with phospholipids. Aside from their catalytic 
domains RhoGEFs and GAP contain a diverse set of protein domains that 
enable them to link activation of Rho signalling to different upstream signalling 
cascades. Different protein domains also permit RhoGEFs and GAPs to be 
sequestered at different subcellular sites. This is often mediated by interaction 
with adaptor/ scaffold proteins that also bind RhoGTPase effectors thus 
coordinating spatial activation of RhoGTPases with a specific type of effector. 
RhoGEFs and GAPs may also behave as scaffolds themselves by binding 
RhoGTPase effectors, a function that in part determines Rho signalling 
specificity and can lead to autonomous feedback loops that allow tight control of 
Rho signalling.  
RhoGTPases and their regulation in the assembly and function of junctions 
  
A role for small GTPases in junction formation was first demonstrated using a 
non-hydrolysable GTP analogue, GTPγS, which inhibited junction formation in 
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calcium switch experiments 200. The calcium switch technique is a method to 
study de novo junction formation. It involves culturing cells in a medium that 
contains low calcium, preventing formation of cell-cell junctions; addition of 
calcium to the medium then triggers junction formation 201. The use of C3 
transferase, which inactivates RhoA-C (referred to as Rho), but not Rac or 
Cdc42, was also shown to inhibit junction assembly as well as to affect the 
permeability properties of TJs; similar observations were made when mutant 
Rho GTPases were expressed in epithelial and endothelial cells 202-206. In rat 
brain endothelial cells, C3 transferase was reported to inhibit lymphocyte 
transmigration, indicating that Rho is required for junction dynamics 207. Overall, 
these studies suggest that activities of Rho family GTPases need to be finely 
balanced in order to obtain optimal junction integrity.  
 
Despite the clear importance of RhoGTPases in the assembly and function of 
TJs, how their activities are controlled in a TJ specific context is less clear.  
Heterotrimeric G-proteins have been implicated in Rho activation as well as in 
the regulation of TJs and hence might represent a functional link 200, 208, 209. For 
example, when the prostaglandin EP3β receptor, which is coupled to Rho 
activation via heterotrimeric G proteins, was transfected and activated in MDCK 
cells, an increase in TER as well as an increase in paracellular tracer mannitol 
was observed 210. This suggests that Rho activation by heterotrimeric G 
proteins could be one of the mechanisms that regulate TJ permeability. 
However, the molecular mechanisms mediating G protein-induced Rho 
activation at TJs is not known. Several Rho GEFs can interact with 
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heterotrimeric G proteins (see section Regulation of Rho signalling), which 
results in their activation, but none of them is known to localize to TJs.  
 
Currently, only two TJ-associated GEFs for RhoGTPases have been identified 
and functionally linked to TJs. Tuba, an activator for Cdc42, has only recently 
been shown to be recruited to TJs in ZO-1-dependent manner and to regulate 
junction assembly in a Calcium-switch experiments 86. Despite affecting 
junctional configuration and Cdc42’s importance for polarization, Tuba does not 
seem to play an important role in establishing polarized epithelial cells in 
standard cultures. As ZO-1 depletion also only affects epithelial morphogenesis 
in three-dimensional cultures 211, it would be important to test the importance of 
tuba in more complex tissue culture systems.  
 
The second TJ-associated Rho GEF is GEF-H1, an activator of RhoA 212. GEF-
H1 regulates paracellular permeability in epithelial and endothelial cells, as well 
as disassembly of junctions in response to calcium removal 27, 212 , 213. At TJs, 
GEF-H1 interacts with Cingulin, a junctional adaptor, resulting in inhibition of its 
exchange factor activity 64. However, Cingulin depletion does not induce 
increased permeability despite increased Rho activation 64, 214, suggesting that 
compensatory mechanisms might counteract prolonged RhoA activation. 
Moreover, GEF-H1 also interacts with JACOP/paraCingulin, which also affects 
junctional recruitment of GEF-H1 62, suggesting that Cingulin and 
JACOP/paraCingulin may have overlapping functions. Nevertheless, the GEF-
H1/Cingulin complex represents an important Rho signalling pathway in 
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epithelial cells as it stimulates epithelial proliferation by regulating G1/S phase 
transition and gene expression 64, 215.  
 
GEF-H1 is known to interact with various different cellular components in 
different cell types, which includes microtubules and various protein kinases 180-
182, 191, 216. In the context of TJs and regulation of epithelial permeability, most of 
these interacting proteins have not been analyzed in great detail. Some of 
them, however, are likely to play important roles in epithelia if analyzed under 
appropriate conditions as they also associate with epithelial junctions. 
Examples include 14-3-3 proteins, which bind GEF-H1 in a PAK-1-regulated 
manner 181, and Par1/MARK kinases, which are known to regulate epithelial 
morphogenesis 215, 217. Moreover, ERK1/2 phosphorylates GEF-H1, a 
necessary event for the induction of cellular responses including proliferation 
and motility 180. GEF-H1 is also a target of TNFα signalling in endothelial and 
epithelial cells, resulting in Rho signalling and stress fiber induction 215, 218 and 
inhibition of Erk1/2 prevents TNFα-induced stimulation of paracellular 
permeability 219. GEF-H1 may thus represent a Rho signalling activator that 
receives input from different types of upstream pathways to regulate junction 
function, as well as assembly and disassembly of the junction.  
 
RhoGTPase effector pathways and regulation of paracellular permeability  
Multiple RhoGTPase effector pathways target the actinomyosin cytoskeleton, 
which is thought to play a central role in the regulation of paracellular 
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permeability 18, 26, 203, 212, 213, 218, 220, 221. On one hand, interactions between TJ 
proteins - such as Occludin, Cingulin and the ZO proteins - and, actin filaments 
are thought to stabilize the junction and might also provide a means to transmit 
force to alter protein-protein interactions within TJs, resulting in increased 
paracellular permeability (Figure 1.3). However, there is currently scant 
experimental proof that any of these actin-binding functions indeed plays a 
direct role in the regulation of permeability. However a recent study has shown 
for the first time that ZO-1 provides a direct link between TJ permeablity barrier 
function and the peri-junctional cytoskeleton 222  . Nevertheless, the C-terminal 
domain of Occludin, which is important for the regulation of paracellular 
permeability 50, interacts via multiple adaptor proteins and with F-actin 28, 49, 223, 
224; hence, functionally important actin-binding proteins might be difficult to 
identify because of functional redundancy.  
 
Nonmuscle Myosin heavy chain II isoforms seem to be major players in Rho-
regulated junctional regulatory mechanisms. Myosin IIA and IIB have been 
linked to cell-cell adhesion in mouse knockout models 225, 226. Downregulation of 
Myosin-IIA, but not of IIB or IIC, expression in SK-CO15 colonic epithelial cells 
resulted in profound changes of cell morphology and cell-cell adhesion 227. 
Myosin II associates with the actin cytoskeleton underlying the apical junctional 
complex and recruitment has been proposed to be mediated by ZO-1 and ZO-2 
228. However, the data supporting the importance of ZO proteins for junctional 
recruitment of Myosin are controversial. In some cell types, depletion of ZO-1 is 
sufficient to inhibit junctional recruitment of Myosin II and in others it favours 
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junctional accumulation 86, 222. It is thus unlikely that ZO proteins play a direct 
role in Myosin II recruitment. 
 
Regulation of Myosin activity seems to play a major role during junction 
assembly and disassembly, as well as for the regulation of paracellular 
permeability. ROCKs (Rho associated kinases) are Ser/Thr kinases that are 
important Rho effectors that regulate TJ permeability 26, 229. ROCKs are known 
to stimulate the activation of Myosin by regulating the phosphorylation state of 
the regulatory light chain (MLC2) 230. ROCKs also phosphorylate and inactivate 
the Myosin phosphatase target subunit (MYPT), leading to inactivation of the 
phosphatase and, hence, increased Myosin activity 231.   
 
Myosin phosphorylation is also mediated by Myosin light chain kinase (MLCK), 
and pharmacological inhibition of MLCK prevents both MLC2 phosphorylation 
and regulation of TJ barrier function in response to physiological and 
pathophysiological stimuli, such as Na+-nutrient co-transport, bacterial infection 
or proinflammatory cytokines 232-235. Overexpression of MLCK in mature 
monolayers further supports a role of MLCK in the regulation of permeability 
and suggests that MLC2 phosphorylation alone is sufficient to induce TJ 
regulation in the absence of any upstream stimuli 236. However, it has been 
suggested that at least in endothelial cells the gradual increase in permeability 
induced by TNF-alpha does not reflect contractile mechanisms mediated by 
Rho, ROCK, and MLCK, but involves long-term reorganization of tight junction 
proteins 218. 
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Apart from the non-muscle heavy chain Myosin II pathway, TJ permeability may 
be controlled by other Rho effectors such as the mammalian Diaphanous-
related formin (mDia), which promotes actin nucleation and filament 
polymerization and is known to represent an opposing Rho effector to ROCK in 
the regulation of AJ formation and actin dynamics 237. In endothelial cells, for 
example, angiopoietin-1 prevents VEGF-induced endothelial permeability by 
sequestering Src through mDia 238. ROCK may also regulate TJ permeability by 
regulating actin filament stability. Another known substrate for ROCK is LIM 
kinase; activated LIM kinase phosphorylates and inactivates cofilin, an actin-
depolymerizing factor, and therefore acts to stabilize the junctional actin 
cytoskeleton 239, 240. The importance of cofilin-based mechanisms is also 
supported by the observation that capsaicin-induced cofilin activation in an 
intestinal epithelial cell line resulted in a decrease in TER as well as changes in 
the localization of TJ proteins and altered the f-actin structure 241. Furthermore, 
LIM kinase 1 promotes endothelial barrier disruption and neutrophil infiltration in 
mouse lungs 242. In agreement, m-Calpain, a cysteine protease, which can 
inhibit RhoA activation, antagonizes overactivation of RhoA/ROCK/LIMK2 
signalling and subsequent cytoskeletal rearrangement in endothelial cells, 
which leads to barrier enhancement 243. The fact the TJ-associated polarity 
protein Par-3 mediates the inhibition of LIM kinase 2 to regulate cofilin 
phosphorylation and tight junction assembly 244 further supports a role of LIM 
kinases in TJ dynamics and adds an additional level of complexity in the 
understanding of the regulation of paracellular permeability by actin 
rearrangements.  
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An alternative mode of regulation of TJ by Rho may involve direct modifications 
of junctional membrane proteins. When a constitutively active form of RhoA was 
over-expressed in MDCK cells, Occludin phosphorylation was increased, 
suggesting that Rho signalling can directly affect TJ proteins 245. When Rho was 
stimulated with either LPA or histamine in endothelial cells, phosphorylation of 
the carboxy terminal domain of Occludin increased, which is thought to regulate 
the interaction of Occludin with the junctional actin cytoskeleton and, hence, 
paracellular permeability 229. Direct phosphorylation of Occludin and claudin-5 
by ROCK has been reported in brain endothelial cells, correlating with 
diminished barrier tightness and enhanced monocyte migration across BBB 
induced by human immunodeficiency virus-1 encephalitis  246. It thus seems 
that Rho signalling can affect paracellular permeability by different molecular 
mechanisms ranging from regulation of actinomyosin contraction and actin 
polymerization to direct regulation of junctional membrane proteins (Figure 1.3).  
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Figure 1. 3 RhoGTPases and regulation of paracellular permeability Different  signaling  proteins  have  been  implicated  in  the  regulation  of  TJ  paracellular  permeability. The  left  hand  side  represents  how  TJ  permeability may  be  regulated  by  RhoGTPase  signaling.  The transmembrane  proteins  (dark  green)  represent  Claudins,  Occludin  and  Tricellulin  as  these components  are  known  to  regulate  paracellular  permeability.  The  cytoplasmic  adaptors  proteins (purple)  represent  proteins  such  as  ZO‐1,  ‐2  and  ‐3, which  act  as  linkers  to  the  actin  cytoskeleton. Stimulation  of  Rho  by  GEF‐H1,  a  TJ  associated  guanine  nucleotide  exchange  factor,  results  in activation of Rho specific effectors such as Rho kinases (ROCKs).  ROCKs phosphorylate and inactivate MLCP (Myosin light chain phosphatase), but phosphorylate and activate MLC2 (Myosin light chain II), leading  to  activation  of  actinoMyosin  contractility  and  increased  paracellular  permeability.  A  Rho effector that contributes to actin filament nucleation is mDia. Rac and Cdc42 have also been linked to actin  cytoskeleton,  cell  polarity  and  paracellular  permeability  regulation.  Possible  Rac  and  Cdc42 effectors in actin rearrangement and paracellular permeability are PAKs and N‐WASP. Alternatively, ROCK can directly phosphorylate TJ proteins such as Occludin and Claudin‐5. Different PKC isoforms  (represented on the right) are also known to phosphorylate TJ proteins, and MLCK which is known to contribute to the regulation of TJ permeability. Diagram used with permission from American journal of physiology 4. 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Tight junction and regulation of gene expression by RhoGTPases  
 
Different molecular mechanisms that regulate gene expression have been 
associated with TJs 66.  These include factors that may regulate chromatin 
structure (e.g., SAF-B), polyadenylation (i.e., symplekin), as well as various 
transcription factors that associate with junctional proteins (e.g., AP-1, Myc); 
generally, these associations are thought to be part of regulatory mechanism 81, 
247, 248.  
Only one TJ-associated signalling pathway has thus far linked RhoGTPase 
signalling to gene expression. This mechanism is based on ZONAB, a Y-box 
transcription factor that binds to the SH3 domain of ZO-1 (Figure 1.4). ZO-1 
binding inhibits ZONAB by cytoplasmic sequestration 80. The ZO-1/ZONAB 
pathway regulates cell proliferation and, in a three-dimensional culture system, 
epithelial morphogenesis 82, 211. ZONAB function can be activated by the heat 
shock protein Apg-2, which binds to ZO-1 and thereby stimulates ZONAB 
dissociation, which also influences proliferation and epithelial morphogenesis 
249, 250. Furthermore, RalA, a member of the Ras superfamily of small GTPases, 
inhibits ZONAB transcriptional activity in a cell density dependent manner and 
expression of oncogenic Ras alleviates transcriptional repression by ZONAB in 
a RalA-dependent manner 251. 
 
A second mechanism of ZONAB stimulation has recently been identified that is 
based on Rho signalling 215. ZONAB activity is Rho-dependent, and the 
transcription factor forms a complex with the TJ-associated Rho activator GEF-
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H1. Modulation of GEF-H1 activity by depletion or overexpression consequently 
inhibits or stimulates, respectively, transcriptional activity of ZONAB. Both GEF-
H1 and ZONAB regulate G1/S phase transition, and GEF-H1 stimulated 
expression of cyclin D1, a cell cycle regulator and key target of RhoA signalling, 
is at least in part mediated by ZONAB 215. 
 
GEF-H1 is regulated by different mechanisms and some also affect regulation 
of gene expression, such as Cingulin 64, 214. However, it is not known whether 
any of those genes are indeed ZONAB target genes. An additional complication 
is that not all mechanisms that stimulate GEF-H1 also activate ZONAB. For 
example, stimulation with TNF-α activates GEF-H1 215, 219, but does not 
stimulate ZONAB activity 215. This suggests additional mechanisms that 
modulate ZONAB activity in different cellular and regulatory contexts. For 
example, RalA, another small monomeric GTPase of the Ras superfamily, is 
known to be activated by TNFα 252, and active RalA binds and inhibits ZONAB 
activity 251; therefore, RalA might inhibit ZONAB in response to TNFα.  
Although ZONAB represents a first direct mechanism that links Rho GTPase 
signalling at TJs to the regulation of gene expression, it is likely that different 
mechanisms exist and it will be important to identify these pathways and 
determine how they interact with each other. Moreover, there is still very little 
known about the pathological relevance of these mechanisms. ZONAB and 
GEF-H1 expression is deregulated in different types of tumours 191, 253-255; 
however, whether this is a cause or a consequence of tumourigenesis is not 
known.
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Figure 1. 4 Tight junction and regulation of gene expression by RhoGTPases Indicated are the main transcriptional pathways involving TJ associated proteins linked to expression of genes that regulate proliferation, differentiation and TJ permeability in response to Rho signaling. Arrows represent  activation  and  T  shaped  lines  represent  inhibition.  If  such  lines  and  arrows  are  in  red,  they represent  a  direct  interaction.    ZONAB  forms  complexes  with  both  symplekin  and  CDK4,  but  it  is  not known whether  these  three proteins  form a  tripartite  complex.  ZO‐1, by  regulating ZONAB  localization, has  been  linked  to  suppression  of  erbB‐2  expression  and  increased  expression  of  PCNA  and  cyclin D1. RalA/ZONAB  association  in  a  GTP‐dependent  manner  inhibits  transcription  of  an  erbB2  reporter promoter, which is also suppressed by symplekin via interaction with ZONAB. Symplekin and ZONAB have also been linked to the stimulation of cyclin D1 expression. ZONAB‐dependent expression of cyclin D1 is also activated by GEF‐H1‐stimulated Rho activation. Cingulin regulates claudin‐2 expression by a RhoA‐dependent  transcriptional  mechanisms.  Cingulin  also  interacts  with  GEF‐H1  and  inhibits  its  activity; however  is  unknown whether  GEF‐H1  is  involved  in  claudin‐2  expression.    Although  one might  expect significant  cross‐talk  between  the  different  regulatory  mechanisms  that  target  ZONAB,  how  far  that indeed  occurs  is  not  known.  Note,  not  all  mechanisms  that  target  GEF‐H1  also  regulate  ZONAB  in  a corresponding manner, suggesting that GEF‐H1 may be part of different pathways or that other regulatory mechanisms  can  counteract  Rho  stimulation  of  ZONAB  (e.g.,  inhibition  by  RalA).  Diagram  used  with permission from American journal of physiology 4  . 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RhoGTPases are crucial components of signalling mechanisms associated with 
TJs. It is clear that they are major factors in regulating TJ permeability and in 
transmitting signals from TJs that regulate gene expression and thus control 
cellular behaviour including proliferation and differentiation.  
 
RhoGTPase dependent regulation of the actin cytoskeleton is very important for 
processes requiring junction dynamics, such as assembly and the regulation of 
paracellular permeability. The available evidence suggests that a major 
pathway by which RhoGTPases regulate permeability of TJs involves GEF-H1 
and RhoA that leads to ROCK activation and regulation of non-muscle Myosin II 
activity, resulting in actinomyosin contractility. It seems, however, that 
alternative RhoGTPase dependent mechanisms that regulate actin filament 
dynamics may also play an important role in the regulation of TJ permeability. 
Activation of RhoGTPase signalling may also result in the direct modification of 
TJ transmembrane proteins by inducing phosphorylation and, thereby, resulting 
in altered permeability.  
 
TJs can also regulate gene expression via RhoGTPase signalling. The 
interaction between activators of RhoA, such as GEF-H1, and the transcription 
factor ZONAB provide a mechanism by which TJs are linked to RhoA signalling 
and gene expression of proliferative genes. However, our knowledge about the 
spatial and temporal regulation of RhoGTPase activity and the interactions with 
different effector pathways is still limited. The identification of RhoGTPases 
regulatory and effector pathways in a TJ-specific context in response to 
 67 
physiological and pathophysiological stimuli to control cell behaviour remain a 
crucial challenge for the future. 
 
Structure and function of the Cornea   
The cornea is an important component of the eye.  It functions as an optical 
lens that transmits light clearly with a marked refractive power and also 
contributes to the rigid structure of the eyeball. The cornea is unlike most other 
organs in the body as it is avasular and transparent. It possesses a relatively 
simple anatomical structure consisting of three main layers. The outmost of 
these being the corneal epithelium followed by the stroma and lastly the 
endothelium see Figure 1.5.      
The corneal epithelium serves as an important barrier to protect the eye from 
the outside environment. Its integrity is essential for the maintenance of corneal 
transparency. The corneal stroma is populated by cornea fibroblasts and 
consists of highly order arrays of collagen fibrils. The ordered arrangement of 
collagen fibers is essential for corneal transparency 256. This arrangement is 
maintained by the tight regulation of water content of the stroma through the ion 
pumping activity of the endothelial layer. The endothelium consists of 
monolayer of cells abundant in mitochondria that are located at the posterior 
surface of the cornea and faces the anterior chamber of the eye. 257 Its 
physiological function is to control the transport of solutes and nutrients from the 
aqueous humor across to the posterior surface of the cornea and transport 
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excess water back to the aqueous humor to maintain the cornea in a slightly 
dehydrated state that is essential for its optical transparency  257. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Structure of the Cornea Above  is  a  histological  section  of  Human  Cornea  that  consists  of  five  different  layers  .  (1)  The  Corneal epithelium is the outer most layer and consists of five‐six cell layers thick. The most basal layer is composed of  cells  that have a  cuboid morphology. Above  the basal  layer are  two additional  layers of  cells known as wing cells because of their wing‐like morphology, above these are two layers of more flattened differentated epithelial cells that from the external surface of the corneal epithelium.   (2) The corneal epithelium sits on thin basement known as Bowma’s layer membrane consisting of collagen fibrils. This membrane separates the epithelium from the stromal layer beneath. (3) The largest layer of the cornea is the stroma it consists of regular  parallel  arrays  of  collagen  filaments  that  permit  scattered  light  to  be  eliminated  by  destructive interference, thus allowing the cornea to appear transparent and permit the efficient transmission of light to the lens. (4) Below the stroma is basement membrane known as Descement’s membrane this membrane is produced by  the endothelial  layer and consists of a different  type of collagen (collagen  type VIII)  than  the stroma.  (5)  The  most  basal  layer  of  the  cornea  is  the  a  single  layer  of  endothelia  cells  Its  physiological function  is  to control  the  transport of  solutes and nutrients  to and  from the cornea  to maintain  the water homeostasis of the stroma that is essential of for the optical transparency of the cornea (6) The stroma of the cornea  is  often  populated  by  corneal  fibroblasts  of  which  the  nuclei  can  be  seen  stained  purple..  Picture adapted from  http://www.images.missionforvisionusa.org/anatomy/2005_10_01_archive.html . 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Corneal epithelium biogenesis and repair. 
 
The corneal epithelium is in constant state of healing and renewal, cells are 
constantly shed from the surface and replenished from cells moving centripetal 
from the limbus and then anteriorly from the basal layer of the epithelium. 258 
The limbus is located on the border of the cornea and the sclera (the white of 
the eye)1. The current prevailing theory is that the self–renewing properties of 
the cornea are reliant on a small population of stem cells located in the basal 
region of the limbus in a specialised area or niche known as the palisades of 
Vogt 1, 259. These stem cells can divide symmetrically to renew themselves or 
asymmetrically to produce transiently amplifying cells that migrate centripetally 
to populate the basal layer of the corneal epithelium 1 (Figure 1.6). The corneal 
epithelium is a dynamic barrier that protects the eye from the environment. It is 
constantly assaulted from an external maelstrom of environmental insults, such 
as chemical, physical and microbial damage. It is estimated that the cornea 
epithelium renews its entire surface every 7-10 days 258.  For the corneal 
epithelium to be able to maintain a state of equilibrium the rate of proliferation of 
basal corneal epithelium cells plus the rate of proliferation and centripetal 
migration must equal the rate of epithelial cell loss from the surface 260. 
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Figure 1.6 The human limbus a site of corneal epithelial stem cells.  Limbal epithelial stem cells reside in the basal layer of the epithelium (Ep), which undulates  at  the  limbus.  Transient  amplifying  cells  (TACs)  divide  and  migrate towards the central cornea (arrowed) to replenish the epithelium, which rests on Bowman's  layer  (BL). The stroma (St) of  the  limbal epithelial  stem cell niche  is populated with fibroblasts and melanocytes and also has a blood supply. Diagram from 1. 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The coordinated regulation of cell proliferation, cell-matrix and cell-cell 
adhesions are crucial to the corneal wound healing response 261. The first 
phase of the wound healing response is a migration of epithelial cells over the 
affected area. This requires cells to attach to the underlying matrix and spread 
over it. Experiments from corneal wound healing experiments in rats show this 
movement is in two phases 262. Shortly after wounding there is an initial ruffling 
and sliding of the basement monolayer (sheet like migration) followed by a 
mass movement of the above layers. During the sheet like movement the 
basement monolayer of epithelial cells have to detach from the remaining 
stratified epithelium a process that involves the disassembly of hemi-
desmosomes (structures linking the cells in the basement monolayer to the 
stratified layers above) 263 and a spreading out over a wide area using 
lamellipodia projections. Attachment to the extracellular matrix ECM is mediated 
by family of receptor proteins known as Integrins 264, which are localised in the 
plasma membrane to form structures known as focal adhesions that are 
structures that are somewhat similar to cell-cell junctions, in that they act as 
platforms for intercellular signaling molecules and are also linked to the actin 
cytoskeleton 264. Intergrins exist as heterodimmers consisting of α and β 
subunits. A large variety of different Integrin subunits are expressed in the 
corneal epithelium 265 . 
 Different matrix substrates are found in the corneal epithelium basement 
membrane (see Figure 1.5), often collagen type I being the predominant matrix 
component, but also collagen type IV, fibronectin and laminin 261. Adhesion to 
ECM has to be tightly regulated as if the adhesions are too strong then cells will 
not be able to migrate. It is therefore proposed that cell movement is likely to 
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depend on a cycle of adhesion and de-adhesion of the cells to the ECM. This 
cycle is likely to depend on degradation of different ECM substrates and 
Intergrin receptors.  For example injury to the cornea often results in the 
destruction of the basement membrane exposing the stroma to the outside 
environment. Corneal epithelial cells are able to migrate over the stroma in the 
absence of the basement membrane. During this initial stage of wound healing, 
fibronectin is synthesised by the epithelial cells and deposited at the site of 
injury and therefore serves as a temporary matrix for epithelial cells to migrate 
over 266. However after the wound is completely healed the expression of 
fibronectin is down regulated and normal complement of matrix proteins is 
restored 266. 
 
Cell-cell adhesion also plays an important role in corneal wound healing. Like 
with cell-matrix interactions, cell-cell adhesion needs to be tightly regulated, for 
example if cells adhere too tightly to each other they might not be able to 
migrate to repair the damaged area. Desmosomes are a type of cell junction 
that contribute to the physical mechanical strength of a tissue as discussed 
previously. Immunostaining experiments observing Desomsomal 
transmembrane proteins, Desmoglein 1 and 2 has been demonstrated that they 
are present in the wing cell layers of rat corneal epithelium 267. After injury 
induced by photoablation of a section of the corneal epithelium, Desmoglein 1 
and 2 proteins were no longer apparent in migrating epithelial cells, however 
expression of these proteins was present after a period of three days after 
photoablation. Thus demonstrating cell-cell contacts in corneal epithelial cells 
need to be able to go through cycles between of adhesion and de-adhesion in 
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order to migrate correctly to produce an effective corneal wound healing 
response. 
 
The rapid reformation of TJ is important in the corneal wound healing response. 
Studies have demonstrated that TJs are the first junctions to form most rapidly 
after wounding of the corneal. Other studies have shown the TJ protein 
Occludin is expressed in the uppermost superficial and sub-superficial layers of 
cells 267. In addition injury of corneal epithelium by chemical removal of the 
superficial cells caused an increase in expression of ZO-1 in sub-superficial 
cells 268. These observations might suggest that the expression of TJ proteins in 
sub-superficial layers permits a rapid response to restore barrier function to 
prevent exposure and activation of the mesenchymal tissue from environmental 
stimuli.  
 
Damage to the cornea often leads to the release of many different cytokines 
and growth factors that influence cell proliferation and migration 269. For 
example EGF and TGFβ are known to enhance corneal epithelial cell migration 
270. Whereas pro-inflammatory cytokines, such as TNFα and IL-1α to also have 
been shown to enhance cell corneal migration, but only in in vitro assay 
systems when cells are plated on fibronectin 271.  
 
Under certain clinical conditions healing of the cornea is delayed 272. Thus 
understanding how corneal epithelial biogenesis and repair is regulated is not 
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only of biological interest, but also of clinical relevance for the treatment of 
diseased corneas.   
RhoGTPase signalling as discussed previously can regulate cell-matrix and 
cell-cell junction formation, migration and proliferation. RhoGTPase are also the 
major downstream targets of physiological and pathological signalling 
pathways, activated by growth factors and inflammatory signals. Several 
studies have demonstrated the importance of the Rho signalling for wound 
healing in corneal epithelial cells by regulating migration, junction formation and 
proliferation 273, 274. However how RhoGTPase signaling is regulated in a co-
orditained manner to control corneal biogenesis and repair remains largely 
unknown.  
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Experimental aims and plan 
 
Aims 
The corneal epithelium forms a barrier to protect the surface of the eye from the 
external environment. For normal vision corneal integrity must be maintained; 
corneal integrity can be compromised by certain diseases, injury or drug 
treatments. It is of clinical and biological interest to understand how corneal 
biogenesis and repair is regulated in health and disease. As discussed 
RhoGTPases are molecular switches that are involved in epithelial 
differentiation, cell-cell adhesion, migration, as well as epithelial proliferation. 
They are major targets of junctional regulatory mechanisms and are also major 
downstream targets of physiological and pathological signalling pathways, 
activated by growth factors and inflammatory signals. It is therefore of 
importance to determine the complex molecular mechanisms present between 
junction assembly and regulation and RhoGTPases, in order to understand 
corneal epithelial biogenesis and repair, in health and disease. The aim of this 
project is to identify regulators and effectors of RhoGTPases in corneal 
epithelial cells that regulate cell adhesion and junction formation, as well as Rho 
regulated signalling pathways that regulate gene expression using a siRNA 
based functional screening approach.  
 
 76 
  
 
 
Plan 
The primary aim of this project will be achieved using a custom-made siRNA 
library that contains pools of siRNAs to genes that are regulators or 
downstream effectors of RhoGTPases. Using this library, functional siRNA 
screens will be performed to observe junction formation and assembly, as well 
as gene expression. The screen will be performed in human corneal epithelial 
cells (HCE), an immortalised SV40 T antigen transformed cell line. HCE cells 
form functional adherens and tight junctions and spontaneously differentiate, if 
grown in keratinocyte serum free medium. 
 
To observe junction assembly, immunofluorescence microscopy will be used. 
Cells will be grown on glass cover-slides and transfected with individual 
components from the siRNA library. This will be performed in duplicate to allow 
staining with two sets of antibodies to membrane and cytosolic components of 
junctions, as well as Golgi complex and DNA markers, to asses the effect on 
junction assembly and cell morphology. Luciferase based reporter assays will 
be used to monitor the effect on gene expression. The siRNA screen will focus 
on identifying candidates that have an effect on the transcriptional regulator NF-
κB, a transcription factor regulated by different RhoGTPases and an important 
mediator of cell survival and the inflammatory response.  
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Candidates identified in the junction assembly screen will be validated using 
individual siRNAs, derived by deconvolution of the original siRNA pool. Due to 
the time limits of this project it may not be possible to validate all candidates 
from the junction assembly and NF-κB activation screens. However priority will 
be given to first validating targets that affect junction assembly.  Because of 
constraints on time for this project one or two of the validated candidates will be 
fully characterised using biochemical and cell biological assays for RhoGTPase 
signalling and epithelial cell behaviour; Rho-activation assays to determine 
RhoGTPase specificity, calcium switch assays to observed de novo junction 
formation and effects on permeability, techniques for observing protein-protein 
interactions such as co-immunoprecipitations and GST pull down assays and as 
well as effects on cell migration using wound healing assays.  
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Materials and Methods  
All chemicals are from Sigma unless otherwise stated.  
DNA methods  
Bacterial transformation 
CaCl2 competent bacteria (E.Coli strain DH5α) were thawed on ice. 1.7µl of a 
1.4M β-mercaptoethanol was added to 100µl of bacteria and incubated for 10 
minutes. 10ng of the appropriate plasmid DNA was added to each 100µl and 
mixed by pipetting up and down once. The bacteria were left to incubate on ice 
for 30 minutes and then heat shocked for 45 seconds at 42°C, after which they 
were immediately put back on ice for 3 minutes. 900µl of LB medium was 
added and the tube was incubated for 45 minutes at 37°C. 100µl of the LB 
bacteria suspension were plated onto LB agar plates containing 100µg/ml 
Ampicillin or 50 µg/ml Kanamycin. The plates were placed at 37°C and the 
bacteria left to grow overnight.   
 
Plasmid DNA Mini/ Midi preps  
A single bacterial colony transformed with the appropriate plasmid was picked 
using a sterile pipette tip and placed into 5ml of LB containing 100µg/ml 
Ampicillin for Mini or 200ml for Midi preps.  This was left to grow overnight in an 
incubator at 37°C with shaking at 225rpm. The following day the bacteria were 
centrifuged at 5000rpm for 30mins and processed according to the standard 
Qiagen Mini and midi prep protocols. The plasmid DNA was re-suspended in 
10mM Tris pH 8.5 0.1mM EDTA. Concentration and purity of plasmid DNA 
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samples were obtained by using a spectrophotometer (Themo Scientific Helios 
β) to measure the absorbance of samples at wavelengths of 260nm and 280nm.   
 
DNA agarose gel electrophoresis 
A 1 % agarose gel was prepared by dissolving 1 g of agarose (Invitrogen) in 
100 ml of TAE buffer (40 mM Tris-acetate, 1 mM EDTA pH8.0) Ethidium 
bromide (1µg/ml) was added prior to gel prior to pouring. 6X DNA loading buffer 
(30% glycerol (v/v), 0.25% bromophenol blue (w/v), 0.25% xylene cyanol (w/v)) 
was added to DNA samples to achieve a final concentration of 1X DNA loading 
buffer. Samples were typically were run at 100 V for approximately 1 hr. DNA 
bands were visualized using a UV transilluminator. 
 
Polymerase Chain Reaction (PCR)  
Standard PCR to amplify fragments for sub-cloning was carried out using 100ng 
of template plasmid DNA and 100pmol of each primmer (Eurofins/MWG see 
table) reactions were carried out in 50µl total volume using 1 µl (2.5Units) of 
expand high fidelity polymerase (Roche Applied Science) and 5mM of dNTP 
mix (Roche Applied Science) where necessary 10% DMSO was added to the 
reaction mix. Reactions were carried out in a PCR machine using a typical 
programme.  
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1    94°C for 2 minutes 
2    94 °C for 30 seconds                
3    50°C for 45 seconds  
4   72°C for 1kb/minutes 
5  Step 2 for X29 cycles   
6    72°C for 10 minutes  
 
Restriction enzyme digests, DNA purification and ligations  
 Typically 5µg plasmid DNA or PCR products were digested in a final volume of 
30µl, using 0.5µl of the appropriate restriction enzymes (New England Biolabs) 
in the provided buffer solutions. Reactions were incubated at 37°C for 1 hr. 
Digested DNA fragments were purified by running on agarose gels, excising the 
appropriate bands under a long wave length UV translumintor, and purifying the 
DNA by adding 1ml of 6M solution of Sodium Iodide and melting the agarose at 
70°C for 10 minutes, allowing to cool and incubating with 50µl silica beads 
(Sigma) for 10 minutes. Samples were then washed twice with silica wash 
buffer (50mM NaCl, 10m|M Tris HCL pH 7.5 2.5mM EDTA, 50% v/v Ethanol). 
DNA was eluted from the beads in 30µl of 10mM Tris pH 8.5 0.1mM EDTA.  
Ligations were carried out using a 1:3 molar ratio of Vector: Insert in a final 
volume of 10µl, using 1 µl ( 5 units) of T4 ligase (Roche) in the provided buffer. 
Reactions were incubated overnight at 4°C and the entire volume used to 
transform 100µl DH5a E.coli. 
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Site directed mutagenesis 
Site directed mutagenesis was performed to generate p114RhoGEF mutants. 
PCR was performed as stated in PCR methods above, but using 2.5 Units of 
Pfu turbo,(Stratagene), 200ng of template DNA and double the normal dNTP 
concentration (see Table 2.0 for template and primer sequences used), using 
the following PCR program ; 
1    94°C for 3 minutes 
2    94 °C for 30 seconds                
3    48°C for 1 minute 
4    68°C for 17.5minutes 
5    Step 2 for X 29 cycles  
6    68°C for 17 minutes  
25µl of this PCR reaction along with 200ng of template DNA as a control was 
digested in 50µl with DpnI (New England Biolabs) for 1.5 hours to digest the 
original methylated template. Samples were heated for 20 minutes at 80°C to 
inactivate DpnI. 4µl of this digest was used to transform 100µl of E.coli DH5α 
and transformed as for normal protocol apart from reducing the recovery time in 
LB broth to just 15 minutes before plating onto LB agar. Several colonies were 
picked and plasmid DNA obtained and sequenced to confirm the mutation.  
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DNA constructs   
All DNA constructs used in this study are listed below in Table 2.0  
 
Plasmid name  Description and Source /Construction 
pCDNA3‐ Myc‐ p114RhoGEF   N‐terminal myc tagged p114RhoGEF kind gift from 188 
pCDN4‐TO‐VSV  Mammalian cell expression vector allows either constitutive or Tetracycline  inducible  expression  of  C‐terminal  VSV  tagged protein.  (Matter Lab) made from pCDNA4‐TO (Invitogen). 
pCDNA4‐TO‐VSV‐GEF‐H1  C‐terminal VSV tagged full length GEF‐H1 (Matter lab) 64 
pCDNA4‐TO‐Myc Cingulin  C‐terminal Myc tagged full length Cingulin (Matter lab) 64 
pCDNA6‐TR  Tetracycline repressor (Invitrogen) 
pCDNA4‐TO‐VSV p114RhoGEF FL  C‐terminal  VSV  tagged  full  length  p114  made  by  PCR  using pCDNA3  Myc  p114RhoGEF  as  template  using  primers                          5’GCCTATCTTAAGGGTATGACGGTCTCTCAGAAAGGG3’ 
5’GCTATT‐CCGCGG‐AA‐GAAGAAGATGACGTCTTCTTTGC3’ 
Cloned into pCDNA4TOVSV using AflII and Sac II sites 
pCDNA4‐TO‐VSV  p114RhoGEF    ∆ DH  C‐terminal VSV tagged  p114 with deleted  DH domains made by  PCR  using  pCDNA3  Myc  p114RhoGEF  as  template  using  primers  
5'GCAATACTTAAGGGTATGGAGTGTGAGAAGGGCCAGCGCC3’ 5’GCTATT‐CCGCGG‐AA‐GAAGAAGATGACGTCTTCTTTGC3’ 
Cloned into pCDNA4TOVSV using AflII and Sac II sites 
pCDNA4‐TO‐VSV p114RhoGEF CTD  C‐terminal VSV tagged p114 with deleted DH and PH domains made  by  PCR  using  pCDNA3  Myc  p114RhoGEF  as  template using  primers 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5’GCCATTCTTAAGGGTATGCAAAGGGCTGTGGAGAGCTGCC3’ 
5’GCTATT‐CCGCGG‐AA‐GAAGAAGATGACGTCTTCTTTGC3’ 
Cloned into pCDNA4TOVSV using AflII and Sac II sites 
pCDNA4‐TO‐VSV  p114RhoGEF Y260A  C‐terminal  VSV  taggedp114  with  catalytically  dead  GEF activity made using single step PCR site directed mutagenesis template pCDNA4TOVSV p114RhoGEF FL  primers 
5’CATAACCAAAGCCCCAGTGCTGG3’ 
5’CCAGCACTGGGGCTTTGGTTATG3’ 
pGEX43T  Bacterial protein expression vector for making N‐terminal GST tagged fusion proteins (GE Lifesciences) 
pGEX43T‐p114RhoGEF FL  N‐terminal GST tagged p114 full length fusion protein made by PCR  using  pCDNA4‐TOVSV  p114RhoGEF  FL  as  a  template using primers  
5’AAAAAA GAATTCCATGACGGTCTCTCAGAAAGGG3’ 
5’AAAAAACTCGAGTTA‐GAAGAAGATGACGTCTTCTTTGC3’ 
Cloned into pGEX43T using EcoR1 and XhoI sites 
pGEX43T‐p114RhoGEF NTD 1‐321  N‐terminal  GST  tagged  p114    fusion  protein  containing  N terminal  domain  1‐321bp  fragment    made  by  PCR  using pCDNA4‐TOVSV p114RhoGEF FL as a template using primers  
5’AAAAAA ‐ GAATTC‐C‐ATGACGGTCTCTCAGAAAGGG3’ 5’AAAAAACTCGAGTTA‐GAAGAAGATGACGTCTTCTTTGC3’ 
Cloned into pGEX43T using EcoR1 and XhoI sites 
pGEX43T‐p114RhoGEF PH  N‐terminal  GST  tagged  p114  fusion  protein  containing  PH domain  958‐1416bp  fragment  made  by  PCR  using  pCDNA4‐TOVSV p114RhoGEF FL as a template using primers  
5’AAAAAAGAATTCCTCTTCCAGCAAACTCAAGAACG 3’ 
5’AAAAAACTCGAGTTAGAAGAAGATGACGTCTTCTTTGC3’ 
Cloned into pGEX43T using EcoR1 and XhoI sites 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pGEX43T‐p114RhoGEF CTD   N‐terminal  GST  tagged  p114  fusion  protein  containing  1308‐3051bp  fragment  made  by  PCR  using  pCDNA4‐TOVSV p114RhoGEF FL as a template using primers  5’AAAAAA GAATTCCCAAAGGGCTGTGGAGAGCTGCC3’ 
5’AAAAAACTCGAGTTAGAAGAAGATGACGTCTTCTTTGC3’ 
Cloned into pGEX43T using EcoR1 and XhoI sites 
p NF‐κB  Contains  the NF‐ κB   promotor region of  ICAM‐1 upstream of  firefly luciferase  
pTCFwt  B‐Catenin/TCF reporter (Matter lab) 
pTCFmut  B‐Catenin/TCF  protor  containing  mutated  TCF  binding  sites (Matter lab). 
pRLEBN  Minimal  erb2‐b  promotor  that  lacks  ZONAB  binding,  driving renilla luciferase expression  251 
pIkBα S 32,34 A  Contains mutant non phosphorylatable IkBα that acts as a NF‐κB repressor (Matter lab) 
p‐Raichu‐RhoA  Allows  active  RhoA  levels  to  be  monitored  spatially  in    live cells.  Contains  YFP  fused  to  the  Rho  binding  domain  of  PKN fused  to  RhoA‐CFP  (kind  gift  from  M.Matsuda,  Osaka University Japan) 275 
shRNA p114 plasmids 1 and 2   Expression  of  shRNA  duplexes    against  p114RhoGEF  shRNA the  sequences  5’‐AAGACACGTCGGGACGCTTG‐3’  and  5’‐AACTACGTCATCCAGAAAATC‐3’    were  cloned  into  plasmid containing a tetracycline regulated mouse U6 promotor 64.  
 
Table 2.0 DNA constructs All DNA constructs used and made are listed above, where a construct has been made shown are the original  template  as  well  as  the  primer  sequences  used  restriction  enzyme  sites  or  where  sites  of point  mutations  are  highlighted  in  red.  All  constructs  when  appropriate  were  confirmed  by sequencing by (Eurofins/MWG). 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Protein techniques  
Preparation of polacylamide gels  
Polyacrylamide gels of the required percentage were prepared a day before 
use,  using a MightySmall minigel electrophoresis system.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Separating gel  (100ml)  12%  10%  8%  6% 
1.5M Tris pH 8.8   25ml  25m  25ml  25ml 
Acrylamide/Bisacylamide mix 30%/ 0.8%  50ml  33.4ml  26.6ml  20ml 
Distilled water  23ml  39.4ml  46.4ml  53ml 
10% SDS  1ml  1ml  1ml  1ml 
10% APS  1ml  1ml  1ml  1ml 
TEMED  0.04ml  0.04ml  0.04ml  0.04ml 
5% Stacking gel  50ml 
0.5 M Tris pH 6.8   6.25ml 
Acrylamide/Bisacylamide mix 30%/ 0.8%  8.5ml 
Distilled water  34ml 
10% SDS  0.5ml 
10% APS  0.5ml 
TEMED  0.05ml 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Running 
Protein samples were prepared for SDS/PAGE analysis by washing cells twice 
with 1XPBS and then adding directly to the cells, one part 3X sample buffer 
(6%SDS, 30%glycerol, 0.003% bromo-phenol blue, 0.3M DTT, 0.1875M Tris/ 
pH6.8) and 2 parts distilled water to give a final 1X concentration of sample 
buffer. Samples were heated at 70°C for 10 minutes and passed 3 times 
through a 23 gauge micro-needle before loading. Gels were placed into a 
running tank filled with running buffer (25mM Tris, 250mM glycine pH 8.3 
0.1%SDS) samples were loaded and gels were run at constant current of 25mA 
per gel for 1 hour.  
 
Transferring /staining  
Polyacrylamide gels were carefully removed from the running apparatus and left 
to soak in transfer buffer (25mM Tris, 250mM glycine pH 8.3 0.1%SDS, 
20%MeOH) along with the nitrocellulose membrane (LI-COR) and Whatman 
paper for 30 minutes. Gels were transferred using a wet transfer apparatus 
(BioRad). Gels were transferred, typically two gels per tank for 2 hours at 4°C at 
100V constant and restricting the current to a maximum of 0.45mA. The 
efficiency of the transfer was assessed by staining the membrane with Amido 
black dye 0.1% for 30 seconds. Then de-staining with (20% MeOH 7.5% acetic 
acid) for 15 minutes. 
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Immunoblotting  
The Amido black stained membrane was washed 2 times for 1 minute in PBS, 
then incubated in blocking solution (5% milk or 5%BSA in PBS 0.1%Tween-20 
0.1%NaN3) for 30 minutes with agitation. The membrane was then incubated 
overnight at 4°C with agitation with the appropriate primary antibody, diluted in 
the blocking solution. The next day the membrane was washed three times for 
10 minutes with PBS 0.1% Tween-20 solution and then incubated with the 
appropriate secondary antibody diluted in PBS 0.1% Tween-20 for 1 hour. The 
membrane was washed twice for 10 minutes with PBS 0.1% Tween-20 solution 
and then once with PBS for 10 minutes. Specific proteins were detected with 
horseradish peroxidase conjugated secondary antibodies using enhanced 
chemiluminescence detection system (ECL, Amersham, Corp. Arlington 
Heights, IL), or detected using an Odyssey detector and IRDye-680- and 
IRDye-800CW-conjugated secondary antibodies (LI-COR). 
 
Immunoprecipitations  
For immunoprecipitations, a confluent 14cm plate of cells was extracted by 
using a cell scraper at 4°C with 2ml of Triton X100 0.5%PBS or GB buffer (10 
mM Hepes (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.5% sodium 
deoxycholate, 0.2% SDS. A cocktail of protease inhibitors, 10 µg/ml leupeptin, 
10µg/ml aprotinin, 10µg/ml pepstatin A 50µg/ml benzamide and 1 mM PMSF 
and phosphatase inhibitors, 10mM sodium fluoride (NaF), 10mM sodium 
pyrophosphate and 4mM sodium orthovanadate (Na3VO4) was added to both 
buffers prior to extraction.  1ml of extract was pre-adsorbed with 100μl of 
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inactive sepharose beads for 15 minutes on ice prior to incubation with 1.5μg of 
antibody conjugated overnight to Protein G sepharose beads for 2 hours at 4°C. 
Samples were washed twice with 1ml of 0.5% triton X100 PBS and once with 
PBS while being kept at 4°C before adding 60 μl SDS-PAGE sample buffer 
boiling for 10 minutes at 70°C and running 15μl on and SDS-PAGE gel. 
 
Expression of GST fusion proteins  
BL-21 pLysS E.coli (Invitrogen) were transformed with the appropriate plasmids 
and were plated onto LB agar plates containing 100µg/ml Ampicillin 34µg/ml 
chloramphenicol. The plates were placed at 37°C and the bacteria left to grow 
overnight.  A single colony was picked per construct into 150ml of LB broth 
containing 100µg/ml Ampicillin 34µg/ml chloramphenicol and grown overnight at 
37°C with agitation at 225rpm. The following day bacteria were centrifuged at 
5000rpm for 15 minutes and re-suspended in 500ml of LB broth containing 
100µg/ml Ampicillin and 0.5mM mM IPTG and placed at 25°C with agitation at 
225rpm for 2 hours to allow protein expression.  Bacteria were centrifuged at 
5000rpm for 15 minutes and re-suspended in 30ml of cold GST protein Lysis 
buffer (PBS /Triton x100 0.5%) containing 1mM DTT and protease inhibitors 10 
µg/ml leupeptin, 10µg/ml aprotinin, 10µg/ml pepstatin A 10µg/ml benzamide 
and 400 µM PMSF and incubated on ice for 30 minutes. The samples were 
then sonicated 3 times for 30 seconds on ice and centrifuged at 10000rpm for 
10 minutes. 15μl (0.5%) of sample was run on a 12% polyacryimide gel and 
stained with Coomassie blue to observe expression levels. Samples were used 
immediately or frozen at -80 °C for long-term storage.  
 90 
 
Purification GST fusion proteins 
For purification of GST fusion proteins, bacterial lysates were thawed on ice and 
the extract was adjusted with lysis buffer to give 30 ml fresh protease inhibitors 
(as stated above) were added and the whole 30ml was incubated with 1.5ml of 
30% Glutathione-agarose beads (Sigma) for 2 hours on a rotor at 4°C. The 
solution containing beads was loaded into a Pierce protein column (Thermo 
Scientific) equilibrated with lysis buffer. The column was washed twice with cold 
lysis buffer and twice with cold PBS. Fusion proteins were eluted with 25mM 
reduced Glutathione in 50mM Tris pH 8. Fractions were pooled and dialysed in 
dialysis tubing (8000MW: BioDesignDialysis tubing) overnight at 4 °C and then 
again for 5 hours at 4 °C against PBS. Protein concentration was quantified on 
SDS-PAGE gels stained with Coomassie blue and by using a 
spectrophotometer (Themo Scientific Helios β) to measure the absorbance of 
samples at wavelengths of 280nm.   
 
GST pull­down assays 
For GST pull-down assays cells were extracted in the same buffer and 
preadsorbed with inactived beads as described above for immunoprecipitations. 
15μg of GST fusion protein extracts were incubated with 50μl of 30% 
Glutathione-agarose beads (Sigma) and washed twice with cold GST lysis 
buffer and once with cold PBS. Cell extracts were incubated with the washed 
50μl of Glutathione-agarose beads coated with fusion proteins and incubated 
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for 2 hours at 4°C before washing and running on a SDS-PAGE gel as 
described above for immunoprecipitations.  
 
Lipid­protein binding assay 
For Lipid –protein interaction assays PIP strip membranes (Echelon 
Biosciences Inc) were blocked in 1% milk PBS for 2 hours at room temperature 
prior to incubation with 1µg/ml of the appropriate fusion proteins ; GST alone, 
the C1 and PH domain of GEF-H1, the PH domain of P114RhoGEF, as well as 
PIP2 Griptm containing the PH domain of PLCδ for a positive control (Echelon 
Biosciences Inc) in 1% milk PBS overnight 4°C with agitation. Membranes were 
washed three times for 10 minutes with PBS 0.1%Tween-20 solution and then 
incubated with the GST antibody 1:2000 in 1% milk PBS 0.1% for 2 hours at 
room temperature. Membranes were washed 3 times as described above 
before adding the secondary antibody diluted in 1% milk PBS 0.1% Tween-20 
for 1 hour. The membrane was washed and specifically bound proteins 
detected as according to immunoblot protocol.  
 
RhoGTPase pull­down activation assay GLISA  
For RhoGTPase activation assays cells were transfected with the appropriate 
siRNAs in 12 well plates, after 72 hours protein was harvested and analysed for 
levels of active RhoA, Cdc42 and Rac1 using the respective GLISA assay kit 
from Cytoskeleton Inc. Protein concentrations were equilibrated before 
incubation with the coated 96 well plates. HRP conjugated secondary 
antibodies were used for detection measuring absorbance at 490nm using a 
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FLUOstar OPTIMA microplate reader (BMGLabTech, Offenburg, Germany) 
samples of cell extracts were immunoblotted for the GTPases to exclude altered 
expression levels. 
 
Cell culture  
Cell lines 
Human adenocarcinoma Colon cells (Caco-2) 276, Human corneal epithelial 
cells (HCE) transformed with SV-40 T antigen (Gift from Chang. M.S Vanderbilt 
University Nashville Tennessee)34 and Madin-Darby Canine Kidney cells 
(MDCK) were cultured in DMEM media containing 10% heat inactivated FBS 
(20%FBS for Caco-2) with 100µg/ml streptomycin and 100µg/ml penicillin (PAA 
cell culture) at 37°C with 5% CO2. Cells were cultured on tissue culture plastic 
plates or glass cover-slides for immunostaining. MDCK cell lines expressing 
Tetracycline inducible p114RhoGEFP were made by calcium phosphate 
transfection of 10µg/ml of Tet repressor pCDNA6-TR and the appropriate 
p114RhoGEF plasmids. Cells were selected for 10 days in media containing 
5µg/ml Blasticidin and 200µg/ml of Zeocin (Invitrogen). The GEF-H1 expressing 
cell line was made as previously described 64. 
 
MDCK and Caco­2 cysts  
Three dimensional cultures of MDCK cells were generated as previously 
described. 211 and for Caco-2 cells a recently described method was used 277. 
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Freezing cells  
A single well of a 6 well dish containing 80% confluent cells were trypsinsied for 
15 minuites at 37°C with 2ml of 2 times Trypsin EDTA (PAA cell culture), 5ml of 
DMEM was added to inactivate Trypsin. The cells were centrifuged at 1000rpm 
for 5 minutes. The supernatant was then discarded and the cells re-suspended 
in freezing media (DMEM containing 10% DMSO 20% FBS). 1ml of cell 
suspension was added to each cryotube and placed in -80°C freezer for one 
day and then transferred to liquid nitrogen for long term storage.  
 
 
 
DNA transfection methods   
Calcium phosphate  
For transfections using calcium phosphate, confluent layers of cells were 
trypinised for 15 mins at 37°C and plated out at the appropriate density. The 
appropriate plasmid DNA was precipitated by mixing 10µg/ml of plasmid DNA in 
2XHEPES buffer, (280mM NaCl, 50mM HEPES, 1.5mM NaPO4, pH 7.1) with 
an equal volume of 0.25M CaCl2 added drop-wise, shaking vigorously after 
each drop. The precipitate was allowed to form by leaving the tube for 30 
minutes at room temperature. The precipitate was vortexed once, added to cells 
where the media was aspirated beforehand and incubated for 15 minutes at 
37°C, before an additional volume of media was added and left overnight at 
37°C. For a 96 well plate 20µl of precipitate and 80µl of media. The following 
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day the media was removed, the cells were washed once with PBS and fresh 
media was added before leaving the cells for 24-48 hours in the incubator. 
 
Lipofectamine  
For transfections using Lipofectamine, confluent layers of cells were trypsinised 
for 15 minutes at 37°C. Cells were plated so that they were 90-95% confluent 
the next day in DMEM without antibiotics. For example, 0.5ml a 10ml 
suspension derived from one well of a fully confluent 6 well plate was used for 
1well of 24 well plate. In one tube 0.9µg of plasmid DNA was added to 
OptiMEM medium (Gibco/Invitrogen) to make total volume of 50µl. In another 
tube 4µl of Lipofectamine 2000 reagent (Invitrogen) was added to 46µl of 
OptiMEM, both tubes were left at room temperature for 5 minutes. The contents 
of both tubes were mixed together and left for further 20 minutes at room 
temperature. The 100µl of DNA-lipofectamine mixture was added directly to 
each well of cells containing 0.5ml of the appropriate media and left to incubate 
for 4h at 37°C. The media was then removed and replaced with 0.5ml of fresh 
media. Cells were left typically between 24-48 to allow expression of protein 
before being processed.  
 
JetPEI 
For transfections using JetPEI a single well of a 6 well plate of 90 -100% 
confluent cells were trypsinised and diluted into 35ml of DMEM without 
antibiotics. 0.5ml/per well of cells were plated into a 48 well plate and left for no 
longer than 20 hours before transfection. Cells were transfected with the 
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appropriate DNA using JetPEI transfection reagent (Polyplus transfection). 
JetPEI and 150mM NaCl were votexed and warmed to room temperature, in 
one tube 0.5µg/48 well of plasmid DNA was mixed with 25µl of 150mM NaCl 
and vortexed, in another tube 1µl of JetPEI was diluted in 25µl of 150mM NaCl 
and vortexed and added to the first tube containing the DNA. This was left at 
room temperature for 15 minutes during this time the media on the cells was 
discarded and replaced with 250µl of DMEM with no antibiotics. The 
Transfection mix was then added to the cells and the plate was gently shaken 
to mix, before cells were placed back in the incubator. Cells were fixed or 
protein extracted typically after 24 hours.    
 
RNAi  
For RNAi experiments siRNAs were transfected into cells using Dharmafect or 
Interferin transfection reagents  (see below for tranfection details). Individual or 
pools of siGenome or On-Target plus siRNAs for targeting specific genes, as 
well as non-targeting control siRNA were purchased from Thermo Scientific, 
Dharmacon. 
Sequences for individual p114RhoGEF siGenome siRNAs were 5’-
UCAGGCGCUUGAAAGAUA-3’ and 5’-GGACGCAACUCGGACCAAU-3’ 
Sequences for p114RhoGEF ON-Target plus siRNA used as pool were   
5’-UCAGGGCGCUUGAAAGAUA-3’, 5’GCAGUGACCGGAAUUAUGU-3,’       
 5’-CACAACGCAUAACCAAAUA-3’ ,5’-GGACGCAACUCGGACCAAU-3’ 
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For the expression of shRNA duplexes in MDCK cells, the sequences 5’-
AAGACACGTCGGGACGCTTG-3’ and 5’-AACTACGTCATCCAGAAAATC-3’ 
were targeted using a plasmid with a tetracycline regulated mouse U6 promotor 
64.(For complete list of siRNA sequences using in RhoGTPase Library see 
Appendix section) 
 
Transfection of siRNAs using Dharmafect  
The day before transfection confluent layers of cells were trypsinised for 15 
minutes at 37°C. Cells were plated in medium without antibiotics and at an 
appropriate density, so that they were 50% confluent the next day. siRNAs were 
purchased from Dharmacon as pools of 4 different siRNAs targeting a specific 
gene a non specific control siRNA was also purchased from Dharmacon. 
siRNAs were prepared to a stock concentration of 20µM, by dissolving in 
1XsiRNA buffer (Dharmacon). For a transfection per well of a 48 well plate: In 
one tube 1µl of 20µM siRNA (100nM final siRNA concentration) was mixed with 
19µl of 1XsiRNA buffer and 20µl of DMEM without antibiotics. In another tube 
1µl of DharmaFECT solution 4 (Dharmacon) was mixed with 40µl of DMEM. 
Both tubes were left at room temperature for 5 minutes, before being mixed 
together and left for further 20 minutes at room temperature. 120µl of DMEM 
without antibiotics was added to the mixture and this was added to the cells and 
left overnight.  
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Transfection of siRNA using INTERFERin  
For siRNA transfections using INTERFERin a single well of a six well plate of 
cells were cultured to approximately 80% confluent trypsinised and diluted in 
1/50ml 1/100ml, 0.5ml per single well of 48 well plate of cells were plated. 
Transfection was performed no longer than 20 hours after plating. siRNA was 
transfected using INTERFERin (Polyplus transfection). INTERFERin was 
votexed and the desired amount of OPTimen was taken from the stock, both 
were left to stand to reach room temperature. All values are for 48 well plates 
using a final siRNA concentration of 40nM.  In a tube 0.5µl of 20mM siRNA was 
added to 50µl of OPTimen and left for 5 minutes at room temperature 1µl of 
INTERFERin was added and the mixture was pipetted up and down once to mix 
and left for 10 minutes at room temperature. Media on cells was discarded and 
replaced with 200µl of DMEM containing no antibiotics. The transfection mixture 
was added to the cells and shaken to mix. Media was changed the next day 
and cells were fixed or lysised after a further 72 hours.  
 
 Luciferase Reporter assays  
A single well of a six well plate that was one hundred percent confluent was 
trypsinised and diluted in 40ml of DMEM. In a 96 well plate, 100µl of diluted 
cells were plated per well. The following day a calcium phosphate transfection 
was performed, using 10µg/ml of one of three different firefly luciferase reporter 
plasmids (pNF-κB (NF-κB reporter), pTCFwt (beta Catenin reporter) and 
pXB1EBS (ZONAB reporter) ) and 10µg/ml of control Renilla luciferase plasmid 
pRLEBN. Transfections were performed in quadruplicate, using final volume of 
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20µl /well of precipitate. A further 80µl of DMEM was added to each well and 
the cells were left overnight. The following day cells were washed with PBS 
(200µl /well), fresh media was then added to cells (100µl/well) and left in the 
incubator for one further day. The next morning the cells were washed once 
with PBS (200µl /well) and lysed, in 1X passive lysis buffer (20µl /well) from 
Dual luciferase Kit (Promega). Lysates were incubated on a shaker for 20 
minutes at room temperature, before performing a Luciferace assay, using a 
Dual luciferase Kit (Promega) according to manufacturers protocol, using 12µl 
of protein extract and 30µl of substrate solutions.  
Antibodies  
All antibodies used for this study are listed in the Appendix section 
  
Immunostaining and Microscopy   
Cells were grown typically for 4 days after plating on glass cover slides in 24 or 
48 well plates. Cells were fixed by the addition of cold methanol (-20°C) 
(0.5ml/well of 24 well plate) and transferred immediately to the freezer for 5 
minutes. The methanol was discarded and the cells were re-hydrated with 
1XPBS for 5 minutes at room temperature. The fixed cells were blocked prior to 
staining in PBS-0.5%BSA -0.1%NaN3 for 30 minutes. Cells were also fixed with 
3% PFA /PBS pH 7.4 (0.3ml/well) for 20 minutes at room temperature, 
permeabilised with 0.3ml/well of 0.3%triton 0.3% BSA for 5 minutes at room 
temperature then washed twice with 0.5%BSA 20mM Glycine PBS and left to 
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stand for 30 minutes before discarding solution and adding blocking solution 
0.5% BSA, 0.1% NaN3 PBS.  The appropriate primary antibodies was added to 
cells at the appropriate dilution in the blocking solution 0.5%BSA, 0.1%NaN3 
PBS and incubated for 2 hour at room temperature or overnight at 4°C. The 
cells were washed three times for 10 minutes with blocking solution and 
incubated with the appropriate fluorescent secondary antibody conjugated to 
either FITC, Cy3, Cy5 or AMCA (Jackson ImmunoResearch Inc.) diluted 1:300 
in blocking solution or incubated with either FITC or TRITC conjugated 
Phalloidin 1:2000 (Sigma) or DNA stain Hoechst 33258 1:4000 (Invitrogen) for 
1 hour. The cells were washed twice for 10 minutes in blocking solution and 
given a final wash for 10 minutes in PBS. Cover slides were mounted onto 
microscope slides in ProLong gold antifade mounting media (Molecular 
probes/Invitrogen). Slides were observed under a Leica DMIRB fluorescent 
microscope or a LSM Zeiss 510 and LSM 700 confocal laser scanning 
microscope using 63x immersion oil lens. Images were acquired using simple 
PCI and LSM510 and ZEN operating software and processed (i.e., adjustment 
of brightness) with Adobe Photoshop ver 7.0. 
 
Fluorescence Resonance Energy Transfer  (FRET)  
For FRET experiments, siRNA transfected cells were plated into ibid multi-well 
chamber slides and then transfected with p-Raichu-RhoA. The FRET analysis 
was performed at 37°C with a Leica SP2 microscope using the manufacturer’s 
software measuring donor recovery after acceptor bleaching (YFP was 
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bleached  to 30%). FRET efficiency maps were then produced with the Lecia 
software. For quantification, CFP images were subtracted and then quantified 
with ImageJ calculating the ratio of (CFP after bleaching –CFP before bleaching/CFP after 
bleaching). For each image, all cell-cell contacts were quantified and as many 
internal areas; averages of all cell-cell contacts and all internal areas then gave 
one value each per image, and these values were used for the final statistical 
analysis. Normalisations were performed by dividing obtained values for 
specific fields by values obtained for the entire field imaged.  
 
RhoGTPase siRNA library screen  
RhoGTPase library   
The siRNA library used in this study contains siRNAs from custom made 
libraries that target specific classes of genes. It contains siRNAs to 207 
RhoGTPase regulators or downstream effectors of RhoGTPases. In addition it 
also contains 58 siRNAs from a library containing, actin regulatory and binding 
proteins. The siRNAs in the library contain double stranded RNAs that are 
made up of pools of 4 different individual siRNAs per gene, at a final 
concentration of 20µM to total siRNA. The library was made by Dharmacon 
(siArray siRNA libraries) and uses siGENOME siRNAs. For complete list of 
genes and siRNA sequences used in the library see appendix section 
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Junction assembly screen   
For the siRNA screens, HCE cells were plated out the day before transfection 
on glass coverslides in 48 well plates for the immunofluorescent screen and 96 
well plates for the NF-κB reporter assay, in medium without antibiotics. They 
were plated at the appropriate density so that they were 50% confluent the day 
of the transfection. HCE cells were plated out on glass cover slides in 48 well 
plates. The following day cells were transfected with 100nM of each siRNA pool 
from the library the transfection was performed in duplicate to allow staining of 
two cover-slides with different sets of antibodies. The siRNA library was 
transfected by mixing in individual wells of a 96 well plate. 1µl of each siRNA 
pool of the library, 19µl of 1XsiRNA buffer and 20µl of DMEM without 
antibiotics. This was left at room temperature for 5 minutes. In another tube 
300µl of DharmaFECT solution 4 (Dharmacon) was mixed with 12ml of DMEM 
without antibiotics and was left at room temperature for 5 minutes. 41µl of the 
DharmaFECT solution 4/DMEM mix was added to each well of the 96 well plate 
and left for further 20 minutes at room temperature. Then 120µl of DMEM 
without antibiotics was added to the mixture in each well and 201µl of this 
mixture was added to the cells in the 48 well plates and left overnight. Cells 
were grown a further 72 hours and then fixed with methanol. One cover slide for 
each transfection was stained with Set 1 antibodies (β-Catenin, ZO-1 and 
Giantin (Golgi) ) and the other cover slide was stained with Set 2 antibodies ( 
Occludin, α-Catenin and Hoechst (DNA) ).   
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NF­κb reporter assay screen   
HCE cells were plated out in 96 well plates. The following day cells were 
transfected with 100nM of each siRNA pool. The siRNA library was transfected 
in triplicate, a 3X mix was made by mixing in individual wells of a 96 well plate. 
1.2µl of each siRNA pool of the library, 22.8µl of 1XsiRNA buffer and 24µl of 
DMEM without antibiotics. This was left at room temperature for 5 minutes. In 
another tube 1.2µl of DharmaFECT solution 4 (Dharmacon) was mixed with 
48µl of DMEM without antibiotics and was left at room temperature for 5 
minutes. 49.2µl of the DharmaFECT solution 4/DMEM mix was added to each 
well of the 96 well plate and left for further 20 minutes at room temperature. 
Then 48µl of DMEM without antibiotics was added to cells in each well and to 
this 32.4µl of the siRNA mixture was added to the cells in each well of the 96 
well plates and left overnight. The following day a calcium phosphate 
transfection was performed (see Calcium phosphate transfection for details) to 
transfect 10µg/ml of pNF-κB (NF-κB reporter) plasmid and 10µg/ml pRLEbn 
plasmid. As a control for NF-κB inhibition 10µg/ml of IkBα  S32,34A plasmid 
was also transfected.  Cells were left a further 48 hours, before performing a 
Dual luciferase reporter assay. The amount of firefly luciferase activity was 
divided by the amount of renilla luciferase activity to standardise results for 
differences in cell density. An average of this ratio was calculated from triplicate 
plates and from this the fold difference from control (non targeting siRNA) was 
calculated.  
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TER and permeability assays   
Caco-2 cells were cultured in normal calcium media conditions, transfected with 
the appropriate siRNAs and plated onto glass cover slide for 
immunofluorescence or on filters for TER and permeability measurements in 
low calcium medium (Sigma spinner culture medium with 2 mM glut / 1 mM Na-
pyruvate / PenStrep 10% dialyzed FCS) (Sigma) and left for 24 hours before 
the addition of normal calcium media. Samples were fixed at various time points 
for immunostaining or TER measurements were taken using a AC square wave 
current of ± 20 µA at 12.5 Hz with a silver electrode and measuring the voltage 
deflection elicited with a silver/silver-chloride electrode using an EVOM (World 
Precision Instruments, Sarasota, FL), as previously described 278 over a period 
of 48 hours after which the permeability of 4 kDa FITC- conjugated Dextran and 
70kDa Rhodamine B (REF company) conjugated dextran tracer were measured 
using a FLUOstar OPTIMA microplate reader (BMGLabTech, Offenburg, 
Germany)  
Wound healing assays   
For wound healing assays a single well a six well plate of cells grown to 80% 
confluence was trypsinised and diluted into 30 ml and plated onto 12 well plates 
1ml /well. The following day siRNAs were trasfected using INTERFERin (see 
siRNA transfection using INTERFERin) for 1 well used 2µl of siRNA 20mM 
stock 4µl INTERFERin in 200µl of OPTImem. The next day 3 wells for each 
siRNA were trypsinised with 0.4ml of trypsin and combined into one tube to give 
1.2ml, this was centrifuged in bench-top centrifuge for 5 minutes at 3000rpm. 
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The trypsin was discarded and cells carefully resuspended in 600µl of DMEM. 
80µl of cells were plated in each side of the insert of a culture –insert plate from 
Ibidi.  Cells were left overnight or until confluent before generation of the wound 
by removal of the insert. Images were taken at the start and at various times 
after to monitor wound closure. The percentage of the area of the wound was 
quantified from the images using Image J.  
 
Statistical analysis   
Mean averages and Standard deviation were calculated using standard 
formulae for calculation of statistical significance between two different data 
sets a two tailed students t-set was used. 
 
 
Drosophila fly stocks    
Flies were kept under standard conditions. y,w,hsflp122;Tub>GFP>GAL4 
expressing heat shock inducible flip recombinase and GFP from a minimal 
tubulin promotor (kind gift from Gary Struhl). y1,w;P{Act5C-GAL425FO1}/CyO,y+  
Permits ubiquitous expression of GAL4 driven from an actin promoter. 
(Bloomington Stock number 4412) (flybase.org). RNAi stocks containing shRNA 
to cg10188 under the control of a yeast UAS promoter were obtained from the 
Vienna Drosophilla RNAi center VDRC. Transformant ID numbers 18029 and 
103391 both contain different shRNA sequences that target cg10188.   
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Immuno­staining of Imaginal discs  
  
Larvae were heat shocked at 37°C for 30 minutes to induce expression of flip 
recombinase and drive expression of cg10188 specific shRNA. Lavrae were left 
for a further 48 hours before imaginal discs were dissected and fixed at room 
temperature for 20 minutes in 4%PFA /PBS. Discs were washed three times 30 
seconds with PBST (1XPBS + 0.3% Triton x100) before incubation overnight at 
4°C with primary antibodies. The next day discs were washed as above in 
PBST and incubated with fluorescent secondary antibodies or TRITC 
conjugated Phalloidin for 5 hours in the dark at room temperature before three 
further washes with PBST for 30 seconds and a final wash for 1 hour, before 
mounting discs on slides with Vector shield mounting media (Vector labs).     
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CHAPTER 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screen for 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of 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and 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Chapter 3 –Functional siRNA screening for regulators and 
effectors of RhoGTPases.  
Overview  
This chapter contains the results from a functional siRNA screen to identify 
regulators and effectors of RhoGTPases in human corneal epithelial cells that 
regulate cell adhesion and junction formation, as well as Rho regulated 
signalling pathways that regulate gene expression. The screen was performed 
using a siRNA library containing 265 siRNA pools that specifically target 
proteins that are regulators or downstream effectors of RhoGTPases, including 
the 20 known RhoGTPases. 
 
 HCE cells were chosen as a model epithelial cell line to study regulation of 
RhoGTPase signalling in junction formation because they form functional 
epithelial junctions and express many of the major junctional and polarity 
markers. HCE cells can be grown in sufficient quantities for a short space of 
time on glass cover slides. They can be efficiently transfected with siRNA to 
perform RNAi experiments and can be transfected with different firefly luciferase 
constructs to perform gene reporter assays, thus making them an ideal model 
for functional siRNA screening. I transfected the siRNA library into HCE cells 
grown on glass cover slides fixed and immuno-stained cover slides with two 
different sets of antibodies/fluorescent dyes for markers that stained specific 
structures associated with polarity, such as the Golgi complex along with 
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several components of Tight and Adherens junctions and observed if polarity 
and junction morphology was perturbed.  
 
To identify components of RhoGTPases that have effects on gene regulation, 
firefly luciferase based NF-κB, TCF/β-Catenin reporter assays were optimised 
for use in HCE cells. However due to time constrains of this project only a 
RhoGTPase siRNA screen for components that affected NF-κB activity was 
performed.  
 
By performing the siRNA screen to observe effects on epithelial junction 
morphology I identified 26 components that had strong and 36 that had weaker 
effects on junction morphology. We also indentified a number of components of 
RhoGTPase signalling that regulate NF-κB reporter activity by identifying 
several candidates that had strong inhibitory or stimulatory effects on 
constitutive NF-κB activity. I discovered the RhoGTPases, RhoA and Cdc42 
had the strongest effects on junction formation, with Rac1 seeming to give a 
weaker effect in HCE cells. I also identified a number of GEFs, GAPs and 
downstream effectors of both RhoA and Cdc42, as potential candidates that 
regulate junction formation from the screen. I validated a subset of these 
candidates, as well as several candidates that were identified as having effects 
on junction formation, from a similar screen performed in Caco-2 cells (Matter 
2007 unpublished results), by de-convolution of the siRNA pool into individual 
siRNAs. I chose to fully characterise the function of one of these validated 
candidates, p114RhoGEF. This analysis is presented in chapter 4.  
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Establishing HCE cells as a model epithelial cell line for performing 
functional siRNA screening. 
  
HCE cells are an immortalised SV40 large T–antigen transformed human 
corneal epithelial cell line. When cultured in vitro, HCE cells assemble functional 
adherens and tight junctions and spontaneously differentiate when grown in 
serum free keratinocyte growth medium 34. HCE cells express many of the 
known major structural and regulatory components of tight and adherens 
junctions (Occludin, ZO-1,2,3 Cingulin, Claudin 4, ZONAB, GEF-H1, E-
Cadherin, β-Catenin and α-Catenin as well as conserved polarity genes Crb 2 
and 3  and the components of the PAR3/6/aPKC complex 34, 279 (Matter 2007 
unpublished results), making them suitable for use as a model for early junction 
assembly and differentiation. To establish the culture conditions needed to test 
the suitability of HCE cells for functional siRNA screening, I needed to establish 
if they could be grown on glass cover slides at a relatively low confluence to 
permit efficient siRNA transfection.  Starting at a low confluence would allow 
sufficient time for discreet junctions to form, as well as enabling a robust 
knockdown of the target protein. Establishing if RNAi could be performed 
efficiently in HCE cells by transfection of siRNAs was addressed using a β-
Catenin siRNA pool as a control.   
 
Figure 3.0 shows β-Catenin protein levels are reduced 72 hours post 
transfection of β-Catenin siRNA pool compared to non-targeting control siRNA. 
Immunostaining for β-Catenin and ZO-1 was performed on non-targeting and β-
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Catenin siRNA transfected cells (Figure 3.0). In the control (non-targeting 
siRNA), there was recruitment of ZO-1 and β-Catenin to distinct junctional 
complexes. Control cells appeared to have a normal morphology indicating the 
transfection reagent used (Dharmafect solution 4) was not toxic and the non-
targeting siRNAs did not effect morphology or junction formation of HCE cells. 
Transfection with β-Catenin siRNAs led to a clear reduction in β-Catenin at cell-
cell junctions and the appearance of large spread cells, indicating RNAi is 
working efficiently to repress β-Catenin expression. However ZO-1 recruitment 
to junctions seemed to remain unaffected indicating that β-Catenin is not 
required for ZO-1 recruitment to junctions. 
Before I performed the functional siRNA screen I stained HCE cells grown for 4 
days with two different sets of antibodies. Figure 3.1 clearly shows HCE cells 
form distinct tight and adherens junctions within 4 days of culturing, making 
them suitable to screen for genes regulating the early stages of junction 
formation. Furthermore the combinations of two different sets of antibodies can 
be used as markers in the screen, as they all work in methanol fixed cells and 
no cross reactivity was observed between the different antibodies.  
 
 
 
 
 
 111 
 
 
 
 
 
 
 
Figure 3. 0  RNAi can be efficiently performed in HCE cells using siRNAs.  HCE cells cultured in DMEM 10%FBS were transfected with 100nM of non‐targeting control  or  a  pool  of β‐Catenin  siRNAs  using  Dharmafect  solution  4.  The  efficiency after  72  hours  of  siRNA  mediated,  knockdown  of  β‐Catenin  was  assessed  by Immunoblot using a β‐Catenin specific antibody and immunoblotting for levels of α‐tubulin as a  loading control.  Immunofluorescence staining with β‐Catenin and ZO‐1 antibodies in methnol fixed HCE cells transfected as above is also shown with control non targeting or β‐Catenin siRNAs. 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Figure 3.1 HCE assemble distinct Tight and Adherens Junctions. 
HCE  cells  cultured  on  10mm  glass  cover‐slides  in  DMEM  10%  FBS,  fixed  with methanol and stained with two different sets of antibodies/markers SET1: β‐Catenin, Adherens  junction  marker  (red),  Giantin,  Golgi  marker  (green)  and  ZO‐1,  Tight junction marker (blue).  SET 2: α‐Catenin, Adherens junction marker (red),  Occludin, Tight junction marker (Green), Hoechst 33258, DNA stain (blue). 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Establishing luciferase based reporter gene assays to monitor NF­κB and β­
Catenin/TCF activity in HCE cells.  
 
To study the effects RhoGTPase signalling has on gene expression pathways 
in the corneal epithelium, lucfierase based reporter assays of three 
transcriptional regulators, (NF-κB and TCF/β-Catenin) were optimized for use in 
HCE cells. NF-κB is a transcription factor important in mediating pro-
inflammatory responses, cell growth and survival 111, 124, as well as genes 
important for EMT 115. NF-κB activity can be regulated by components of 
junctions, such as E-Cadherin and p120 Catenin 121, 124. Many growth factor and 
cytokine induced signalling cascades also result in the activation of NF-κB. 
Signalling that activates pro-inflammatory responses often results in increased 
paracellular permeability or even disassembly of cell-cell junctions. 
RhoGTPases are crucial regulators of junctions and are important regulators of 
NF-κB signalling.  I wanted to investigate how RhoGTPase signalling regulated 
NF-κB activity in HCE cells.  I performed NF-κB reporter assays in HCE cells 
grown in normal serum (DMEM/10%FBS) or serum free conditions (K-SFM), as 
Fetal bovine serum contains a complex mix of growth factors that alter NF-κB 
activity. I performed the NF-κB reporter assay in these two conditions and 
indeed detected constitutive activation of NF-κB when the assay was performed 
in the presence of serum. This level of activity was not seen in serum free 
conditions (Figure 3.2).  
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To test if the constitutive activity could be inhibited a plasmid containing a 
mutant non-phosphorylatable form of IkB S32 34A, a strong inhibitor of NF-κB 
activation was co-transfected. The dominant mutant inhibited NF-κB activity by 
about 2 fold. It was also tested if the low basal NF-κB activity in serum free 
conditions could be induced by TNF-α, a pro-inflammatory cytokine and potent 
stimulator of NF-κB. This activity was induced about 5 fold, by stimulation with 
20ng/ml of TNF-α for 5 hours (Figure 3.3 B). This inducible activity could be 
inhibited by the expression of IkBαS32,34A. These experiments demonstrate, 
NF-κB activity can be measured by reporter assays in HCE cells as either 
constitutive or TNF-α induced activity.  
 
 
 
 
 
  
 
 
Figure 3.2 NF­κB reporter assay performed in HCE cells. NF‐κB  reporter  assay  was  performed  in  HCE  cells  in  DMEM  10%FBS  (+serum)  or  in  K‐SFM  (‐serum). Constitutive activation of NF‐κB in serum conditions can be inhibited by transfection of 10µg/ml of inhibitory IkBα S32 34A protein. Values are plotted as a ratio of  firefly  luciferase activity divided by Renilla  luciferase. Bars represents mean average from quadruplicate wells. Error bar represent +/‐ 1 standard deviation. 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Figure 3.3 NF­κB activity can be induced in HCE cells with TNFα  stimulation   NF‐κB reporter assay was performed in HCE cells in serum free conditions without or  after  5  hours  stimulation  with  20ng/ml  of  TNFα  (  shown  on  graph  as  ‐  or  +). Stimulation with TNFα caused a 5 fold increase in activity which can be inhibited by transfection of 10µg/ml of inhibitory IkBα S32,34A protein. NF‐κB reporter activity was  calculated  as  a  ratio  of  firefly  luciiferase  divided  by  Renilla  lucferase.  Results were  normalised  to  control  experiments.  Bars  represent  mean  of  quadruplicate wells. Error bars represent +/‐ 1 standard deviation. 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Next, I adapted two assays for transcription factors known to be regulated by 
cell-cell adhesion. β-Catenin is a multifunctional protein that is a key component 
of AJs and is known to interact with multiple binding partners that function in 
cell-cell adhesion and transcriptional regulation 106. In epithelial cells β-Catenin 
recruitment to AJs is thought to result in inactivation of its transcriptional role by 
preventing it from translocating to the nucleus. However when cell-cell contacts 
are forming or disrupted it is thought that more cytoplasmic β-Catenin is 
present. This shift in the equilibrium of cytoplasmic β-Catenin, permits greater 
amounts to translocate to the nucleus, where it associates with LEF/TCF 
transcription factors leading to their activation and transcription of genes 
required for proliferation.  
 
First I performed a β-Catenin/ TCF reporter assay in the presence of serum. 
(Figure 3.4 ). The reporter assay was performed after transfection with control, 
non-targeting and β-Catenin siRNAs. A three fold reduction was observed in 
cells transfected with β-Catenin siRNA, providing evidence that the activity 
observed was specifically dependent on β-Catenin. A control plasmid was also 
transfected along with control siRNAs. This plasmid contained a version of the 
β-Catenin/ TCF promoter that had its TCF binding sites deleted rendering it non 
functional. This construct gave no observable activity. 
 
In summary NF-κB and β-Catenin/TCF activity can be measured by reporter 
assays in HCE cells. In addition, depletion of these two transcriptional 
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regulators can be obtained by transfection of specific siRNAs. Thus the 
conditions for performing siRNA mediated depletion of specific proteins to 
observe effects on NF-κB and β-Catenin/TCF activity by reporter assays, are 
now optimized for use in HCE cells. The initial aim of this study was to use 
these three assays to perform siRNA screens using the RhoGTPase siRNA 
library to observe changes in β-Catenin/TCF and NF-κB activity and thus 
identify components of RhoGTPase signalling pathways important for gene 
expression.  However due to the limited time and resources for this study the 
RhoGTPAse siRNA screen was only performed for NF-κB activity and not β-
Catenin/TCF activity.  
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Figure 3.4 Establishing β­Catenin/TCF reporter assays in HCE cells  Luciferase based β‐Catenin/TCF reporter assays performed in HCE cells in serum conditions. Non‐targeting control and β‐Catenin siRNA pool were transfected into HCE  cells,  luciferase  activity  β‐Catenin/TCF  reporter  was  measured  72  hours post siRNA transfection. Knockdown of β‐Catenin resulted in a 3 fold reduction of 
β‐Catenin/TCF activity. To test the specificity of the assay, a construct containing mutations  in  the TCF promotor  binding  site  (TCF mutant) was  transfected  and demonstrated to give very low luciferase activity. Values are plotted as a ratio of firefly  luciferase  activity  divided  by  renilla  luciferase  activity.  Bars  represent mean  average  from  quadruplicate  wells.  Error  bars  represent  +/‐1  standard deviation. 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siRNA screen for regulators and effectors of RhoGTPases that effect junction 
formation.  
 
Using the conditions established for performing RNAi in HCE cells (Figure 3.0), 
I performed a siRNA RhoGTPase library screen to identify regulators and 
effectors of RhoGTPases that effect junction formation. The screen was 
performed on HCE cells grown on glass cover slides in 48 well plates, pools of 
4 siRNAs to each target protein in the library were transfected in duplicate to 
allow staining with two different sets of antibodies (Figure 3.1). A total of 63 
candidates were identified with 26 being classified as having a strong effect and 
37 having weaker effects on junction formation (Table 3.0). I defined a strong 
effect as broken or discontinuous junctions in most of the cells observed 
compared to control (see Figure 3.5, RhoA and Cdc42 and p114RhoGEF for 
examples) and weak effects, when a smaller proportion of cells had broken or 
discontinuous junctions (see Figure 3.5, Rac1). 
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Table  3.0  siRNA  screen  results  for  regulators  and  effectors  of  RhoGTPases 
that effect junction formation.  A total of 64 candidates were identified from the siRNA screen, 26 candidates had a strong effect on junction formation shown in red and 38 had a weaker effect, shown in grey. 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RhoA and Cdc42 are essential for junction formation and polarity in HCE 
cells.  
 
Cdc42, Rac1 and RhoA are the three most well characterised family members 
of RhoGTPases 144 , all three have been identified to have crucial roles in 
epithelial junction formation and the maintenance of polarity 18. The siRNA 
screen identified Cdc42 and RhoA as having strong effects on junction 
formation (Figure 3.5). The effects observed on junction morphology with the 
RhoA specific pool of siRNAs were validated to control for off target effects by 
de convolution of the siRNA pool into four individual siRNA. All four RhoA 
siRNAs gave the same phenotype as the RhoA pool (Figure 3.9), validating the 
importance of RhoA  for junction formation. 
 
Depletion of both of these RhoGTPases prevents normal TJ formation (Figure 
3.5), as ZO-1 a marker for TJs appeared broken and discontinuous at cell-cell 
contacts. AJs were also effected, demonstrated by β-Catenin staining at cell-cell 
contacts being broken and having a more undulating appearance than control 
cells. Cdc42 depletion severely effected cell polarity, as the appearance of the 
Golgi looked fragmented and disorganised. However Rac1 appeared to have a 
weaker effect on junction formation than Cdc42 and RhoA, with AJs remaining 
largely unaffected, but ZO-1 recruitment to cell-cell contacts was perturbed in 
some small patches (Figure 3.5). Rac1 is known to be critical for the initial 
stages of assembly of cell-cell contacts, becoming activated upon E-Cadherin 
engagement 130, 280. Its weaker effects observed in the screen could be 
 122 
explained simply by a less efficient knockdown of Rac1 levels. Alternatively its 
functional role in early junction formation may occur before time has elapsed to 
give a sufficient knockdown of Rac1 levels, explaining the appearance of a 
weaker phenotype. Furthermore it is possible that Rac1 is not as important in 
HCE cells as in the other epithelial models in which it was studied. The 
importance of Cdc42, RhoA and to a lesser extent Rac1 in junction formation in 
HCE cells (Figure 3.5), confirms established roles of these RhoGTPases in cell-
cell adhesion, polarization and differentiation and support the aim of the screen 
to identify novel regulators of Rho signalling. 
 
RhoA and Cdc42 had the strongest effects in the screen therefore we focused 
on sorting the hits based on evidence from the literature into GEFs, GAPs and 
downstream effectors of these two RhoGTPases (Table 3.1). GEFs and GAPs, 
are reported sometimes to activate/inactivate more than one RhoGTPase. For 
example the GAPs DLC2 and 3 identified in this screen were shown in vitro to 
have GAP activity for Cdc42 and RhoA, but not Rac1 281  282, therefore it is 
present in both Cdc42 and RhoA tables.   
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Figure 3.5  RhoGTPases Cdc42, RhoA, and Rac1 all affect junction formation.  
 HCE cells transfected with non‐targeting control siRNA or a pool of 4 siRNAs specific to Cdc42,  RhoA  and  Rac1.  Cells  were  methanol  fixed  72  hours  after  RNAi,  cells  were immunostained with ZO‐1, β‐Catenin and Giantin (golgi marker). Note Cdc42 and RhoA are good examples of  strong effects, whereas Rac1 is an example of a weak effect. 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Morphology  
CDC42 
GEFS 
ARHGEF6 / a-PIX / cool 2 
BCR 
DOCK10 
FGD5 
ITSN1 /Intersectin-1  
PLEKHG2, Clg 
MCF-2L, Dbs 
GAPs 
RALBP1 
RACGAP1 
 SPATA13 
STARD13, DLC2 
STARD8, DLC3 
 Effectors 
CDC42EP2 / MSE55 / Borg5 
CDC42BPA; MRCKalpha 
CDC42BPB / MRCK2 (beta) 
PAK7 
PARD6G 
PARD6A 
TRIP10 /CIP4 
 
Morphology  
RhoA 
GEFS 
ARHGEF/18/p114RhoGEF 
ARHGEF12 LARG 
NGEF/ephexin-1 
FLJ10665 /PLEKHG6 
KIAA0720 /PLEKHG5 
MCF-2L, Dbs 
GAPs 
STARD12/DLC1 
STARD13/DLC2 
STARD8/ DLC3 
Table 3.1 Candidates grouped into RhoA or Cdc42 specific regulators or downstream effectors.  
Candidates were grouped into two lists according to if they were a GEF or GAP or downstream effector of RhoA or Cdc42 based on literature and predictive methods. Candidates that had a strong effect are highlighted in red and candidates that had weak effects highlighted in grey. It is worth noting there is some  degree  of  promiscuity  of  GEFs  and  GAPs  as  to which  RhoGTPase  they  preferentially  activate/ inactivate. For example, DLC2 and 3 appear both as RhoA and Cdc42 GEFs. 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Figure  3.6  p114RhoGEF  was  identified  from  the  siRNA  screen  as  strongly 
affecting TJ formation.   HCE  cells  transfected with  non‐targeting  control  or  a  pool  of  4  siRNAs  specific  to p114RhoGEF.  Cells  were  methanol  fixed  after  72  hours  RNAi,  cells  were immunostained  with  ZO‐1,  β‐Catenin,  Giantin  (golgi  marker),  Occludin,  α‐Catenin and DNA stain, Hoechst 33258. 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siRNA screen for regulators and effectors of RhoGTPases that effect NF­κB 
activity  
RhoGTPases are major targets of junctional regulatory mechanisms and are 
also major downstream targets of physiological and pathological signalling 
pathways, activated by growth factors and inflammatory signals. NF-κB is a 
transcriptional regulator mediating transcription of genes associated with pro 
inflammatory responses and cell survival as well as genes important for 
epithelial to mesenchymal transition (EMT) 111, 113, 115, 117, 283, 284. I wanted to 
indentify components of Rho signalling pathways that regulate NF-κB activity in 
HCE cells. 
 
I performed a screen using the siRNA RhoGTPase library to observe the effects 
on NF-κB activity in HCE cells grown in the presence of serum. I decided to 
perform the screen in serum conditions as it was technically difficult to achieve 
robust knockdowns of target proteins in HCE cells using serum free conditions. 
The fold difference in activity from control (non targeting siRNA) was calculated 
for all candidates (Figure 3.7). Potential candidates were sorted, based on 
having a stimulatory or inhibitory effect on NF-κB activity. As a control for 
repression of NF-κB activity the dominant negative IkB mutant was also 
transfected and suppressed activity by 60%. Candidates that gave a strong or 
weak effect on morphology, identified in immunofluorescent screen are also 
merged with the data shown in Figure 3.7. Using these data I plotted the results 
in a Venn diagram (Figure 3.8). The results show very little correlation between 
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proteins that regulate junction formation and regulate NF--κB activity, however 
as the screen was performed in the presence of serum, which causes 
constitutive NF-κB activity I felt candidates that produced inhibitory effects, 
rather than stimulatory effects maybe more valid to study. MAP4K1, RacGAP1 
and OBSCN were all candidates that had a strong effect on morphology and 
strong inhibitory effects on NF-κB activity. Two candidates MCF2L and 
RhoBTB1 had weaker effects on morphology, but also gave strong inhibitory 
effects on NF-κB activity. Validation of these candidates will need to be 
performed by repeating NF-κB reporter assays with individual siRNAs derived 
by deconvoluting the pool of siRNA used in this screen to each potential 
candidate. Due to time constraints candidates were only validated from the 
junction morphology screen. However, it will be important to validate hits in the 
future to understand the involvement of Rho signaling in NF-κB activation in 
HCE cells.  
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Luciferase based NFκB
 reporter assays were performed after transfection of siRNA Rho library in HCE cells grown in the presence of serum. Results are plotted as fold difference from non‐targeting 
siRNA control. As a control for inhibition cells were transfected with 10µg/ml of a dominant negative mutant IkB
αS32,34A. Candidates were sorted based on if they had a strong stimulatory effect >2 
fold (dark blue), weak stimulatory 1.8‐2.0 (turquoise), no change 0.8‐1.8 (blue), weak inhibitory 0.7‐0.5 (orange), Strong inhibitory >=0.4 (red). * Represent candidates that have strong effect on 
morphology * represents weaker morphological effect. Bars and error bars represent mean and +/‐ 1 SD of triplicate experiments. 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Figure 3.8 Summary of potential candidates from Immunofluorescent screen 
correlated with the data from screen for NF­κB activity.  
 A total of 85 Candidates were grouped into three categories represented by circles. Weak effect on morphology (left), effect on NF‐κB activity (centre) or strong effect on  morphology  (right).  Numbers  represent  candidates  that  fall  into  particular categories. The colours  represent effect on NF‐κB activity Red= strong  inhibitory effect.  Blue=  Strong  stimulatory  effect.  Orange=weak  inhibitory  effect. Turquoise=weak stimulatory effect. Black = no effect. 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Validation of Candidates from junction formation screen.  
 
To validate potential candidates from the primary screen for junction formation, 
pools of siRNAs were deconvoluted into individual siRNAs. Candidates were 
validated by transfecting individual siRNA and testing for their ability to 
reproduce the phenotype observed in the initial screen. This was to control for 
“off target” effects produced by pools or specific siRNAs. The initial aim was to 
validate hits from both junction formation and NF-κB activity screens, however 
due to the time constraints of this project I focused on just validating hits that 
effected junction morphology. Validation was performed for example for RhoA 
(Figure 3.9), with all four individual siRNAs producing the same phenotype 
when using the RhoA siRNA pool and hence confirmed the effect targeting of 
RhoA has on junction formation. 
 
 p114RhoGEF was validated as knockdown of p114RhoGEF by two different 
individual siRNAs, derived from the pool in the initial screen produced the same 
phenotype of disrupted TJs observed in the initial screen.  A pool of these two 
individuals also produced the same phenotype as well as, a pool containing On-
target plus siRNAs that had different p114RhoGEF specific siRNA sequences to 
the original siGenome pool of siRNAs (Figure 3.11). Knockdown experiments 
using these individual and pools of siRNA, produced similar phenotypes and 
seemed to affect the formation of TJ in Caco-2 cells. However unlike in HCE 
cells, TJs were warped and gave an uneven appearance, reminiscent of 
phenotypes caused by the manipulation of Myosin II activation or if actin 
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dynamics are pharmacologically perturbed 236. Immunoblotting, HCE and Caco-
2 cell lysates revealed that efficient knockdown of p114RhoGEF was achieved 
using two different individual siRNAs, as well as a pool of the two individuals 
siRNAs. (Figure 3.10). I also validated the effects observed on junction 
assembly of a subset of candidates. I confirmed as valid candidate by two or 
more individual siRNAs reproducing the same effect on junction morphology 
(Table 3.2). Examples are shown for effects on Junction formation for the 
Cdc42 and RhoA GEF, MCF2L a.k.a Dbs (Figure 3.12), and two Cdc42 effector 
proteins MRCKα and β (Figure 3.13-14).   
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Figure 3.10 siRNAs efficiently knockdown p114RhoGEF in HCE and Caco­2 
cells. Immunoblot of HCE and Caco‐2 cells lysates 72 hours after siRNA transfection of control  non  targeting  siRNA  or  two  different  individual  p114RhoGEF  specific siRNAs  (siRNA  1  and  2),  as  well  as  a  pool  of  the  two  individual  sequences (siRNA1/2).  Membranes  were  blotted  with  p114RhoGEF  and  α‐Tubulin  as  a loading control. 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Figure 3.11 Validation of p114RhoGEF siRNAs in HCE and Caco­2 cells.  
HCE and Caco‐2 cells methanol fixed and immunostained with TJ marker proteins ZO‐1, Occludin and Cingulin,  72  hours  after  transfection  with  control  non  targeting,  or  two  different  individual p114RhoGEF  specific  siRNAs  (siRNA  1  and  2)  as  well  as  a  pool  of  the  two  individual  sequences (siRNA1/2) and an on target plus pool of p114RhoGEF siRNAs (siRNA OnT) 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Candidate  Effect on junction morphology  
 
Class of 
protein 
RhoGTPase  
RhoA  Strong disruption of TJ and AJ junctions very disordered  RhoGTPase                ‐ P114RhoGEF  Strongly disrupted broken TJs, weaker effect on AJs  GEF  RhoA MCF2L/Dbs  Weak disruption of both TJs and AJs junctions broken, cells appear flatter    GEF  RhoA/Cdc42 DLC1  Strong disruption of TJs broken discontinuous, weaker effect on AJs  GAP  RhoA 
DLC2  Weak disruption on TJs  weak effects on AJs  GAP  RhoA / Cdc42 DLC3  Strong disruption of TJ and AJ very disordered    GAP  RhoA / Cdc42 MRCKα  Weak disruption of TJs, cells appear flatter,  weak effect on AJs   Effector  Cdc42 MRCKβ  Strong effect on TJ broken disordered AJs very disordered look irregular  Effector  Cdc42 Obscurin/OBSCN  Strong disruption of TJs, weaker effect on AJs, cells appear flatter.    GEF  Not determined OPHN1  TJs broken discontinuous cells appear larger and flatter weaker effect on AJs  GAP  RhoA PLXNA1  TJ broken discontinuous weak effect on AJ,  Cells appear flat and larger   Semaphorin  Receptor                  ‐ PLXNB1  TJ broken and discontinuous, weaker effect on AJs, cells appear large and very flat   Semaphorin  Receptor                  ‐ TC10/RhoQ  TJ broken disorganised, AJ appear disordered, cells appear flatter  RhoGTPase                  ‐ Trio  Strong effect on TJs broken  discontinuous  no effects on AJs   GEF  Rac1/ RhoA Vav3  Strong effect on TJs broken discontinuous, increased cytoplasmic distribution of TJ components, disorganized AJs, cells appear flatter   GEF  RhoG/ RhoA, possible Rac1 
Table 3.2 Summary of validated candidates 
A  subset  of  candidates were  validated  by  deconvolution  of  the  siRNA pool  used  in  the  primary  screen. Individual siRNAs deconvoluted from this pool, were used to confirm if the same phenotypes on junction morphology observed with siRNA pools could be reproduced. Shown is a short description of the effect on junctions, the class of protein they are GEF/GAP etc. and what RhoGTPase they are known to regulate or be an effector of.  Note several of the candidates shown here PLXNA1, PLXNB1, TC10, Trio and Vav3 were not  identified in the primary screen in HCE cells, but were known to effect  junction formation in Caco‐2 cells  (Matter  2007  unpublished  results)  these  proteins were  also  validated with  individual  siRNAs  and gave effects on Junction formation in HCE cells. 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Chapter 3 – Discussion 
 
In this study I set out to identify novel regulators and effectors of RhoGTPase 
signalling that regulate junction formation and gene expression in HCE cells. To 
do this I used a RhoGTPase siRNA library, combined with functional assays to 
observe junction formation gene expression. Effects on junction formation were 
observed using immunofluorescent microscopy with antibodies to known 
junctional components and effects on gene expression were measured using a 
luciferase based reporter assays to observe constitutive NF-κB activity. In this 
discussion I will primarily focus on candidates identified from the siRNA screen 
that effected junction formation, as a subset of these were validated in contrast 
to the non-validated candidates identified from the siRNA screen that effected 
NF-κB activity.  
 
A total of 63 candidates were identified from this initial screen as having effects 
on junction morphology.  Candidates were sorted into different bins according to 
if there was a strong or weak effect on junction morphology.  A total of 26 
candidates were classified as having strong effects on junction formation.  
Amongst the strong category in the junction assembly screen were the 
RhoGTPases RhoA and Cdc42. It was unsurprising that these two 
RhoGTPases had strong effects on TJ, AJ and polarity, as they both have 
established crucial roles in epithelial junction formation and the maintenance of 
polarity 18. However the RhoGTPase, Rac1 gave weaker effect on junction 
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formation. This is a surprising result as Rac1 is known to be critical for junction 
formation, specifically in the initiation of adhesion 280. This discrepancy could be 
simply explained by less efficient suppression of Rac1, but alternatively maybe 
due to insufficient suppression of Rac1 at the early stages of junction formation 
were it is known to play a prominent role.  
 
In addition to the RhoGTPases, RhoA, Cdc42 and Rac1, the RhoGTPase 
RhoBTB3 also had effects on junction formation. RhoBTBs are atypical 
GTPases that are thought to be constitutively active by binding GTP. This 
means it is not regulated by GEFs or GAP proteins, but by  protein expression 
phosphorylation 142.  The RhoBTB family consists of three members RhoBTB 1 
and 2 and 3 all contain a characteristic BTB (Bric-a-brac, tramtrack, Broad 
complex) domains. RhoBTB 1 and 2, are most similar and have been identified 
as tumour suppressor genes, with RhoBTB2 having been shown to be 
downregulated in several tumour types 285.  RhoBTB3 has recently been shown 
to be involved in retrograde trafficking from endosomes to Golgi trafficking 
acting as a downstream effector of the RabGTPase, Rab9 286. Interestingly this 
study identified RhoBTB3 to bind and hydrolyse ATP rather than GTP. This 
ATPase activity was thought to be important for the release of cargo from 
endosomes to permit efficient docking and fusion to the Golgi. Rab13 has been 
linked to the recycling of tight junctional protein Occludin 287 and has been 
proposed to play a role in TJ development in the trophectoderm of the mouse 
blastocyst 288. It is possible that RhoBTB3 together with Rab9 forms a new 
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pathway that is critical for junction formation and maintenance, by recycling 
junctional though endosomes back to the membrane. 
 
The screen identified a number of GEFs and GAPs and downstream effectors 
of the RhoGTPases RhoA and Cdc42. These two RhoGTPases clearly gave the 
strongest effects on junction morphology. I therefore decided to sort candidates 
into two lists based on known information from the literature, about which 
RhoGTPase they are known to regulate or are a downstream effector for. 
Several of these candidates from this list (Table 3.1) along with several 
additional candidates not identified from the primary screen in HCE cells, but 
identified in an identical screen in Caco-2 cells (Matter 2007 unpublished 
results), were chosen for validation using individual siRNAs derived from the de-
convolution of the original siRNA pool used in the screen. A complete list of 
validated candidates was produced (Table 3.2) I will now focus this discussion 
on a few examples of these validated candidates (Dbs, MRCKα and β and 
p114RhoGEF).  
 
The GEF MCF2L a.k.a Dbs was one of these validated candidates; absence of 
Dbs caused junctions to form with broken discontinuous lines and cells also 
appeared flatter. AJ and TJ seemed affected as both had perturbed 
morphology. Dbs was discovered in a screen for cDNAs that had transforming 
ability when overexpressed in fibroblasts 289 Dbs is known to stimulate 
nucleotide exchange for Cdc42 and RhoA in vitro 290, 291. However RhoGTPase 
specificity seems to be cell type dependent 156, 292. The PH domain of Dbs binds 
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to phosphoinositide lipids, and lipid binding is known to be required for its 
transforming activity. Interestingly the PH domain also mediates binding to the 
active, GTP bound Rac in vitro, suggesting Dbs can act as a Rac effector 292. 
Dbs was also indentified as inhibiting constitutive NF-κB activity in HCE cells 
suggesting a role in proliferation /cell survival. However, this result has not yet 
been validated using individual siRNAs, but this result is in agreement with a 
previous study that demonstrates that Dbs promotes growth by activation of 
transcription from the cyclin D in an NF-κB dependent manner 291. Further 
studies will need to be performed to confirm its RhoGTPase specificity in HCE 
cells and other epithelia. This will require investigations that dissect the 
molecular mechanisms involved in spatially coordinating RhoGTPase signalling 
during junction assembly and proliferation. 
 
Two other candidates MRCKα and β were also validated for their effects on 
junction assembly. Absence of MRCKα caused flatter cells with broken and 
discontinuous TJs, but had weaker effects on AJs causing them to appear more 
undulated than straight AJs in control transfected cells. MRCKβ seemed to 
cause a stronger phenotype than MRCKα with TJs and AJs appearing broken 
and very warped and undulated. MRCKs are both known to be effectors of 
Cdc42 and regulate cytoskeletal reorganization though several mechanisms. 
MRCKs are related to the Rho kinases ROCKs, sharing high sequence identity 
in their kinase domains, and act on similar substrates, but contain different 
RhoGTPase binding domains to ROCKs 293. MRCKs can phospholyate MLC 
leading to Myosin II activation, in a manner that is independent of RhoA/Rock or 
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MLCK signalling. MRCKs can also phospholyate ERM proteins, that contribute 
to the cytoskeletal organization that directs filopodia formation 294. Evidence 
from several studies has also demonstrated MRCKs to have important roles in 
cell migration contributing to the invasive properties of cancer cells 295 296. 
During cell migration MRCKs are involved in regulating actin retrograde flow, a 
process whereby actin filaments flow from the front to the back of the extreme 
margin of the cell lameliipodia in a Myosin II dependent manner 296. It will be 
interesting to investigate the molecular mechanisms, whereby MRCK α and β 
regulate the junction associated actin cytoskeleton.  
One possibility for the function of MRCKs in junction formation is via 
actinomyosin contractility of the perijunctional actin cytoskeleton during the later 
stages of junction maturation. Calcium switch experiments will need to be 
performed to identify the precise stages of junction formation that MRCKs 
regulate. However there is a large amount of evidence that implicates RhoA 
signalling to regulate actinomyosin contractility during junction formation. 
Interestingly a recent study highlighted the role of different isoforms of Myosin II 
play during junction assembly 139. Myosin IIA is regulated by a RhoA/ Rock 
signalling pathway, and IIB by signalling from the GTPase Rap.  Activation of 
Rap1 could lead to activation of Cdc42 297, that may result in Myosin IIB 
activation via MRCK. Dissecting out the contribution of RhoA/ Rock and Cdc42 
MRCK mediated Myosin activation in junction assembly and how these two 
pathways coordinately regulate different Myosin II isoforms remains a challenge 
for future experiments.  
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p114RhoGEF was the final candidate to be validated. Its absence 
predominately affected TJ formation in HCE and Caco-2 cells. p114RhoGEF 
was previously reported to be an exchange factor for RhoA188 In the next 
chapter (Chapter 4). I greatly expand on the function of p114RhoGEF in 
epithelial cells, and identify the molecular mechanisms that underlie its function 
in junction formation.  
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CHAPTER 4  
 
Spatially restricted activation of 
RhoA by p114RhoGEF drives 
epithelial junction formation 
and morphogenesis. 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Chapter  4  ­Spatially  restricted  activation  of  RhoA  by 
p114RhoGEF  drives  epithelial  junction  formation  and 
morphogenesis. 
 
The  results  in  this  chapter have been accepted as a manuscript  in November 2010 
titled  ‘Spatially  restricted  activation  of  RhoA  signalling  at  epithelial  junctions  by 
p114RhoGEF  drives  junction  formation  and  morphogenesis’  to  the  Journal  Nature 
Cell Biology 
 
Overview  
 
This chapter contains a full detailed analysis of p114RhoGEF a candidate from 
the siRNA screens, that upon depletion inhibits the assembly of tight junctions 
in different epithelial cell types. p114RhoGEF is a gene that is widely expressed 
in different tissue types 188 and belongs to the family of Dbl GEF proteins having 
a characteristic tandem DH-PH domains. It is known to function as a specific 
activator of RhoA in vitro and to induce the formation of stress fibres and 
activating serum response element mediated gene transcription 298. Here I 
greatly expand on the function of p114RhoGEF in epithelial cells, by identifying 
it as a novel tight junction-associated activator of RhoA that regulates epithelial 
differentiation, barrier formation and epithelial three-dimensional 
morphogenesis in MDCK and Caco-2 cultures. I demonstrate that p114RhoGEF 
drives the spatial activation of RhoA at cell-cell contacts and subsequently the 
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activation of the junctional actinomyosin cytoskeleton, ultimately regulating the 
organisation of the junctional cytoskeleton during junction assembly. I 
discovered mechanistic evidence for p114RhoGEF being part of a junction-
associated Rho signalling module formed by p114RhoGEF, Myosin IIA, Rock II 
and the junctional adaptor protein Cingulin. I show that the formation of this 
complex is dependent on the assembly of cell-cell junctions and that junctional 
adaptor Cingulin is required for efficient recruitment of p114RhoGEF to cell-cell 
junctions.   
 
Localisation of p114RhoGEF in epithelial cells   
I investigated the cellular localisation of p114RhoGEF in HCE and Caco-2 cells 
and discovered it localised to apical cell junctions, but also had a diffuse 
cytoplasmic distribution (Figure 4.0). By performing p114RhoGEF RNAi using a 
pool of p114RhoGEF specific siRNAs, I observed a reduction in the cytoplasmic 
and junctional staining in p114RhoGEF knockdown cells compared to the 
control. This established that the staining observed was specific for 
p114RhoGEF (Figure 4.0). I wanted to establish if p114RhoGEF was localised 
specifically to TJs in HCE cells by observing if p114RhoGEF co-localised with 
Occludin a protein known to localise to TJs, or more with E-Cadherin, an 
integral transmembrane protein associated with AJs (Figure 4.1).  I found it 
difficult to determine if p114RhoGEF was localised to TJs in HCE cells as TJs 
and AJs appeared difficult to resolve clearly as they form a flatter monolayer 
than Caco-2 cells,  that have a more columnar shape and TJs and AJs can be 
more clearly resolved. In Caco-2 cells p114RhoGEF localisation demonstrated 
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clear co-localisation with Occludin and very little co-localisation with E-Cadherin 
(Figure 4.1), thus demonstrating p114RhoGEF is present at TJs. 
 
 
 
 
 
 
 
 
      
 
A 
B 
Figure 4.0 p114RhoGEF is localised to apical cell junctions and the cytoplasm. 
A HCE and Caco‐2 cells  immunostained with p114RhoGEF (red), β‐Catenin  (green) and the TJ protein Occludin (Blue) B HCE and Caco‐2 cells fixed with methanol and immunostained  for  p114RhoGEF  after  72  hours  transfection  with  control  non targeting and pool of p114RhoGEF siRNAs. 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Figure 4.1 p114RhoGEF is localised to TJs   A single confocal x/y section of HCE( top panels) and Caco2 cells (bottom panels), immunostained with p114RhoGEF (red) and the TJ protein Occludin (green) on the left is a slice through the z axis 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RhoGTPase specificity of p114RhoGEF   
p114RhoGEF had been characterised  previously as being a GEF for RhoA, but 
also Rac1, but not Cdc42 298. To investigate the RhoGTPase specificity of 
p114RhoGEF in HCE cells. I suppressed levels of p114RhoGEF by transfection 
of two individual siRNAs, as well as a pool made up of these two individual 
siRNAs. I measured active levels of the three main RhoGTPases RhoA, Rac 
and Cdc42, using a RhoGTPase activation assay (GLISA). I discovered that 
depletion of p114RhoGEF specifically reduced active RhoA, but not Rac or 
Cdc42, suggesting that it is mainly required for RhoA activation (Figure 4.2). 
 
  
 
 
Figure 4.2 p114RhoGEF specifically 
activates RhoA.   GLISA assay performed in HCE cells 72 hours  after  transfection  with  control non‐targeting  siRNA  or  with  two different  individual  p114RhoGEF siRNAs  or  a  pool  of  both  the individuals.  Levels  of  active  RhoA, Cdc42  and  Rac  are  shown  normalised to  control  levels. Bars  represent mean average  of  triplicate  experiments. Error bars represent +/‐1 SD.  
 151 
p114RhoGEF is required for the assembly of functional epithelial barriers  
 
I investigated if epithelial cells depleted of p114RhoGEF can form functional 
epithelial barriers, by testing the permeability properties of TJs. To observe de 
novo junction formation, I performed a calcium switch assay in Caco-2 cells 
depleted of p114RhoGEF, using two different siRNA pools (si-Genome and On-
Target plus), I measured the TER (a measure of the instantaneous ion 
conductance of an epithelial sheet) over a period of 48 hours to follow barrier 
formation (Figure 4.3). There was a clear impairment of TER development in 
p114RhoGEF depleted cells, having a 3 fold lower TER compared to controls, 
indicating increased permeability of the epithelial barrier to ions (Figure 4.3). 
Permeability after 48 hours in normal calcium medium of the epithelial 
monolayer to two different sizes of dextran tracers, was found to be greatly 
increased in p114RhoGEF depleted cells (Figure 4.3), indicating TJs were 
permeable to hydrophillic tracers. These experiments thus provide strong 
evidence that p114RhoGEF is essential for the formation of functional epithelial 
barriers. Levels of active RhoGTPases were measured 20 hours after the 
restoration of normal calcium conditions in Caco-2 cells. A clear reduction of 
active RhoA, but not Cdc42 and Rac1 was observed (Figure 4.4) providing 
supporting evidence that p114RhoGEF acts specifically to activate RhoA during 
the assembly of junctions. 
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Figure 4.3 p114RhoGEF regulates epithelial 
barrier formation. 
 Caco‐2 cells transfected with control (non targeting) or  to  two  different  pools  of  p114RhoGEF  specific siRNA (siRNA 1/2 (a pool of two individual siGenome siRNAs  and  On  Target  plus  pool)  were  trypsinised and  plated  onto  filters  in  low  calcium media  for  24 hours  to  prevent  formation  of  cell‐cell  contacts. Normal  calcium  media  was  added  and  cell‐cell contact formation was monitored during the next 48 hours  by  measuring  Trans  epithelial  resistance (TER). Shown are mean averages and SD of triplicate experiments.  Paracellular  tracer  permeability  after 48 hours was determined using two different sizes of fluorescently labelled dextrans. Bars represent mean averages and error bars SD of triplicate experiments.   Expression  of  p114RhoGEF  and  other  junction proteins  (  GEF‐H1  and  Occludin),  as  well  as  α‐Tubulin as a loading control were assayed at the end of the experiment by immunoblot. 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Figure  4.4  p114RhoGEF  specifically  activates  RhoA  during  junction 
assembly. G‐Lisa  assay  performed  in  Caco‐2  cells  depleted  of  p114RhoGEF.  After depletion  Caco‐2  cells  were  trypsinised  and  plated  out  in  low  calcium media  for  24  hours  to  prevent  formation  of  cell‐cell  contacts.  Normal calcium  media  was  added  to  induce  cell‐cell  contact  formation  for  20 hours, after which levels of active RhoGTPases RhoA, Cdc42 and Rac were determined. Bars represent mean averages and error bars SD of triplicate experiments. 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Morphological analysis of cells incubated at different times after calcium 
replenishment revealed p114RhoGEF depletion did not affect initial cell 
spreading and the initiation of cell-cell contacts, as ZO-1 accumulation was 
observed at forming junctions, already after 1 hour and f-actin staining revealed 
well spread cells. (Figure 4.5). However ZO-1 staining remained discontinuous 
after 24 hours. Similar observations were made with other junctional markers 
after 4 hours, (Figure 4.7).  As a control for the specificity of the impaired 
junctional formation effects of p114RhoGEF depletion, I reduced levels of GEF-
H1, another TJ associated RhoA specific GEF. As expected with previously 
reported results 64 GEF-H1 depleted cells spread more slowly with “roundish” 
looking cells being detected 1 hour after calcium replenishment  (Figure 4.6). 
However, GEF-H1 depleted cells did established morphologically normal 
junctions. p114RhoGEF and GEF-H1 seem to function at different stages of 
junction formation. In agreement with previous observations GEF-H1 is not 
required for junction formation, but to regulate the early stages of cell spreading 
and the initial stages of cell contact formation 212, 255, 299, whereas p114RhoGEF 
functions at a later stage of junctional maturation.  
 
I discovered p114RhoGEF to be recruited to cell-cell junctions already after 1 
hour of junction reformation (Figure 4.8). Myosin IIA, a downstream target for 
RhoA activation in junction formation 300 280, also associated with junctions at 
this early time point; however,  it was not recruited to cell-cell junctions in 
p114RhoGEF depleted cells and instead localised to intense actin stress fibre 
arrays at the base of cells (Figure 4.8). GEF-H1 was not recruited to the forming 
junctional complex in p114RhoGEF depleted cells where it normally would be 
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inactivated, therefore GEF-H1 may contribute to activation of RhoA and lead to 
the increase in the basal stress fibres (Figure 4.9).  
 
                        
 156 
 
 
    
Figu
re 4
.5
 p
1
1
4
R
h
oG
E
F is in
volved
 in
 ju
n
ction
 m
atu
ration
 as op
p
osed
 to G
E
F­H
1
 th
at regu
lates cell 
sp
read
in
g an
d
 early ad
h
esion
.    
Caco2 cells transfecfected with control non‐targeting, p114RhoGEF and GEF‐H1 specific pools of siRNA were 
plated in low calcium. Cells were fixed at various times indicated in hours after the replenishment of calcium 
and immunostained for the TJ protein ZO‐1. Expression of p114RhoGEF, GEF‐H1 and α‐Tubulin as a loading 
control were assayed at the end of (24 hours after calcium replenishment) the experiment by immunoblot. 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Figure  4.6  Cell  morphology  during  junction  reformation  in 
p114RhoGEF and GEF­H1 depleted cells.  Caco‐2  cells  depleted  of  GEF‐H1  and  p114RhoGEF were  trypsinised  and plated onto glass for 24 hours in low calcium media (0 hours). The media was replaced with normal calcium media for 1 hour before being fixed and stained    for  f‐actin  with  TRITC  conjugated  phalloidin.  Note,  rounded appearance of GEF‐H1 depleted cells after 1 hour. 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Figure 4.7 Recruitment of different junctional proteins to reforming 
juctional complexes in p114RhoGEF depleted cells. Caco‐2  cells  depleted  of  p114RhoGEF were  trypsinised  and  plated  onto glass  for  24  hours  in  low  calcium  media  (0  hours).  The  media  was replaced with  normal  calcium media  for  4  hours  before  being  fixed  and stained for TJ markers Cingulin, Occludin and AJ markers α and β‐Catenin. 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Figure 4.8  p114RhoGEF is recruited to junctions early and its absence 
causes redistribution of Myosin IIA from forming junctions to basal 
stress fibre arrays.  Caco‐2 cells depleted of p114RhoGEF were trypsinised and plated onto glass for 24 hours in low calcium media before the media was replaced with normal calcium media.  Cells  were  at  fixed  at  1  hour  and  24  hour  time  points  and stained for Myosin IIA and p114RhoGEF. 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Figure 4.9 Absence of p114RhoGEF causes redistribution of Myosin IIA and 
GEF­H1 Caco‐2 cells depleted of p114RhoGEF were trypsinised and plated onto glass for 24  hours  in  low  calcium  media  before  the  media  was  replaced  with  normal calcium media. Cells were at fixed at 24 hour time point and stained for Myosin IIA and p114RhoGEF and GEF‐H1. 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p114RhoGEF regulates epithelial morphogenesis in three dimensional cysts.     
I wanted to analyze if p114RhoGEF was a regulator of epithelial morphogenesis 
by using a three dimensional culture system that allows the formation of 
polarised cysts with a central lumen 301. p114RhoGEF was depleted in Caco-2 
cells by siRNA transfection of a p114RhoGEF specific siRNA pool and in MDCK 
cells by expression of p114RhoGEF specific shRNAs( Figure 4.10). Depletion 
affected both cell types and resulted in cysts that had a disorganised 
appearance often having multiple lumens (Figure 4.11-12). Confocal 
microscopy revealed an irregular distribution of ZO-1. However, podocalyxin an 
apical marker in MDCK cells still accumulated in lumens, suggesting absence of 
p114RhoGEF does not cause a loss of polarity, but a disorganised cyst 
structure, possibly due to a perturbation of actinomyosin tensile forces required 
to maintain normal cyst morphology.    
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Figure 4.10  Efficiency of p114RhoGEF in 3D MDCK and Caco­2 Cysts.   For  Caco‐2  cyst  cultures  p114RG  was  depleted  using  pool  of  p114RG  specific siRNA. For MDCK cyst cultures stable cells lines expressing control, non targeting shRNA,  two  different  individual  p114RG  shRNAs  (shRNA1  and  shRNA2)  and another  expressing  both  shRNA  (shRNA1/2  two  different  clones  shown  8  and 38). Depletion of p114RhoGEF  in cyst cultures was analysed by  Immunobloting membranes with p114RhoGEF and with α‐Tubulin as a loading control. 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Figure 4.11 p114RhoGEF regulates epithelial morphogenesis in Caco­2 3D cyst 
cultures.  p114RG  was  depleted  in  Caco‐2  cells  by  transfection  of  p114RG  specific  siRNAs.  After 5 days control (non targeting) transfected siRNA and p114RG depleted cultures were analysed by Phase contrast microscopy and quantified by counting the number of cysts  that had a single  lumen or structures  that had disorganised appearance or multipliable lumens, the mean and SD+/‐ are shown for n=3.The cultures were then fixed  and  stained  and  processed  for  confocal  microscopy  using  staining  for  ZO‐1 (green) f‐Actin (red) and DNA (blue). Scale bar represents 10µm. 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Figure 4.12 p114RhoGEF regulates epithelial morphogenesis in MDCK 3D cyst 
cultures.  p114RG was depleted  in MDCK cells by generating cell  lines expressing shRNAs  to p114RG.    After  5  days  control  (non  targeting)  shRNA  expressing  and  p114RG depleted  cultures  were  analysed  by  Phase  contrast  microscopy  and  quantified  by counting  the  number  of  cysts  that  had  a  single  lumen  or  structures  that  had disorganised  appearance  or multipliable  lumens. Mean  and  SD  are  shown  for  n=3. The  cultures  were  then  fixed  and  stained  and  processed  for  confocal  microscopy using staining for ZO‐1 (red) f‐Actin (blue) and polarity marker podocalyxin  (green). Scale bar represents 10µm. 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Spatially restricted activation of RhoA and subsequent Myosin II activation is 
regulated at cell­cell contacts by p114RhoGEF  
 
The localisation of a RhoGTPase to a specific membrane domain or 
compartment, where a specific GEF is recruited or resides is thought to be 
essential to the spatially restricted control of a RhoGTPase. The recruitment of 
p114RhoGEF to junctions and the apparent effects of its depletion on Myosin 
recruitment and distribution suggested that p114RhoGEF, may stimulate Rho 
signalling at the junctional complex in a spatially restricted manner. I wanted to 
investigate if this was a function of p114RhoGEF by using a FRET 
(Fluorescence Resonance Energy Transfer) –based RhoA biosensor to 
visualise active RhoA in live cells after depletion of p114RhoGEF and as a 
control of another specific RhoA GEF, GEF-H1 (Figure 4.13).  
 
In control cells transfected with non-targeting siRNA the most intense FRET 
signal, indicating active RhoA, localised along cell-cell junctions. There was also 
a small amount of less intense FRET signals distributed throughout the 
cytoplasm. Depletion of p114RhoGEF led to a dramatic redistribution of the 
intense FRET signal away from cell junctions and was increased throughout the 
cells including the basal domain.  Depletion of GEF-H1 did not change 
distribution of the FRET signal indicating these effects were specific to 
p114RhoGEF. I quantified the amounts of FRET signal at cell-cell junctions and 
at internal areas (Figure 4.14) and discovered the change in the distribution of 
the FRET signal at cell-cell junctions and internal regions in p114RhoGEF 
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depleted cells vs that of control or GEF-H1 depleted cells was statistically 
significant. I performed the FRET experiments in Caco-2 and HCE cells and 
found comparable results, indicating that p114RhoGEF is required for spatially 
restricted activation of RhoA at cell-cell junctions.   
 
    
 
Figure  4.13  p114RhoGEF  regulates  spatially  restricted  activation  of  RhoA 
signalling at cell junctions.  
Caco‐2 and HCE cells were transfected with control non‐targeting and p114RhoGEF and GEF‐H1 specific  siRNAs,  then 2 days after with a plasmid containing  the FRET RhoA  biosensor.    RhoA  activity  was  imaged  by  gain  of  CFP  fluorescence  after acceptor  bleaching,  displayed  as  the  level  of  FRET  efficiency.  Shown are  images  of control, p114RhoGEF and GEF‐H1 depleted cells. 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Figure 4.14 Quantification of FRET signal at cell­cell contacts and Internal 
areas in Caco­2 and HCE cells.   
 Images were  quantified  by  normalising  FRET  efficiency  in  specific  cellular  regions (cell‐cell  contacts  (grey bars) or  internal cytoplasm (Green bars)), against  the  total FRET efficiency  in  the quantified  fields of view. Bars represent mean of 12  images, error bars =  +/‐ 1 SD. 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p114RhoGEF regulates active Myosin IIA distribution   
RhoA is an important regulator of cytoskeletal dynamics. One of the main 
targets of RhoA signalling is the phospholyation of the regulatory light chain of 
Myosin II (MLC) at Threonine 18 and Serine 19, leading to Myosin activation, 
and actinomyosin contraction. Based on the evidence that p114RhoGEF 
activates RhoA at cell-cell junctions and its effect on Myosin distribution, I 
wanted to observe the effects on the organisation of the actin cytoskeleton and 
Myosin activation in p114RhoGEF depleted cells.   
 
I found a disruption of the actin cytoskeleton in p114RhoGEF depleted cells, 
with peri-junctional f-actin appearing reduced and more loosely bundled 
compared to control cells. I also surprisingly observed an increase in the 
formation of stress fibres at the base of cells (Figure 4.15). In control cells 
Myosin II and MLC were distributed along the junctional complex and to a 
lesser extent along the basal membrane in Caco-2 and HCE cells (Figure 4.16-
17).  In the absence of p114RhoGEF there was a dramatic redistribution of 
Myosin IIA and MLC from junctions to stress fibres (Figure 4.16-17). This 
reflected redistribution of active Myosin, as phosphorylated MLC was located 
along junctions in control cells (in Caco-2 cells in a punctuate manner and HCE 
cells, in a more continuous distribution) and redistributed to stress fibre arrays in 
p114RhoGEF depleted cells. Total levels of phosphorylated MLC remained 
unchanged in Caco-2 cells and were slightly reduced in HCE cells. In addition 
levels of phospholyated (inactive) Myosin phosphatase target subunit (MYPT) a 
substrate of ROCK, that functions to inactivate Myosin II via dephospholyation 
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of MLC, also remained unchanged (Figure 4.18). This suggests that the 
increase in active Myosin observed on basal stress fibres may compensate for 
loss of active Myosin II at junctions. Thus total levels of phospholyation of these 
two Myosin regulators appear unchanged.   
 
 
          
Figure  4.15  p114RhoGEF  depletion  causes  disorganisation  of  peri­ 
junctional actin and leads to increase in stress fibres.  Caco‐2  and HCE  cells were depleted of p114RhoGEF by  siRNA  for 72 hours (bottom  pannels)  after  being  fixed  and  stained  with  TRITC‐  conjugated phalloidin to visualise f‐Actin. For Caco‐2 cells two fields of view were taken an apical (left) and basal (middle). 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Figure 4.16 Absence of p114RhoGEF causes redistribution of Myosin IIA 
from cell­cell contacts to basal stress fibre arrays.   Caco‐2 cells were depleted of p114RhoGEF using siRNA for 72 hours after being fixed  and  immunostained  with  Myosin  IIA  and  Myosin  light  chain  (MLC2) antibodies. Apical and basal fields of view are shown for each antibody stain. 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Figure 4.17 Active Myosin  II  is  redistributed  from cell­cell  junctions  to stress 
fibres in Caco­2 and HCE cells.  Caco‐2  and  HCE  cells  depleted  of  p114RhoGEF  by  siRNA  for  72  hours  after  being fixed  and  immunostained with  an  antibody  that  recognises  phospholyated Myosin light  chain  (pThr18p‐Ser19MLC2 and ppMLC2). For Caco‐2 cells  two  fields of view are shown apical and basal (top panel ). For HCE cells Myosin IIA staining is shown in addition to active Myosin IIA. 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Figure 4.18 Levels of  active Myosin  II  and Myosin phosphatase  remain 
unchanged in p114RhoGEF depleted cells.  Whole  cell  lysates  from  Caco‐2  and  HCE  cells  transfected with  control  non targeting  siRNA or  p114RhoGEF  specific  siRNAs.  After  72  hours RNAi were immunobloted  for  p114RhoGEF  ,  Myosin  IIA,  Myosin  light  chain  (MLC2), active  phospholyated  MLC2  (ppMLC2),  Myosin  phosphatase  target  subunit MYPT, inactive phospholyated MYPT (p‐MYPT) and α‐ tubulin to assess total protein levels. 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In summary these observations suggest p114RhoGEF is required for spatially 
restricted control of RhoA and subsequent activation of Myosin at cell-cell 
junctions. Its absence leads to defective junction assembly, cell spreading and 
increases in RhoA signalling along the basal domain of cells leading to the 
formation of stress fibres decorated with activated Myosin II.   
 
Overexpression of p114RhoGEF induces,  junctional actinomyosin 
contraction   
If p114RhoGEF regulates the activation of junction associated Myosin, 
overexpression may induce junctional actinomyosin contraction. To test this 
hypothesis, I made C-terminally VSV tagged expression constructs of 
p114RhoGEF to study the effects of its exogenous expression on actinomyosin 
contraction.  
 
Indeed cells expressing VSV tagged p114RhoGEF caused cells to have an 
apically contracted, rounded morphology and increased peri-junctional actin 
filaments (Figure 4.19-21). In HCE cells compaction was very striking with 
overexpressing cells greatly increased in height and adopting an elongated  
“dome like” appearance compared to normal relatively flat non-transfected cells. 
(Figure 4.20). To determine if these morphological effects required RhoA 
activation, I mutated a highly conserved tyrosine residue to alanine (Y260A) 
present in the DH domain of 114RhoGEF. Analogous mutations were 
previously shown to inactivate the GEF activities of GEF-H1 and Lbc 302, 303. I 
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tested if the Y260A mutation was able to inhibit p114RhoGEF catalytic ability to 
activate RhoA by making stable MDCK cell lines to allow inducible expression 
of wild type and mutant p114RhoGEF. Overexpression of the Y260A mutant did 
not activate RhoA levels, compared to that of wild type p114RhoGEF, validating 
its use as a catalytically inactive mutant (Figure 4.22).  Expression of the Y260A 
mutant severely abrogated cell elongation with the majority of overexpressing 
cells having a normal relatively flat morphology (Figure 4.20), demonstrating 
RhoA activation is required for this effect.  Overexpression of GEF-H1, a RhoA 
specific exchange factor that is not active at junctions 64, did not induce 
contraction of the perijunctional actinomyosin ring, indicating that the phenotype 
observed is specific for p114RhoGEF and not a general effect of transfection of 
a RhoA GEF (Figure 4.21). In stably transfected MDCK cells up-regulation of 
the active p114RhoGEF GEF led to increased f-actin and phospholyated MLC 
at cell junctions, as well as ROCK-dependent rounding and monolayer 
contraction. (Figure 4.22-23). Furthermore, I found increased total levels of 
phosphorylated MLC, in addition to increased phospholyated levels of cofilin 
(Figure 4.25), a protein that is inactivated by phospholyation  and that functions 
to disassemble actin filaments 304 241, indicating the inactivation of cofilin may 
have a role in the enrichment of peri-junctional actin in p114RhoGEF over-
expressing cells.  
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Figure 4.19 Changing of cell morphology in response to 
p114RhoGEF overexpression.   Caco‐2  and  HCE  cells  were  transfected  with  cDNAs  encoding  C‐terminal tagged VSV p114RhoGEF (p114RhoGEFVSV) and catalytically inactive  mutant  p114RhoGEF  (p114RhoGEF  Y260A‐VSV).  Cells  were left to express the proteins for 20 hours before fixation and processing for immuno fluorescent staining with VSV and Occludin antibodies. 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Figure 4.20 Quantification of change in cell morphology caused by 
overexpression of active p114RhoGEF. Images  shown  in  figure  4.18  for HCE  and Caco‐2  cells  expressing wild  type p114RhoGEF(WT)  or  inactive mutant  p114RhoGEF(Y260A) were  quantified by  counting  transfected  cells  with  a  rounded/contracted morphology  (grey bars), normal/ flat cells (red bars) as well cells having abnormal morphology apart from rounding (green bars). Bars represent mean of 3 experiments. 100 cells counted per experiment. Error bars represent +/‐ 1 SD. 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HCE cells were transfected with cDNA containing p114RhoGEF‐VSV, mutant p114RhoGEFY260A 
and GEF‐H1‐VSV. Proteins were expressed for 20 hours and fixed and processed for immuno fluorescent staining using FITC‐conjugated phaloidin to visualise f‐actin 
(green) VSV antibody (red) and DNA stain Hoechst 33258(blue). Shown are z line scans and xy sections grey lines on xy section represent were z line was taken. Note 
the contracted appearance of cells expressing active p114RhoGEF; scale bars in grey represent 10µm. 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Figure 4.22 Levels of active RhoA in stable MDCK cells overexpressing 
p114RhoGEF­VSV and p114RGY260A­VSV  
 Expression of p114RhoGEF and p114RhoGEFY260A was induced by tetracycline in stable MDCK cells lines for 24 hours before performing GLISA assay to observe levels of active RhoA. Note inactive mutant p114RhoGEFY260A does not increase activate  levels  of  RhoA  when  overexpressed,  whereas  wild  type  p114RhoGEF does. Bars represent mean average of 3 experiments normalised to p114RhoGEF –tet control, error bars +/‐ 1 SD. 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Figure 4.23 Overexpression of p114RhoGEF causes ROCK dependent cell rounding 
and monolayer contraction.   MDCK cells induced for stable expression of VSV tagged p114RhoGEF or inactive mutant p114RhoGEFY260A by Tetracycline for 24 hours, fixed and imaged using phase contrast microscopy.  Note  that  only  overexpression  of  active  p114RhoGEF‐VSV  causes  cell rounding and monolayer contraction, an event that is Rock dependent as addition of the Rock inhibitor Y‐27632 at the time of induction attenuates this effect.  
Figure 4.24 Peri­juctional actin and 
active Myosin are increased in 
MDCK cells stably expressing 
p114RhoGEF. 
 MDCK  cells  induced  for  stable expression  of  VSV  tagged  p114hoGEF by  Tetracycline  for  24  hours  before fixing  and  immunostaining with  FITC‐conjugated  phaloidin  (green)  and active  phospholyated  MLC  (ppMLC), (red) 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Figure 4.25 Overexpression of p114RhoGEF in MDCK cells causes increases 
in levels of phospholyated MLC and Cofilin.   Stable  MDCK  cells  lines  expressing  VSV  tagged  proteins  p114RhoGEF, p114RhoGEF Y260A and GEF‐H1 were induced for expression for 24 hours by the addition  of  Tetracycline  before  protein was  extracted  and  immunoblotted with specific  antibodies  to  VSV,  phospholyated  MLC  (p‐T18  p‐19MLC2),  Cofilin phospholyated  Cofilin  (p‐Cofilin),  p114RhoGEF  and  α‐Tubulin  as  a  loading control. 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p114RhoGEF forms a complex with Myosin II, Cingulin and the RhoA effector 
Rock II. 
  
As p114RhoGEF was known to regulate the junctional recruitment of Myosin, I 
investigated whether the two proteins were part of a common complex by 
immunoprecipitation. Indeed, p114RhoGEF immunoprecipitates contained 
Myosin IIA, as a control for the specificity of this interaction no Myosin IIA was 
detected in immunopreciptates of the negative control (goat IgG).  For efficient 
signal transduction, RhoGTPases are often in a complex with the GEF that 
activates them, as well as downstream effectors 148. We tested if this was the 
case for p114RhoGEF and discovered the RhoA effector, Rock II, but 
interestingly not Rock I was present in p114RhoGEF immunoprecipitates. 
(Figure 4.26). Cingulin a tight junction-associated adaptor known to form a 
complex with Myosin 63, 305 and regulate RhoA signalling 64, was also 
immunoprecipitated with p114RhoGEF, but not in negative IgG controls, 
suggesting that it might function in p114RhoGEF recruitment (Figure 4.26). 
Cingulin can also bind GEF-H1; however, co-immunoprecipitation of the two 
GEFs or Myosin or Rock II with GEF-H1 was not observed suggesting they are 
part of different complexes.  
 
To give mechanistic insight into how p114RhoGEF complexes containing 
Myosin, Cingulin and Rock II form, I repeated the immunoprecipitation 
experiments in cells plated in low calcium media to prevent the formation of cell-
cell junctions. I observed Myosin II, Cingulin or Rock II was not detected in 
 182 
p114RhoGEF immunopreciptates (Figure 4.25), indicating the requirement of 
cell-cell junctions for all members of this complex to form.   
 
I used GST fusion proteins of p114RhoGEF to map the domain of 
p114RhoGEF required for these interactions (Figure 4.27). I found full-length 
p114RhoGEF pulled down Myosin IIA, Cingulin and Rock II; however, the 
efficiency of pulldown was low, possibly reflecting the need for activation of 
many GEFs before they can bind signalling partners. This may be the case for 
p114RhoGEF as much of its cellular pool is located in the cytosol (Figure 4.0), 
possibly requiring activation for an efficient complex formation at cell junctions. 
The Pleckstrin Homology (PH) domain pulled down Myosin and Cingulin most 
efficiently out of all the GST- fusion proteins tested; however, it is difficult to 
make a direct comparison to the full-length protein as it has a weaker 
expression than the different p114RhoGEF fragments. Pull down of Rock II was 
less efficient, suggesting that Rho activation might be needed for efficient 
complex formation.  
The PH domain of some Dbl GEFs can bind to specific phosphatidylinositol 
lipids that can regulate the recruitment of the GEF to specific membrane sites 
160 and can also influence the activity of the GEF by the nature of the 
phosphatidylinositol lipid that is bound 158. I tested if the PH domain of 
p114RhoGEF bound to any specific lipids by performing a lipid-binding assay 
using a recombinant GST- PH domain fusion protein of p114RhoGEF (Figure 
4.28). I discovered the PH domain of p114RhoGEF did not bind to any lipids, as 
a control I used the C1 domain of GEF-H1, which was known to bind to 
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Phosphatidylinositol phospholyated at the 3,4 or 5 position ( PI(3)P, PI(4)P, or 
PI(5)P ). I also used the PH domain of GEF-H1 and demonstrated this did not 
bind any lipid either Indicating that the PH domains in these two GEFs, may 
function in protein-protein rather then lipid binding.  
 
I investigated if Cingulin was a factor required for the recruitment of 
p114RhoGEF to cell-cell junctions. Indeed depletion of Cingulin by siRNA in 
Caco-2 cells inhibited the association of p114RhoGEF to TJs. In HCE cells 
Cingulin was required for tight junction formation: as depletion lead to a loss of 
junctional staining of Occludin and ZO-1, but not E-Cadherin a component of 
AJs, thus producing a phenotype reminiscent of cells depleted of p114RhoGEF 
(Figure 4.29 and 4.7).  Cingulin and p114RhoGEF co-localised by confocal 
microscopy (Figure 4.30) and overexpression of Myc tagged Cingulin resulted 
in a redistribution of p114RhoGEF and Myosin IIA from the cytosol to peri-
junctional areas where the overexpressed Cingulin was localised(Figure 4.31-
32), further supporting evidence for a role of Cingulin in the recruitment of 
p114RhoGEF to TJs.  
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Figure 4.26 p114RhoGEF forms a complex with Myosin IIA, Cingulin and Rock II 
when cell­cell junctions are present.  p114RhoGEF  was  immunopreciptated  from  Caco‐2  cell  extracts  in  cells  grown  in media containing standard amount of calcium or cells grown in media containing low calcium to prevent the formation of cell‐cell junctions.  Two different goat IgGs were used  as  a  negative  control.  Co‐Immunoprecipitating  proteins  were  analysed  by immunoblotting with the antibodies described above. Note: Myosin IIA, Cingulin and Rock II do not form a complex with p114RhoGEF in the absence of cell‐cell junctions. And ZO‐1,2,3 and GEF‐H1 do not Coimmunopreciptate with p114RhoGEF. 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Figure 4.27  Myosin II, Cingulin and Rock II are pulled down using 
p114RhoGEF­GST fusion proteins.   
 A  schematic  representation  of  p114RhoGEF  (top)  showing  following  domains  DH (red)  PH  (yellow)  coiled  coil  (orange)  proline  rich  (puple).    GST  fusion  proteins containing full length and different domains indicated, in the schematic above were bound to beads and used for pulldown experiments in Caco‐2 cells. Pulldowns were analysed  via  immunoblot  for  Myosin  IIA,  Cingulin,  Rock  II  and  GST  to  observe amounts of fusion protein added. 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Figure 4.28 The PH domain of p114RhoGEF does not bind phospholipids.    A lipid binding assay was performed by incubating membranes containing different types  of  immobilised  lipids  with  1  µg/ml  of  different  recombinant  GST  fusion proteins.  Lipid  binding  was  detected  by  incubating  the  membrane  with  GST antibody.   Positive controls for protein that bind different lipids were the C1 domain of  GEF‐H1  and  PIP  GRIP  (containing  the  PH  domain  of  PLCδ),  GST was  used  as  a negative  control.    Note  no  lipid  binding  was  observed  using  the  PH  domains  of p114RhoGEF and GEF‐H1.   to investigate if the PH domain of p114RhoGEf   The PH domain of p114RhoGEF does not bind phospholipids 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Figure 4.29 Cingulin is required for efficient recruitment of p114RhoGEF to junctions. 
Caco‐2 and HCE Cells depleted of Cingulin by transfection of siRNAs.  After 72 hours cell lystates were immunoblotting  with  Cingulin,  p114RhoGEF  and α‐Tubulin  in  Caco‐2  cells,  or  cells  were  fixed  for immunostaining with Cingulin, p114RhoGEF and Occludin antibodies. Stars show cells that have more Cingulin due to less efficient knockdown. Scale bar represents 10µm. 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Figure 4.30 Cingulin and p114RhoGEF colocalise with each other at 
apical cell junctions. Caco‐2  cells  immunostained  with  p114RhoGEF  (red)  and  Cingulin (green)  and  the  DNA  stain  Hoechst  33258  (blue)  were  imaged  using confocal microscopy.  Shown  are  z  line  scan  and  xy  sections.  The  grey line on xy section represent were a z line was taken. Scale bars in grey represent 10µm. 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Figure  4.31  Overexpression  of  Cingulin  causes  redistribution  of 
p114RhoGEF Myc‐tagged  Cingulin  was  overexpressed  in  Caco‐2  and  HCE  cells  for  24  hours before cells were fixed and immunostained with p114RhoGEF (red), Myc (green) antibodies  and  the  DNA  stain  Hoechst  33258  (blue)  Note  overexpression  of Cingulin  causes  redistribution  of  p114RhoGEF  from  the  cytosol  to  cell‐cell junctions. 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Figure 4.32 Overexpression of Cingulin causes redistribution of Myosin II Myc‐tagged  Cingulin  was  overexpressed  in  Caco‐2  and  HCE  cells  for  24  hours before  cells were  fixed and  immunostained with Myosin  IIA  (red), Myc  (green) antibodies  and  the  DNA  stain  Hoechst  33258  (blue)  Note  overexpression  of Cingulin  causes  redistribution  of  Myosin  IIA,  observed  more  clearly  in  Caco‐2 cells from the cytosol to cell‐cell junctions. 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Chapter 4 –Discussion  
Here I have presented results showing p114RhoGEF a GEF identified from a 
siRNA screen for junction assembly, regulates spatially restricted activation of 
RhoA at epithelial junctions, driving junction assembly and junctional 
actinomyosin activation. RhoA signalling is well established to be crucial in the 
regulation of junction assembly and function 4 however the identification of the 
GEF that activates RhoA at cell-cell junctions had been unknown until now. 
 
p114RhoGEF forms a signalling module complex containing the Rho effector 
Rock II and Myosin II two proteins known to regulate junctional dynamics 299. 
Interestingly the RockI isoform was not part of this complex. This is in 
agreement with previous studies that support evidence for Rock II to have a 
more predominant role in junctional dynamics 299. Junctional recruitment of 
p114RhoGEF requires Cingulin a TJ adaptor protein has been previously linked 
to RhoA signalling via interaction with GEF-H1  64. Cingulin is present in a 
complex with p114RhoGEF Myosin and Rock II. I have shown evidence for this 
by demonstrating p114RhoGEF and Cingulin co-localisation by confocal 
microscopy and by showing that repressing levels of Cingulin prevents 
p114RhoGEF from being recruited to TJ. In complete contrast, when Cingulin is 
overexpressed levels of p114RhoGEF and Myosin II are redistributed and 
enriched at cell-cell contacts. Cingulin is also known to bind to GEF-H1; 
however, no coprecipitation of p114RhoGEF and GEF-H1 was observed, 
suggesting that they are part of distinct complexes. The formation p114RhoGEF 
/Myosin II/Rock II/ Cingulin complex seems to be dependent on cell-cell 
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junctions being present. As no interactions were observed when co-
immunopreciptation experiments were performed in cells devoid of cell-cell 
junctions, suggesting that this complex forms during the stages of junction 
formation. This is supported by the observation that p114RhoGEF and Myosin II 
are recruited at similar time to forming junctions during Ca switch experiments. 
The domain of p114RhoGEF important for mediating interactions with Myosin II, 
Cingulin and Rock II was mapped to the PH domain. PH domains of some GEF 
are known to bind specific phospholipids. PH domain/lipid interactions are 
known to be able to regulate activity of some GEFs158 or their subcellular 
localisation 306; however, no lipid binding was observed with the PH domain of 
p114RhoGEF.  The PH domain pulled down Rock II less efficiently than Myosin 
II or Cingulin suggesting that Rho activation may be required for efficient Rock II 
recruitment. The interaction of PH domain of p114RhoGEF with Myosin II and 
Cingulin could be important in mediating recruitment, but also in stimulating its 
GEF activity towards RhoA. 
 
p114RhoGEF regulates spatially restricted RhoA activation at cell-cell contacts 
in different epithelial cell types. In agreement with previous studies GEF-H1 was 
not found to be required for junction formation or RhoA activation at junctions. 64 
Absence of GEF-H1 seemed to retard the initial stages of junction formation, by 
regulation of cell spreading and initial cell shape changes, but did not affect 
formation of junctions as such. This was in direct contrast to p114RhoGEF, 
where its absence did not affect early adhesion and cell shape changes, but did 
prevent junction formation by effecting contraction of the actinomyosin belt and 
junctional maturation.  p114RhoGEF and GEF-H1 therefore seem to represent 
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two opposing pathways of RhoA regulation at cell junctions. p114RhoGEF is 
recruited to the forming junctional complex where it promotes junctional 
maturation via actinomyosin contractility whereas, GEF-H1 is recruited and 
inactivated  to forming junctions, contributing to inhibition of RhoA signalling that 
promotes proliferation and cell morphological changes at low cell confluence .  
Depletion of p114RhoGEF did not only inhibit RhoA activation at cell junctions, 
but caused increased non-junctional RhoA activation and increased MLC 
phospholyation along the basal domain.  As counterintuitive as this may seem 
this evidence supports the specificity of p114RhoGEF for spatial activation of 
junctional RhoA signalling and its importance for junction formation. RhoA 
activity is well known to be down regulated in response to cell confluence, thus 
interfering with junction formation stimulates RhoA signalling in different spatial 
areas of the cell.  GEF-H1 is not recruited normally to junctions in p114RhoGEF 
depleted cells giving a more diffuse cytoplasmic distribution, and hence may 
contribute to overall activation in these cells. GEF-H1 is known to induce stress 
fibres in response to stimuli such as TNFα 215 219.  Other unidentified RhoA 
specific GEF proteins that are inhibited by junction formation may also 
contribute to non-junctional RhoA activation. However there are other 
mechanisms that contribute to the inhibition of RhoA activity as cells reach 
confluence, such as the regulation of p190RhoGAP 307 or possibly the junction 
associated GAP Myosin-IXb 308.    
 
The junction associated actinomyosin cytoskeleton is critical for the formation 
and function of junction dynamics, and also drives processes in tissue 
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remodelling during development, such as apical constriction 309-312.  
Overexpression of p114RhoGEF induces actinomyosin contraction, causing 
cells to greatly increase in height and adopting an elongated  “dome like” 
appearance. Overexpression of active p114RhoGEF led to increased f-actin 
and increased activated Myosin II at cell junctions and ROCK-dependent 
rounding and monolayer contraction in MDCK cells. This evidence correlates 
with the loss of active Myosin II at junctions when p114RhoGEF levels are 
suppressed. p114RhoGEF is a critical factor required for epithelial 
morphogenesis. Depletion of p114RhoGEF in three dimensional cyst culture 
systems of two different epithelial cell types resulted in cysts that had a 
disorganised appearance with multiple lumens. However some degree of 
polarity was maintained. The disorganized cyst appearance is possibly as a 
result of the loss of actinomyosin tensile forces required to maintain normal cyst 
morphology313. Supporting evidence, comes from a recent study that identified 
p114RhoGEFregulating epithelial morphogenesis in an siRNA screen in three 
dimensional MDCK cultures 314.  
 
This evidence supports a model (see Figure 4.33), where p114RhoGEF 
associates with and activates a Rho signalling module that is central to activate 
actinomyosin contractility and drives epithelial junction formation and 
morphogenesis. Given the physiological roles of junctional RhoA signalling, 
p114RhoGEF represents a regulator of central importance. It will be important 
to identify the signalling components that stimulate p114RhoGEF during 
physiological and developmental processes to drive spatially restricted Rho 
signalling and Myosin activation at cell junctions. Additionally it will also be 
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important to identify if the p114RhoGEF- RhoA Myosin II signalling module is 
important for different epithelial processes other than cell-cell adhesion, such as 
cell migration. In Chapter 5, I present some preliminary data that suggests a 
role for p114RhoGEF in wound healing induced cell migration.    
                        
Figure 4.33 Regulation of epithelial morphogenesis by the reciprocal spatial activation of RhoA 
by two different Tight junction associated GEFs. 
 p114RhoGEF  is  recruited  from  an  inactive  state  in  the  cytoplasm  to  TJs  by  the  adaptor  protein Cingulin as  junctions are assembling, where p114RhoGEF forms a complex with Myosin  IIA and the RhoA effector Rock II. p114RhoGEF activates RhoA leading to Myosin II activation and subsequently, ActinoMyosin  contraction,  thus driving  junction  formation and epithelial morphogenesis. GEF‐H1  is also recruited to junctions by Cingulin as they are assembling, but is in a different complex to  Cingulin /p114RhoGEF/ Myosin IIA and Rock II. GEF‐H1 Guanine nucleotide exchange ability is inactived by its interaction with Cingulin.  At low cell confluence, where junction are not established, GEF‐H1 is active in the cytoplasm where it activates RhoA and contributes to stress fiber formation and proliferation. Certain  junction associated GAPs, such as p190RhoGAP or Myosin  IXb may also contribute  to active  levels of non‐junctional  RhoA activation. 
  
   Inactive 
GEF/GAP 
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Chapter 5­ p114RhoGEF regulates cell migration  
 
Overview 
Cell migration requires dynamic and spatially coordinated changes to the actin 
cytoskeleton and cell adhesion. RhoGTPases as important regulators of the 
cytoskeleton are crucial in coordinating cellular responses required for cell 
migration. Before cell migration occurs, cells have to first establish a front –rear 
asymmetry or polarise, this is then followed by membrane protrusion from the 
front leading edge and retraction at the trailing rear. This process occurs 
through the coordination of cytoskeletal dynamics and intergin mediated 
attachments to the substratum 315, 316.  
 
Early studies demonstrated RhoGTPases Rac and Cdc42 function to produce 
different types of actin based protrusive membrane structures 144. Active Rac is 
known to produce lamellipodia, a protrusive sheet like structure containing a 
mesh of branch like actin filaments, whereas active Cdc42 causes formation of 
filopodia, finger-like actin-rich protrusions.  In contrast active RhoA leads to 
stress fibre formation and regulates actinomyosin contractility. This has lead to 
a generally proposed model that Cdc42 and Rac function at the leading edge to 
organise cell polarity, induce formation of lamellipodia in the formation of new 
adhesions to the substratum and RhoA functions towards the rear to mediate 
cell body contraction and tail detachment. However, recent studies using FRET 
based biosensors of active RhoGTPase have enabled insight into their spatial 
activation during cell migration 317. Several of these studies suggest RhoA is 
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activated at the trailing end of migrating cells where it regulates cell body 
contraction and detachment of the trailing end, but may also play a role at the 
leading edge of cells 317 318. One of these studies317 that employed 
simultaneous visulisation of active RhoA and Rac1 or RhoA and Cdc42, 
revealed that activation of RhoA was synchronous with leading edge extension 
and Cdc42 and Rac1 were found to be activated a short time after and 2µm 
behind the leading edge. Suggesting Rho has a role in the initial events of 
protrusion whereas Cdc42 and Rac1 function downstream of the initial burst of 
RhoA activation.  
 
It is well established that GEFs are known to have important roles in activation 
of different RhoGTPases during cell migration For example the RhoA GEFs 
p115RhoGEF/lsc and GEF-H1 have both have been shown to regulate cell 
migration in neutrophills319 and in HeLa cells 320  respectively. The Cdc42 GEF 
Pixα regulates directional cell migration in chemotaxic leukocytes 196 and Tiam -
1 and Dbs have recently been shown to regulate Neurotrophin-3-induced cell 
migration in Schwann cells 321 and in breast cancer epithelial cells through the 
activation of Cdc42 and Rac1322. This chapter contains some preliminary 
experiments that demonstrate p114RhoGEF regulates migration of HCE cells 
and could be important in cancer metastasis.   
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p114RhoGEF regulates cell migration in HCE cells  
To test if p114RhoGEF functions in cell migration I performed wound healing 
assays in HCE cells depleted of p114RhoGEF by an siRNA pool or as a control 
transfected with non-targeting siRNA. I discovered p114RhoGEF depleted cells 
failed to close the wound, 7 hours after creating the wound (Figure 5.0- and 
5.1). However, p114RhoGEF depleted cells did eventually close the wound 
after 24 hours suggesting that absence of p114RhoGEF causes cells to migrate 
significantly slower. I next tested if p114RhoGEF was upregulated in different 
breast cancer cell lines (Figure 5.2). Immunoblotting for p114RhoGEF in total 
cell lysates revealed p114RhoGEF to be highly expressed in MDA-MB231 cells, 
a tumour cell line that is completely dedifferentiated and known to be 
metastatic. However expression levels of p114RhoGEF were normal in MCF7 
cells, derived from a benign and partially differentiated tumour and MCF10A 
cells, a non-cancerous partially differentiated cell line.  
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Figure 5.0 p114RhoGEF regulates cell migration during wound healing in 
HCE cells.  HCE  cells  depleted  of  p114RhoGEF  or  transfected  with  control  on‐targeting siRNA  were  cultured  in  a  two  chamber  system  until  confluent.  The  chamber division  was  removed  resulting  in  a  defined  cell  free  gap  between  the  two monolayers. Cells were imaged 0 at 3, 7 and 24 hours after removal of the insert. Note p114RhoGEf depleted cells do eventually close  the wound completely, but migrate at a slower rate. 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Figure 5.1 Quantification of wound healing in p114RhoGEF depleted HCE 
cells  From the images in figure 5.0, cell free areas were quantified at time points 0, 3 and 7 hours after  removal of  insert. Bars  represent mean 3 experiments. Error bars +/‐1 standard deviation. An Immunoblot was performed at the end of assay to observe p114RhoGEF levels, using α‐tubulin as a control. 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Figure 5.2 Expression levels of p114RhoGEF are upregulated in metastatic 
breast cancer cell lines.  Expression levels of p114RhoGEF were tested by Immunoblot, in different mammary epithelial  cell  types  compared  to  caco‐2  cells.  MCF‐7  are  derived  from  a  partially differentiated  tumour, MDA‐MB231  from  a  dedifferentiated  and migratory  tumour and MCF‐10A from normal breast epithelium partially differentiated. Levels of GEF‐H1  and α‐tubulin  were  as  measured.  Note  p114RhoGEF  is  greatly  upregulated  in metastatic tumour cell line MDA‐MB‐231. 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As absence of p114RhoGEF causes HCE cells to migrate slower I investigated 
where p114RhoGEF localised in migrating HCE cells.  I discovered 7 hours 
generating a wound, p114RhoGEF localised diffusely in the cytoplasm and at 
TJs as previously described (see Chapter 4), but interestingly, also to the tips of 
membrane projections of cells in front line of the migrating monolayer. E-
Cadherin and ZO-1 were also present at the tips of these membrane projections 
in control and p114RhoGEF depleted cells. Absence of p114RhoGEF caused 
disruption of TJs as previously reported (see Chapter 4). However, some cells 
in the migrating monolayer were observed to have more long finger-like 
filopodia projections, perhaps indicating over activation of Cdc42.  
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Figure 5.3 p114RhoGEF is localised to the leading edge of migrating HCE cells.  HCE cells depleted of p114RhoGEF for 72 hours were fixed after immediate removal or the chamber divider (0 hours top panel) and 7 hours after removal (bottom panel). Cells were immunostained with the indicated antibodies. Staining for p114RhoGEF was  reduced  in  p114RhoGEF  depleted  cells,  with  cells  having  broken  discontinuous  ZO‐1  distribution  at  junctions,  as previously  described.  The  bottom  panel  shows  an  enlarged  area  of  marked  by  white  box,  and  shows  p114RhoGEF(red)  is localized  to  the  leading  tips  of  cells,  localizing with E‐Cadherin  (blue)  and ZO‐1  (green).   Note  in  all  images  the wound was generated to the left of the monolayer. 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Discussion   
In this chapter I have discovered p114RhoGEF regulates migration of HCE 
cells. Evidence from breast cancer cells show expression levels of 
p114RhoGEF are normal in partially differentiated, normal and benign breast 
cancer epithelial cells. However, p114RhoGEF is highly overexpressed in a fully 
de-differentiated metastatic breast cancer cell line. This result correlates well 
with the data in migrating HCE cells during wound healing, suggesting 
p114RhoGEF may play an important role in migration and possibly invasion of 
breast cancer cells during cancer progression.  Experiments involving RNAi 
mediated depletion and overexpression of p114RhoGEF during wound healing 
will need to be performed in different breast epithelial cells as well as invasion 
assays to further support this preliminary result.  Moreover, it will be important 
to analyse p114RhoGEF expression in characterised cancer tissues to 
determine the pathological significance of its upregulation in a metastatic 
tumour cell line.  
 
p114RhoGEF was discovered to localise to the tips of membrane projections of 
migrating HCE cells. The functional relevance for this localisation is currently 
unknown, but warrants further investigation, as E-Cadherin and ZO-1 also 
localised to membrane tips with p114RhoGEF.  Interestingly a number of other 
studies have also identified junctional proteins such as ZO-1 the aPKC/PAR3/6 
complex PatJ and Occludin at the leading edge of migrating epithelial cells 
during wound healing where they are known to regulate directional migration 323, 
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324. It will be interesting to test if p114RhoGEF colocalises with these 
components at the tips of membrane projections in HCEs and if depletion of 
p114RhoGEF or these components perturbs their or p114RhoGEF localisation 
at the leading edge.  
 
 RhoA was recently shown to be activated spatially at the leading edge of 
migrating cells 317, 318. I have shown earlier that p114RhoGEF spatially activates 
RhoA at cell-cell contacts to drive junction formation. It could therefore be 
possible that p114RhoGEF spatially activates RhoA at the leading edge of 
migrating cells. A recent study has showed GEF-H1 is also localised to the 
leading edge of migrating cells where it to also spatially activates RhoA 320. 
However, in this study, the spatial activation of RhoA after GEF-H1 depletion at 
the leading edge was examined in single randomly migrating HeLa cells. As 
HeLa cells are a highly transformed cancerous cell line that do not form 
junctions, it would be interesting to test if this result can be reproduced in a 
different non transformed epithelial cell type that form functional cell-cell 
junctions. It is intriguing to speculate if GEF-H1 together with p114RhoGEF 
forms part of the same RhoA signalling module or forms two distinct signalling 
modules to coordinate spatial activation of RhoA at the leading edge or towards 
the rear of migrating cells. It will also be interesting to monitor the spatial 
coordination of RhoA signalling by these two GEFs and the functional 
consequence of RhoA activation during migration during single cell migration 
and when cells are migrating in a monolayer during wound healing in a variety 
of epithelial cells types.   
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Chapter  6  ­  Characterisation  of  cg10188  the  putative 
p114RhoGEF ortholog in Drosophilla  development 
 
Overview   
In this chapter I performed some preliminary experiments to investigate the 
function of the putative p114RhoGEF ortholog in Drosophila cg10188. I 
discovered that its absence causes lethality during development somewhere 
between embryogenesis and pupation. However, no effects on junction 
morphology were observed when cg10188 expression was ablated by RNAi in 
cells of larval imaginal discs.  
 
Drosophila have just 7 RhoGTPases and 20 proteins that encode RhoGEFs 
and 22 RhoGAPs325  compared to the 20 RhoGTPases and over 70 proteins 
that encode RhoGEFs and GAPs in mammals. However the ratio of GEFs or 
GAPs to RhoGTPases is still approximately 3:1 in both species, suggesting that 
RhoGTPases are still just as tightly regulated in Drosophila. Many Drosophila 
GEFs are larger than their mammalian orthologs. For example DRhoGEF2 the 
putative Drosophila ortholog of GEF-H1 contains a C1 domain followed by a DH 
and PH domains, but unlike GEF-H1 has a large N-terminal extension of 
approximately 1000 amino acids. This N-terminal extension contains a PDZ 
domain and an RGS like domain that is involved in binding to Gα subunits of 
heterotrimeric G proteins 326. The mammalian GEFs PDZ-GEF, 
p115RhoGEF/lsc and LARG also contain RGS and or PDZ domains sharing 
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some identity to DRhoGEF2 327. DRhoGEF2 seems to be functionally 
analogous to GEF-H1 as its GEF activity is regulated by microtubule binding 
and it regulates processes requiring actinomyosin contractility via the activation 
of Rho1 the Drosophila ortholog of RhoA.  326 328. However DRhoGEF2 unlike 
GEF-H1 is known to be regulated by Concertina a Gα subunit of heterotrimeric 
G proteins 326 and therefore also shares functional orthology with p115RhoGEF, 
LARG and PDZ-RhoGEF, GEFs known to be regulated by Gα12 and Gα13 
subunits of heterotrimeric G proteins. Thus, it appears that some GEFs in 
Drosophila are much larger and seem to be fusions of several mammalian 
GEFs, suggesting that a single GEF in Drosophila maybe performs the function 
of several different mammalian GEFs.  
 
cg10188 was annotated in the Drosophila genome as being a putative ortholog 
of p114RhoGEF. I wanted to investigate how similar it was to p114RhoGEF 
orthlogs from different species. I aligned sequences annotated as being 
orthologs of p114RhoGEF in the genome sequence databases for different 
organisms, including the p114RhoGEF sequence of the human isoform 2, the 
isoform I have analysed in epithelial cells (Figure 6.0).  There was a high 
degree of sequence conservation unsurprisingly around the DH and PH 
domains of all p114RhoGEF orthologs; however, the N-terminal and C-terminal 
regions were more divergent across species displaying less sequence identity. 
Indeed, the Drosophila ortholog, cg10188 was the most divergent having a 
large N terminal extension, of about 325 amino acids. The 325 extension 
however did not contain any known domains when run through the pfam 
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database. cg10188 displayed the least sequence identity to mammalian 
p114RhoGEF sequences, as expected from an organism more evolutionary 
distant to mammals.  
 
Depletion of Cg10188 by RNAi during Drosophila development causes 
lethality  
I was interested in exploring if cg10188 had a similar function to p114RhoGEF 
in Drosophila. I first tested the effect of loss of cg10188 has on fly development 
by using RNAi. I crossed flies that ubiquitously expressed GAL4 driven under 
an actin promoter and contained the CyO allele on a balancer chromosome 
(The CyO gene is used as a marker that produces flies with curly wings), with 
two different strains of fly that permitted expression of two different shRNA 
sequences against cg10188, under the control of a UAS element (Figure 6.1).  
GAL4 binds to UAS elements and activates transcription driving the expression 
of the shRNA and so drives cg10188 RNAi in the whole organism during 
development. All the progeny analysed from these crosses had the curly wing 
phenotype, indicating that cg10188 RNAi was lethal (Figure 6.1). The precise 
stage of development that is disrupted is not known, however no pupal cases 
were found that had flies arrested in development, suggesting development is 
affected somewhere between embryogenesis and larval pupation.  
 
Based on the function of p114RhoGEF in cell junction formation and apical cell 
membrane constriction in mammalian cells, I hypothesised cg10188 might be 
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involved in developmental processes involving apical constriction. I decided to 
observe if cg10188 depletion by RNAi affected development of cell-cell 
junctions in larval imaginal discs, epithelial structures that require apical 
construction to bend and fold to undergo morphological changes to form eyes, 
antennae wings and legs in the adult fly. To investigate this I used a heat shock 
inducible GFP-flip-out clone system. This system allows cells that turn on 
cg10188 RNAi to be indentified by the lost of GFP expression (Figure 6.2).  I 
discovered that depletion of cg10188 by RNAi did not disrupt cell-cell junctions 
in imaginal discs, a wing disc is shown as an example in Figure 6.3.  Staining 
with armadillo (β-Catenin) and f-actin appeared normal in cells that had lost 
expression of GFP. The absence of a phenotype on junction morphology could 
be the result of inefficient suppression of cg10188 by RNAi, as discs were 
dissected only 48 hours after the induction of RNAi. Without an antibody to 
cg10188 it was impossible to confirm if cg10188 expression was reduced in 
GFP negative cells.  However, areas of cells that had lost GFP expression, 
were quite small suggesting that cg10188 RNAi maybe inhibits proliferation or 
causes apoptosis.  
     
p114 species alignment with D.melanogaster_Cg10188isoformA sequence  
 
Homo_sapiens_isoform2               -------------------------------------------------- 
Canis_familiaris                    -------------------------------------------------- 
Mus_musculus                        -------------------------------------------------- 
Ornithorhynchus_anatinus            -------------------------------------------------- 
Galus_galus                         -------------------------------------------------- 
Xenopus_tropicalis                  -------------------------------------------------- 
Danio_rerio                         -------------------------------------------------- 
D_melanogaster_Cg10188isoform_      MDNAGEDSDNDVVTDFLNSNCSESSEALVNGGSTNRGASIESQNYCIPVI 50 
                                                                                       
 
Homo_sapiens_isoform2               -------------------------------------------------- 
Canis_familiaris                    -------------------------------------------------- 
Mus_musculus                        -------------------------------------------------- 
Ornithorhynchus_anatinus            -------------------------------------------------- 
Galus_galus                         -------------------------------------------------- 
Xenopus_tropicalis                  -------------------------------------------------- 
Danio_rerio                         -------------------------------------------------- 
D_melanogaster_Cg10188isoform_      NAPVPGPARAPIAPPPASNPASNTINNNNMIPTINVTPHSPALASKYNNI 100 
                                                                                       
 
Homo_sapiens_isoform2               -------------------------------------------------- 
Canis_familiaris                    ------------------MVTVGTNFLPSRPAVSANTVGEDAALS-RRIT 31 
Mus_musculus                        -------------------------------------------------- 
Ornithorhynchus_anatinus            -------------------------------------------------- 
Galus_galus                         -------------------------------------------------- 
Xenopus_tropicalis                  -------------------------------------------------- 
Danio_rerio                         -------------------------------------------------- 
D_melanogaster_Cg10188isoform_      FEDTLSQLQNIRETVVQMKNSSSPSQHMQDGSLANHGLLSAAILSTSLPD 150 
                                                                                       
 
Homo_sapiens_isoform2               -------------------------------------------------- 
Canis_familiaris                    WRYKNSTARPRTALGLGAPTVNMGNTHSKSSDRDSALHGRPELSFYSSFP 81 
Mus_musculus                        -------------------------------------------------- 
Ornithorhynchus_anatinus            ----------------GDPGVNMGNTNSKSSCRNNTIPGHPELSFYGSFS 34 
Galus_galus                         -------------------------------------------------- 
Xenopus_tropicalis                  -------------------------------------------------- 
Danio_rerio                         -------------------------------------------------- 
D_melanogaster_Cg10188isoform_      LTGTGTGPASGGSNYAMWSSTAPQQCQFLHTDRRKSWTAVDDGSGAGDCT 200 
                                                                                       
 
Homo_sapiens_isoform2               -------------------------------------------------- 
Canis_familiaris                    RKWSENVFLDNELLTTKILSVLRPQSERGFR-------------PGHLRY 118 
Mus_musculus                        -------------------------------------------------- 
Ornithorhynchus_anatinus            RKWNENVFLDNELLTSKILNVLRPHSERDLR-------------AGNLHC 71 
Galus_galus                         -------------------------------------------------W 1 
Xenopus_tropicalis                  -------------------------------------------------- 
Danio_rerio                         -------------------------------------------------- 
D_melanogaster_Cg10188isoform_      NKSVSLSSLDSEEQETIRVTEQRRRSARNSTGGISTHSLNEAELARDFER 250 
                                                                                       
Homo_sapiens_isoform2               -------------------------------------------------- 
Canis_familiaris                    PAHFLSTNSVFASVAASLKEHPRATLV-SDGSSALSRNVG---------- 157 
Mus_musculus                        -------------------------------------------------- 
Ornithorhynchus_anatinus            PAHFLSTNSVFASVAASLKEQPRGSLLGSDGTPVVSRNVG---------- 111 
Galus_galus                         LEQLCGTQS-----AASLKEQPRSLLLGPDGTPVLPRSLG---------- 36 
Xenopus_tropicalis                  -------------------------------------------------- 
Danio_rerio                         -------------------------------------------------- 
D_melanogaster_Cg10188isoform_      IAAKRSLATEIISRIPLQKSISTSSIIAKEDIKAIARHLTDSEDENQSLL 300 
                                                                                       
Homo_sapiens_isoform2               ------------------------------MTVSQKGGPQPTPSPAGPGT 20 
Canis_familiaris                    ------------------------------MTVSQKGGPQPAPSPVGTGT 177 
Mus_musculus                        ------------------------------MTISQKGGLQPTPSPAGSGV 20 
Ornithorhynchus_anatinus            ------------------------------MTVSQRGSPQSASNAAGTVN 131 
Galus_galus                         ------------------------------MTIAQRGTSPSSFNTAGAVS 56 
Xenopus_tropicalis                  -------------------------------------------------- 
Danio_rerio                         -------------------------------------------------- 
D_melanogaster_Cg10188isoform_      RAHAKIEVYDTVEKRPKRGSIFFRKKKPKAKTKSLVGGQLSACDVCGAAI 350 
                                                                                       
 
Homo_sapiens_isoform2               QLGPITGEMDEADSAFLKFKQ-----------TADDSLSLTSPNTESIFV 59 
Canis_familiaris                    QLGPVTGEMDEADSVFLKFKQ-----------AADDSLSLTSSNAEPIFV 216 
Mus_musculus                        RLGPIAGDMDEADSVFLKLKQ-----------TADDSLSLTSSNAESVFI 59 
Ornithorhynchus_anatinus            RFGPITGEMDEADSGFIKLKQ-----------AADDSLSLVSSATETIFV 170 
Galus_galus                         KFGLISGDMDEGDSGFIKFKQ-----------TSDDVVSLAPSTADSIFL 95 
Xenopus_tropicalis                  -------------------------------------------------- 
Danio_rerio                         --------MDDID--YYRSKP-----------LAEESN-FQTTNYDAISI 28 
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D_melanogaster_Cg10188isoform_      TLAQIKEHHLECKVKKMGGGQDYYDGPDASTFSNPEDQPLIRSDLQFLNE 400 
                                                                                       
 
Homo_sapiens_isoform2               EDPYTASLRSEIESDGHEFEAESWSLAVDAAYAKKQKREVVKRQDVLYEL 109 
Canis_familiaris                    EDPCTASLRSEIESDAREFEAESWSLSVDAAYAKKQKREVVKRQDVLYEL 266 
Mus_musculus                        EDPYIASLRCEIESDAHEFEAESWSLSVDLAYAKKQKKEVVKRQDVLYEL 109 
Ornithorhynchus_anatinus            EDSYSASLRSEIEADALEFEAESWSLSVEPGYAKKQKREVVKRQDVIYEL 220 
Galus_galus                         EDAYSLSLRSEIETDAHEFEAESWSVAVEQSYAKRQKKEVVKRQDVIYEL 145 
Xenopus_tropicalis                  ---------------------------------------------VFSEL 5 
Danio_rerio                         DECHYNVLRDDLESDARDFEAPTWSLAVDPQYLKNFSKDAVKRQDVIHEL 78 
D_melanogaster_Cg10188isoform_      APIEAQDLGADPVLGIVLKEHDSWTPNVPRELLKTLKDLQIKRQEHIYEF 450 
                                                                                  : *: 
 
Homo_sapiens_isoform2               MQTEVHHVRTLKIMLKVYSRALQEELQFSSKAIGRLFPCADDLLETHSHF 159 
Canis_familiaris                    VQTEAHHVRTLKIMLKVYSRALQEELQFSSKAISRLFPCVDELLDIHSHF 316 
Mus_musculus                        MQTEAHHVRTLKIMLKVYSRALQEELQFSGQAVSRLFPCADDLLDMHSHF 159 
Ornithorhynchus_anatinus            MQTEMHHVRTLKIMLKVYSKALKEEMQFSSKDINRIFPCVDDLLEMHGQF 270 
Galus_galus                         MQTEMHHVRTLKIMLKVYSKAMKEELQFSNAVINKLFPCVDELLEMHGQF 195 
Xenopus_tropicalis                  MQTEMHHVRTLKIMLRVYSRALSEELQYGNKDIHQIFPCVDDLLELHVNF 55 
Danio_rerio                         IQTEINHVRTLKIVLNVYIRELRNTLQMDETRLERLFPQVENLLEVHQFF 128 
D_melanogaster_Cg10188isoform_      IMTEKHHCQTLIVMQKVFVESLERHFPSLN--LNSMFPRLQQLTDLHTCF 498 
                                    : ** :* :** :: .*: . : . :      :  :**  ::* : *  * 
 
 
Homo_sapiens_isoform2               LARLKERRQESLEEGSDRNYVIQKIGDLLVQQFSGENGERMKEKYGVFCS 209 
Canis_familiaris                    LSRLKERRQESLEEGSDRNYVIQKIGDLLVQQFSGENGDRMKEKYGVFCS 366 
Mus_musculus                        LARLKERRQEFLEEGSDRNYVIQKIGDVLVQQFSGETGERMKEKYAVFCS 209 
Ornithorhynchus_anatinus            LFRLKERRKESLEEENGRNYVIQKIGDLLVQQFSGENGERMKEKYGVFCC 320 
Galus_galus                         LLQLKERRKESLEEGSDRNYIIQNIGDLLVKQFSGENGERMKEKYGVFCS 245 
Xenopus_tropicalis                  LARFKERRKESMEEGSDRNYMIQKVGDILVQQFSGESGERMREKYGIFCS 105 
Danio_rerio                         LDNLKLRRLDSMEPGSSQNYCIHNLGDILITQFSGEIGSRLRYLYGMFCS 178 
D_melanogaster_Cg10188isoform_      LRQLRLKQRE--------QHMVDSIADILLDFFSLEQAQCLRLAYGEFCA 540 
                                    * .:: :: :        :: :..:.*:*:  ** * .. ::  *. **. 
 
Homo_sapiens_isoform2               GHNEAVSHYKLLLQQNKKFQNLIKKIGNFSIVRRLGVQECILLVTQRITK 259 
Canis_familiaris                    GHNEAVNHYKLLLQQNKKFQSLIKKIGNFSIVRRLGVQECILLVTQRITK 416 
Mus_musculus                        GHNDAVGHYKLLLQQSKKFQNLIKKIGNFSIVRRLGVQECILLVTQRITK 259 
Ornithorhynchus_anatinus            GHNEAVSHYKELLQQNKKFQNLIKKIGNFSIVRRLGVQECILLVTQRITK 370 
Galus_galus                         GHNEAVSHYKDLLQSHKKFQNLIKKIGNCSIVRRLGVQECILLVTQRITK 295 
Xenopus_tropicalis                  QHNKAVSRYKDLLRDSKKFQNLMKKIGNSSIVRRLGVQECILLVTQRITK 155 
Danio_rerio                         RHTDAVNFYKDLMQNNKKFQNLIRKICQLSIVRRLGIPEIILLITQRITK 228 
D_melanogaster_Cg10188isoform_      NHRSALDQFKLCLTEP-SFAEWYKHCLQNPLLKKKGIPECILFVTQRLTK 589 
                                     * .*:. :*  : .  .* .  ::  : .:::: *: * **::***:** 
 
Homo_sapiens_isoform2               YPVLVERIIQNTEAGTEDYEDLTQALNLIKDIISQVDAKVSECEKGQRLR 309 
Canis_familiaris                    YPVLVERIIQNTEAGTEDYRDLTQALNLIKDIISRVDAKVSECEKGQRLR 466 
Mus_musculus                        YPVLVERIIQNTEAGTEDYKDLSQALSLIKDIISQVDAKVSEYEKDQRLK 309 
Ornithorhynchus_anatinus            YPVLVERILHNTVAGTEDYEELTQALGLIKDTITQVDAKVNEREKGQRLR 420 
Galus_galus                         YPVLVERIIQNTEVGTKDYEDLIQALSLIKHTITHVDAIVNECEKGQRLK 345 
Xenopus_tropicalis                  YPVLVERIIQNTEEGTEDYETLTQAIALIKDTITDVDSRVHESEKVQRLR 205 
Danio_rerio                         YPVLFERVIKYTEDESEEQMDLIKGPDFLKDTIAQVNAHVDEAEKEARLR 278 
D_melanogaster_Cg10188isoform_      YPLLIEPLLKSARDNKLETDKLQHALNLVKSLLVDVDACVAEKELRERQL 639  
                                    **:*.* ::: :   . :   * :.  ::*  :  *:: * * *   *   
 
Homo_sapiens_isoform2               EIAGKMDLKSSSKLKNGLTFRKEDMLQ--RQLHLEGMLCWKTTSG----- 352         
Canis_familiaris                    EIAGKMDLKSSSKLKNGLTFRKEDMLQ--RQLHLEGTLCWKTTSG----- 509 
Mus_musculus                        EIAAKTDQKSSGKLKNGLTFRKEDMLQQ-RQLHLEGALCWKSTSG----- 353 
Ornithorhynchus_anatinus            EIASKIDLKSSGKLKNGLTFRREDVLR--RQLHLDGMLCWKTASG----- 463 
Galus_galus                         EIMHKMELKSSGKCKNGLFFRKDDMGQ--RRLLLDGMLYWKAASG----- 388 
Xenopus_tropicalis                  EIVSKMELKSSGKLKNG-TFRKQDILR--RQLLHDGVLYWKTASG----- 247 
Danio_rerio                         ELSSKLEPKSQVKMTSGRVFRREDMLQGKRKLLHEGMLNWRVTNNKGKGD 328 
D_melanogaster_Cg10188isoform_      EIYGRVDAKSFAIYKNKPFRKTELGVESRRRLKFDGLATLMQGRA----- 684 
                                    *:  : : **    ..    : :   .  *:*  :*               
 
 
Homo_sapiens_isoform2               RLKDILAILLTDVLLLLQEKD--QKYVFASVDSKPPVISLQKLIVREVAN 400 
Canis_familiaris                    RLKDVLAVLLTDVLLLLQEKD--QKYVFASVDSKRPVISLQKLIVREVAN 557 
Mus_musculus                        RLKDVLAVLLTDVLLLLQEKD--QKYVFASVDSKPPVISLQKLIVREVAN 401 
Ornithorhynchus_anatinus            RLKDILAVLLTDVLLLLQEKD--QKYTFASVDAKPPVISLQKLIVREVAN 511 
Galus_galus                         RLKDILAVLLNDVLLLLQEKD--QKYVFASVDSKPPVISLQKLIVREVAN 436 
Xenopus_tropicalis                  RLKDILAVLLTDILLLLQEKD--QKYSLSPVDNKAPVISLQKLIVREVAN 295 
Danio_rerio                         KHTDVIVLLLSDVLLLLLEKD--SRLTFASLDGKPAVISLLKLIVREAAH 376 
D_melanogaster_Cg10188isoform_      KTQLVLVVVLTDCLCFLSENSGHNKYSFFTPEHKAGVVPLQKLLIREKAG 734 
                                    :   ::.::*.* * :* *:.  .:  : . : *  *:.* **::** *  
 
Homo_sapiens_isoform2               EE-KAMFLISASLQGPEMYEIYTSSKEDRNAWMAHIQRAVESCPDEEEGP 449 
Canis_familiaris                    EE-KAMFLISASLQGPEMYEIYTSSKEERNTWMAHIRRAVESCPDEEEGP 606 
Mus_musculus                        EE-KAMFLISASMQGPEMYEMYTSSKEDRNIWMAHIRRAVESCPDEEEDV 450 
Ornithorhynchus_anatinus            EE-KAMFLISASLKGPEMYEIYTSSKEERNSWMALIRRAVESCPIEEEGP 560 
 214 
Galus_galus                         EE-KAMFLISASLQGPEMYEIHTSSKEERNSWMAHIRRAVESCPDEEGGS 485 
Xenopus_tropicalis                  EE-KAMFLISASNTGAEMYEIHTNSKEERNFWMNIIRGAVESCPVQDAEI 344 
Danio_rerio                         NE-KAMFLISASLDTPEMYEFHTSSAEERNTWTNKIWKAVECCPDVKE-- 423 
D_melanogaster_Cg10188isoform_      TESRGIYIISSNPDFPEMYELKVQTPKDKNTWIQTIRQAVLDCPATDIIE 784 
                                     * :.:::**:.   .****: ..: :::* *   *  **  **  .    
 
Homo_sapiens_isoform2               FSLPEEERKVVEARATRLRDFQERLSMKDQLIAQSLLEKQQIYLEMAE-M 498 
Canis_familiaris                    FSEAEEEKKGLEARALRLRDFQERLNVKDQQIAQSLGEKQQIYLEMAE-M 655 
Mus_musculus                        FSEAEE-KKIAEARTMKLQEFQERLSLKDQLIAQSLLEKQQIYLEMAQ-L 498 
Ornithorhynchus_anatinus            LAGLEEDRKIAEMRAAKLKEFQERLSVKDNAIAQSLYEKQQIYLEMLE-M 609 
Galus_galus                         FYEPETERRMAEARAAKLREFQERLNTKDDLIVQSLTEKQQIYQEMSE-V 534 
Xenopus_tropicalis                  LNEAEEEKKLFTERAAKIKEFQERLNQKDYVIVQSLNEKLQTCMEMAE-L 393 
Danio_rerio                         --------EEPEELSKKIWEFQRKLCVHDASIEQHLTEKLKLFSSIAASV 465 
D_melanogaster_Cg10188isoform_      AEDLTAEEKLRIG--VNKRETIEKMRQKDIEQALLLEEKLMLQFNLLKEQ 832 
                                            .       .  :  .::  :*      * **     .:     
 
Homo_sapiens_isoform2               GGLEDLPQ---PRGLFRGG-DPSETLQGELILKSAMSEIEGIQSLICR-R 543 
Canis_familiaris                    SGLEDVAQ---SRLLFRGG-DPSETMQGEQILKSAMSEIEDIQTLICR-Q 700 
Mus_musculus                        SGLEESAQ---NRGLFRGGGDPSETLRGEQILRSAMSEIEGIQSLICQRH 545 
Ornithorhynchus_anatinus            SGFEDPPQGPRSKLLFRSG-EPLENLQGEMILKSAVTEIEYLQNLICK-H 657 
Galus_galus                         YGFEDHSQG--SRSRLLLG-DIPESLQGEALLKSAVVEAENLQNLIFT-H 580 
Xenopus_tropicalis                  YGYEDLPQE--PRITLLPRAETGENLEGKGILHSAVTILESEQSLCPAQE 441 
Danio_rerio                         TGVSDTSTS--ERHPLRGN--AAEPLQGERLLTGALKDVENLQNLLVMCE 511 
D_melanogaster_Cg10188isoform_      QPFGDVAG----TNSSCSAANFLAAFGSYKDLVSADCDTAELWRRVLNTV 878 
                                        : .                  : .   * .*                
 
Homo_sapiens_isoform2               LGSANGQAEDGGSSTGPPRRAETFAGYDCTNSPTKNGSFKKKVSSTDPRP 593 
Canis_familiaris                    LGSANGQAEDAGGSSGLPRRAETFGGYDTVSSPSKNGILKKTCSS-DPSP 749 
Mus_musculus                        LGSTSSQVEEGSVSAGLPRRAETFGGYDSVGSPSKGGSFKRKVSNSDLRP 595 
Ornithorhynchus_anatinus            LANANYHSEDGSGYSLLPRRAETFGGYDSSTNTNKNGSFKKKVCSSDPRL 707 
Galus_galus                         LGNGSCQSEE-SYAAGLPRRAETFGGYDSPSISNRNNSLGKSGGS-DQRQ 628 
Xenopus_tropicalis                  AGHNKKEQFGSSSTGYTPSRRSLGARLQRLDNPKAKSSKRRAPSPSDEES 491 
Danio_rerio                         QGPTP---FTSRATDLVLKKPHAVTGLENNTHMLPENGFESSMESMGDRI 558 
D_melanogaster_Cg10188isoform_      QDISQLASTIYSAATGQPVPRTLSSVGEKQSEQYASPTLPKRAETFAGFD 928 
                                                               :                       
 
Homo_sapiens_isoform2               RDWRGPPN--SPDLKLSDSDI-PGSSEESPQVVEAPGTESDPRLPTVLES 640 
Canis_familiaris                    RDWQGPVS--SPDLKPSNT---LGASEEAPPAGPVPGADCGPHLPAVLEL 794 
Mus_musculus                        QDWQGPAS--SPDSRPCDNSAPSGCCEESPQAVEMPSTES---LPTVLEL 640 
Ornithorhynchus_anatinus            KDWRSPLT--SSDSQLCDLP---GDSEEGLSTADITRPDYSSSLPATLES 752 
Galus_galus                         WDWRGPAV--SSDVQLPDLP---VDAEEGSQTSDTTRQDDSSGIQPTIES 673 
Xenopus_tropicalis                  EDYSRAPSPILPEPNLSEGELSGSSDQEGNKPSKHSFEAVDTLISSVLET 541 
Danio_rerio                         QVANTDLDPQLRELHLSENQ---ELSADENLSVHFP------------KA 593 
D_melanogaster_Cg10188isoform_      EKRGKLASKLVLTPRLQELEEKREPKSGSSSVSEQP-------------L 965 
                                                  .  :                 .               
 
 
 
 
Homo_sapiens_isoform2               ELVQRIQTLSQLLLNLQAVIAHQDSYVETQRAAIQEREKQFRLQSTRGNL 690 
Canis_familiaris                    ELVQRIQTLSQLLLSLQAVIAQQDSYVEMQRASIQEREKQLRLQSTRGNM 844 
Mus_musculus_isoform1               ELVHRVQTLSQLLLSLQAVIAQQDSYVEMQRTAIQEREKQFRLQSTRGNL 690 
Ornithorhynchus_anatinus            ELVQRIQTLLQLLLNLQAVIVHQDSYIENQRAITIEREKLYRLQSTRGNF 802 
Galus_galus                         QLVQRIQTLLQLLFSLQAVISQQDSYIEVQRATMVDREKQYRLQSTRGNV 723 
Xenopus_tropicalis                  LHLQEPETNVMLLLFMQAVISQQDSYVEVQ----KEREKQFRQQSSRGNM 587 
Danio_rerio                         EFYSTVSQLSRKLYSLQSVVQQLESHIKVQHATIEELK-----SRPRGNS 638 
D_melanogaster_Cg10188isoform_      ENNYAVLQVTHHLQTLLCVISQQMTTINNLQ---------------LQLA 1000 
                                                *  : .*: :  : ::                       
 
Homo_sapiens_isoform2               LLEQERQRNFEKQREERAALEKLQSQLRHEQQRWERERQWQHQELERAGA 740 
Canis_familiaris                    LLEQERQRNFEKQREELAG------------------------------- 863 
Mus_musculus                        LLEQERQRNFEKQREERAGVEKLQSQLRQEQQRWERERARQQQELELAGA 740 
Ornithorhynchus_anatinus            LLEQEKQRNFEKQREELANMQKIQNQLKQEQQRWERERDRQQKELEYTEA 852 
Galus_galus                         LLEQEKQRNFEKQREELMNVQKLQSQLKLEQQRWERERSQQQRELEISEA 773 
Xenopus_tropicalis                  LLEQEKQRNFEKQREELGNVQKMQDQLRLEKQKWERERERQQREAEAMEN 637 
Danio_rerio                         LLEQEKHRNLHKQNEELANFQRLQNQRLQEQRQWEQERERQMLQAEAREK 688 
D_melanogaster_Cg10188isoform_      LYRESPRSSAYTHKDQLEELRNLQDKQQEEKTAWQRQLKQQQEE------ 1044 
                                    * .:. : .  .:.::                                   
 
Homo_sapiens_isoform2               RLQEREGEARQLRERLEQERAELERQRQAYQHDLERLREAQRAVERERER 790 
Canis_familiaris                    --------------------------RRAYQHDLERLREAQRAVEREREQ 887 
Mus_musculus                        RLQEREGEARQMRQRLDQERTELERQRQAYQHDLERLREAQRAVDRERER 790 
Ornithorhynchus_anatinus            RLQEQESESRQLRERLNQEREELDRQREAYQHDLERLRESQRAVEKEKER 902 
Galus_galus                         HLQRREEETRQLKDKLIQDRKELERQREAYQHDLERLREAQRAVEKERER 823 
Xenopus_tropicalis                  MLRQRMGDSELQLQKLHQERDELEAQRKEYQHDLERLRESQKAVEKDRER 687 
Danio_rerio                         ELREREMACSRQEEMLAGEKQELARCREEYQQDLERLRESMRSVEKEKEK 738 
D_melanogaster_Cg10188isoform_      -LAEMRAQQLQLQKQIKAEQEDVRQQREQLYKKMELLSSQGLLLSPSTP- 1092 
                                                              *.   :.:* * .    :. .    
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Homo_sapiens_isoform2               LELLRRLKKQNTAPGALPPDTLAEAQPPS--HPPSFNGEGLE-------- 830 
Canis_familiaris                    LEQQRRLKKQNTVPGALPPDSLAEAQPPS--HTPSFNGEGLEGPTTLAKA 935 
Mus_musculus                        LELLRRFKKQNTVPGALPPEVLAEAQPAS--HPPSFNGDGLEGHSAPAKA 838 
Ornithorhynchus_anatinus            LEQLKRLKKQNTVSG---PTEIGESQSLS--HSSSFNGEGMEGSVQLAR- 946 
Galus_galus                         LDQLRKLKKQNTVSGTFSPELG-QNPMQS--HPVSFNGEGVEPS-----L 865 
Xenopus_tropicalis                  LELMKRIKATSAGAGSFSSDLIPVTMEQPSIHSAASNGEGMLSTEAPSHL 737 
Danio_rerio                         LELQKKYKKNENVPVVYPLENEQIQIPPP--------------------- 767 
D_melanogaster_Cg10188isoform_      ---LPPVSNNHPPPAALLDDSHETDNGLS--------------------- 1118 
                                           .     .              .                      
Homo_sapiens_isoform2               --GPRVSMLPSGVGPEYAERPEVARRDSAPTESR---LAKSDVPIQLLSA 875 
Canis_familiaris                    -PGPRVSVLLSGSGPEFTERPEVARRDSAPTESR---PAKSDVPIQLLST 981 
Mus_musculus                        -PGTQGSAMLHGTGPDNVERPEVARWDSAPPESR---PAKSDVPIQLLSA 884 
Ornithorhynchus_anatinus            -ATPRTSVLLSG--TDYIERPEVIRRDSTTMEGR---PVKNDVPIQLLSA 990 
Galus_galus                         -PVLKASARVSVSGMDYLERSELVRRDSTTLENRPVLALKNEVPIHLLSA 914 
Xenopus_tropicalis                  PLKPLAKTTMSMSAADYLERPEVARRESNVTDIRP--ALKKEVPIHLLSA 785 
Danio_rerio                         ------YPILNIVSPGFTERAPLVPPRRESITGS---LVKPEVPIHLIST 808 
D_melanogaster_Cg10188isoform_      --GSGTGSSTPSVGGTFDRRKEKWLSGSSSCKTP---------PVNLISA 1157 
                                                      .*                       *::*:*: 
 
Homo_sapiens_isoform2               TNQFQRQAAVQ-QQIPTKLAASTKGGKDKGGKSRGSQRWESS----ASFD 920 
Canis_familiaris_                   TNQIQRQAAVQ-QQIPTKLAASTKGGKDKGGKSRGSQRSDSS----ASFD 1026 
Mus_musculus                        TNQIQRQTAVQ-QQIPTKLAASTKGGKEKGSKSRGSQRWESS----ASFD 929 
Ornithorhynchus_anatinus            TNQIQKQAAVQ-QQIPTKLAVFTKGSKEKGGKSKASQRTDSS----VSFD 1035 
Galus_galus                         TNQIQKPAVVQ-QQIPTKLATFTKGSKEKSGKNKASHRTDSS----ASVD 959 
Xenopus_tropicalis                  TNQIQKQAALTRQQIPTHLAMDK--GKEKPSRGKASHRTEST----ASLD 829 
Danio_rerio                         TNQTLKAGSVQ-QKIPTKLAAQPK-GKEKHSKHRNSHQRTNS----AAGI 852 
D_melanogaster_Cg10188       _      NNAPKVNPTLVKQKLPMKLSSLSSSGTSSSRVDKSASFNSASPTPYISAG 1207 
                                    .*       :  *::* :*:     ....    : :     :     :   
Homo_sapiens_isoform2               LKQQLLLNKLMGKDESTSRNRRSLSPILPGRHSPAPPPDPGFPAPSPPPA 970 
Canis_familiaris_                   LKQQLLLSKLMGKDENASRNRRSLSPVLLSSHSSVAPPDPCCPAPP---- 1072 
Mus_musculus_                       LKQQLLLSKFIGKDESASRNRRSLSPVLPAAHGSAPASDPCFPAPSPAPA 979 
Ornithorhynchus_anatinus            LKQQLLLTKLMGRDENTLKNRRSVSPVLP--NSQPAPLNPESSAPT---- 1079 
Galus_galus                         QKQ-LIPPRLVGREEGVLRGRRSASPVLTSSQTTAFQTEIHGSADGQPEA 1008 
Xenopus_tropicalis                  HRLGFPP-KLSGKEDGTVRSRRSASPSPFSSQNPVGQAEPSLDTPFYTPV 878 
Danio_rerio                         EVSHVVPIKVAGREGGSLKAIRSSSPHHLHPDLFTHPDKLSSSVSSHSGN 902 
D_melanogaster_Cg10188              SVQQMFPLKLADRRTATPSNCTTTPTTGMVPQHSRTGSSPAIIQQATTTA 1257 
                                        .   :. .:         : ..     .      .            
Homo_sapiens_isoform2               DSPSEGFSLKAGGTALL---PGPPAPSPLPATPLSAKEDAS----KED VIFF  1015 
Canis_familiaris_                   DVPAEGCSLKPGGG------PVPPSPLPLPTTPLS-KEESS----KED VIFF  1113 
Mus_musculus                        ATPPEAF--KFGGTSLP---PVSPASS-LPTTPLATTDEVS----KED VIFF  1021 
Ornithorhynchus_anatinus            DVPPEPFPSGPGNAYKLSSIPFQPAAAAPTPPQVSSDDDAN----KED VIFF  1127 
Galus_galus                         LSSASPNPFKPNNAH-------AQTLVTSQPTLLNMQDDTS----KED VIFF  1049 
Xenopus_tropicalis                  LYRPSSFH-------------LLPPSFPPQPPPPPAEDEGS----KEN VIYF  913 
Danio_rerio                         SSRKHNHSHN----------SHTSSTHSTHSGHRKTKDSPN----AED IFFF  940 
D_melanogaster_Cg10188       _      TPTQTPVARAESVAHYTRTPTSSRTGIARTAGIAVATGTAPRAKPEEE EIYF  1309 
                                                            .     .               *: ::* 
Figure 6.0 Sequence alignment of p114RhoGEF orthologs   Sequence  alignment  of  human  p114RhoGEF  isoform  2  against  orthologues  of p114RhoGEF from other species, including the putative p114RhoGEF ortholog cg10188 from Drosphophila melanogaster. In the human isoform 2 the DH domain is highlighted in grey, also highlighted  in yellow within  the DH domain  is a conserved QRITKY motif present in all Dbl GEFs. The PH domain and proline rich regions are highlighted in light blue  and  purple  respectively.  Homo  sapiens  isoform  2  Q6ZSZ5­2,  Canis  familiaris 
XP_854251, Mus musculus Q6P9R4, Ornithorhynchus anatinus(platapus) (Ensembl),  Galus 
galus  XP_418249.2,  Xenopus  tropicalis  ENSXETP00000014110  (Ensembl)  ,  Danio  rerio 
Q6NSP2, Drosphophila melanogaster Q9VIV.  
 
 
 
 
 
 
 
 
 
 
Figure 6.1  Depletion of cg10188 by RNAi in during development causes lethality.   Male  flies  containing  shRNA  to  cg10188  driven  under  the  control  of  a  UAS  promoter  (UAS‐RNAi), present  on  chromosome  II were  crossed with  virgin  female  flies  containing ubiquitously  expressed GAL4 driven from an actin promoter Actin/GAL4 on chromosome II1 . The CyO gene was present on a balancer chromosome II2.  . The resulting crosses only produced flies that all had the CyO phenotype (highlighted  in  yellow  in  table)  of  curly  wings,  indicating  that  files  depleted  of  cg10188  by  GAL4 dependent expression of cg10188 shRNA and causes  lethality. All pupal cases observed were empty indicating that lethality occurs at any stage before pupal development.  The experiment was repeated twice  using  two  different  UAS‐shRNA  cg10188  flies  stocks  containing  different  cg10188  specific shRNA sequences both located on chromosome II. 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Figure 6.2 Generation of Heat shock recombinase GFP flip­out clones. Male flies containing shRNA to cg10188 under the control of a UAS promoter were crossed with virgin female flies containing a heat shock inducible flip recombinase and expressing GFP from a minimal tubulin promoter. GFP is flanked by heat shock flip recombinase sites (blue triangles) and one of these contains a stop codon to prevent  expression  of  GAL4.  The  larval  progeny  of  this  cross  were  heat  shocked  at  37°C  to  induce  the expression of heatshock flip recombinase that causes the excision “flipping out” of GFP while simultaneously switching  on  ubiquitous  expression  of  GAL4,  which  drives  expression  of  shRNA  to  cg10188.    This  system produces  tissues  that  have  a  mosaic  expression  pattern  of  GFP,  where  some  cells  have  retained  GFP expression and so do not express shRNAs, whereas some have lost GFP and express shRNAs that mediate the repression of target gene by RNAi, in this instance cg10188.   
Figure 6.3  Absence of cg10188 in imaginal discs does not cause disruption 
of Adherens junctions or effect junctional actin organisation.  Imaginal wing discs were dissected from fly larva containing a UAS driven shRNA specific for cg10188 and a heat shock inducible flip recombinase and GFP/GAL4. Larvae  were  heat  shocked  at  37°C  for  30  minutes  to  induce  flip  recombinase expression  causing  the  excision  of  GFP  and  the  expression  of  GAL4  to  drive shRNA expression.  Imaginal discs were dissected 48 hours post heat shock and immunostained  for  f‐actin  (red)  and  Armadillo  (blue)  GFP  (green).  Shown  is  a maximum intensity projection several confocal sections of the apical membrane of a section of wing disc. Cells marked with asterisk show a subset of examples where GFP expression is lost and shRNA cg10188 expression is switched on. Note no morphological changes are observed in Adherens junctions or junctional actin organisation. 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Discussion   
Investigation of the function of the putative p114RhoGEF ortholog in Drosophila 
cg10188 revealed its depletion by RNAi during development causes lethality. It was 
not determined exactly at which stage of development lethality occurred, but by the 
observation that no pupal cases were found occupied by flies arrested in 
development, indicates development is effected somewhere between 
embryogenesis and just before larval pupation. It will need to be investigated to find 
the precise stage of development affected by repeating this experiment on a larger 
scale to identify the defect(s) at different larval developmental stages.  However, this 
is not conclusive data as all shRNAs have different non- specific off target effects 
that cannot be ruled out from this experiment. Both shRNAs sequences for cg10188 
have a 19 base pair region of identity to cg15336 (VDRC database) a gene 
encoding a small zinc binding protein containing a C2H2 like zinc finger protein 
domain and therefore cg10188 shRNA could also effect cg15336 expression 
causing the observed lethal phenotype. Rescue by overexpression of RNAi resistant 
cg10188 or P-element mediated disruption of cg10188 expression will be required to 
support this evidence to exclude off target effects. 
 
The absence of any phenotype in imaginal discs on junction morphology upon 
stimulation of cg10188 RNAi was surprising based on its lethality when cg10188 
RNAi is constitutively expressed. However, areas of GFP negative cells were small 
suggesting that cg10188 RNAi could prevent proliferation or induce apoptosis, this 
will require further investigation, such as staining with markers for apoptosis 
(caspases).   The lack of any obvious phenotype could be explained by insufficient 
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suppression of cg10188, as dissection was performed just 48 hours after induction 
of RNAi, which may not be a sufficient amount of time to allow full repression of 
cg10188. Overexpression of dicer an important component of the RNAi machinery 
329 could increase the efficiency of RNAi in flies. The experiment could therefore be 
repeated in UAS-dicer flies that overexpress dicer under a UAS promoter to 
enhance the efficiency of cg10188 RNAi. Future experiments will be required to 
investigate if cg10188 is expressed in the imaginal discs by performing in situ 
hybridisation experiments and eventually developing an antibody to confirm if 
cg10188 protein is expressed and observe its subcellular localisation in imaginal 
discs and or other tissues.  
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Final discussion  
 
RhoGTPases are small molecular switch proteins that are important regulators of 
the cytoskeleton and modulators of gene expression. RhoGTPases have thus been 
identified as being major signalling components associated with junctions (see 
Chapter 1 Pages 56-68). An important question I asked at the start of this project is 
how are RhoGTPases regulated to control junction formation and gene expression 
in the human corneal epithelium? To investigate this question I used a siRNA 
screening approach combined with functional assays to observe junction 
morphology and gene expression. This enabled the identification of components of 
RhoGTPase signalling that affected junction assembly and modulated NF-κB 
mediated gene expression in HCE cells.  
 
Regulators and effectors of RhoGTPases that regulate junction morphology and 
modulate NF­κB mediated gene expression 
 
I discovered that the RhoGTPases Cdc42 and RhoA are key regulators of junction 
morphology in HCE cells. I validated candidates that had various effects on junction 
morphology by observing if the same phenotype on junction formation could be 
reproduced with individual siRNAs derived from the deconvolution of the siRNA pool 
used in the primary screen into four different individual siRNAs. Several of the 
candidates chosen for validation were not identified in the primary screen in HCE 
cells as having any effect on junction morphology, but were discovered to have 
effects in a parallel screen performed in Caco-2 cells  (Matter 2007 unpublished 
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results). These candidates were subsequently validated along with a subset of 
candidates identified in the primary screen to give a final total of 14 validated 
candidates that had effects on junction morphology in HCE cells (Chapter 3 Table 
3.2). The 14 validated candidates is by no means a comprehensive list of all 
regulators and effectors of RhoGTPases that may potentially regulate junction 
formation in HCE cells as many more might have effects on junction morphology.  
One of the limitations of the siRNA screen is there is no guarantee that there is 
efficient knockdown of all target proteins.  Different proteins will have different half-
lives to each other, some will be more stable or the same protein may have an 
increased half-life and so be more stable when it is in a complex with different 
proteins. It might be interesting to repeat the siRNA screen with all the candidates 
that did not show any effect on junction morphology by disrupting cell-cell junctions 
after siRNA transfection. Transfecting cells with siRNAs the day after plating as 
before then allowing junctions to form for several days then disrupting cell-cell 
junctions by trypsinising with EDTA before re-plating and performing the analysis 
when junctions have reformed again. Disrupting cell-cell junctions after transfection 
of siRNA may increase the efficiency of depletion of the target protein and therefore 
decrease their stability and permit the identification of additional target proteins.    
 
Many of the validated candidates identified were either GEFs and GAPs or 
downstream effectors of Cdc42 and or RhoA. This result correlates well with RhoA 
and Cdc42 having the most disruptive effects on junction formation and polarity and 
supports many previous studies in different cell types of the importance of these two 
RhoGTPases in the regulation of junctions 4 206, 221, 245, 330. The initial aim of this 
project was to fully characterise several of these validated candidate proteins and to 
 223 
investigate the molecular mechanisms of how they modulate Rho signaling to 
regulate junction formation. One of these candidates p114RhoGEF was fully 
charaterised and shown to drive junction formation by activating RhoA in a spatially 
restricted manner (see Chapter 4).  However, due to the time constraints and 
resources allocated to this project only p114RhoGEF could be investigated in depth. 
A future long-term aim is to perform a detailed analysis on a number of other 
candidates investigating which RhoGTPase signaling pathways they modulate, 
where they spatially activate RhoGTPases during junction formation and what are 
the downstream functional consequences of this activation on cell-cell adhesion.  
 
In addition to candidates identified that affected junction morphology a number of 
components that potentially regulate NF-κB activity were also indentified in HCE 
cells. As the screen was performed in the presence of serum, which causes 
constitutive NF-κB activity I felt candidates that produced inhibitory effects, rather 
than stimulatory effects maybe more valid to study. The data from this NF-κB activity 
screen was plotted with data from the junction morphology screen and revealed a 
number of candidates (MAP4K1, RacGAP1 and OBSCN MCF2L(Dbs) and 
RhoBTB1) that had a strong inhibitory effect on NF-κB reporter activity, as well as 
having an effects on junction morphology. However due to limited time for this 
project none of these candidates were validated by repeating the NF-κB reporter 
activity using individual siRNAs. Future experiments will focus on validating this 
subset of candidates and also performing a further siRNA screens to look for 
RhoGTPase signaling components that regulate β-Catenin/TCF mediated gene 
expression. These future experiments will hopefully indentify novel RhoGTPase 
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signaling pathways that link intercellular cell-cell junctions to NF-κB and β-
Catenin/TCF regulated gene transcription to orchestrate different epithelial cell 
processes, such as proliferation, cell survival, EMT and pro-inflammatory signalling.  
 
p114RhoGEF drives junction formation and epithelial morphogenesis via  the 
spatially restricted activation of RhoA  
In this study I fully characterised p114RhoGEF, a candidate that was validated from 
the siRNA for junction assembly (See Chapter 4). I discovered p114RhoGEF is a 
novel TJ associated activator of RhoA that regulates epithelial differentiation, barrier 
formation and epithelial morphogenesis. I demonstrated p114RhoGEF spatially 
activates RhoA at cell-cell contacts activating junctional actinomyosin contractility a 
process that is essential for driving junction formation. I discovered mechanistic 
evidence for p114RhoGEF being part of a junction-associated Rho signalling 
module by p114RhoGEFs association with a complex containing Myosin II, Rock II 
and the junctional adaptor protein Cingulin. I showed the formation of this complex is 
dependent on the assembly of cell-cell junctions and the junctional adaptor Cingulin 
is required for efficient recruitment of p114RhoGEF to cell-cell junctions.   
 
Given the physiological roles of junctional RhoA signalling, p114RhoGEF represents 
a regulator of central importance. Future experiments will need to focus on 
identifying signalling components that stimulate p114RhoGEF, to drive spatially 
restricted Rho signalling and Myosin activation at cell junctions. One potential 
candidate that may stimulate p114RhoGEF is the kinase Erk1/2. p114RhoGEF 
contains a putative Erk binding site within its C-terminal Proline rich region 
 225 
(Scansite). Within this Erk binding site are two evolutionary conserved serine 
residues S952, 954 that are known to be phosphorylated in vivo (Phosphosite).  
Erk1/2 is known to stimulate the guanine nucleotide exchange activity of other 
GEFs; GEF-H1, for example is phosphorylated by Erk1/2 and this stimulates its 
exchange activity towards RhoA in response to TNFα stimulation 180 219. It will be 
important to test if p114RhoGEF is stimulated by Erk1/2. Investigating the functional 
relavence of phosphorylation of p114RhoGEF via Erk1/2 may permit p114RhoGEFs 
interaction with Cingulin and thus drive its recruitment from the cytoplasm to TJs. 
Phosphorylation may also function to stimulate p114RhoGEF exchange activity 
towards RhoA during junction formation in response to different physiological stimuli 
such as TNFα.  
 
p114RhoGEF a regulator of migration ? 
 
Based on the finding that p114RhoGEF spatially activates RhoA during junction 
formation I decided to investigate if it also had a function in cell migration during 
wound healing. I discovered p114RhoGEF does indeed regulate migration of HCE 
cells. p114RhoGEFs depletion causes HCE cells to migrate at a slower rate during 
wound healing experiments (see Chapter 5). It will be important to repeat these 
experiments in different breast cancer cell lines, as p114RhoGEF was shown to be 
upregulated in a fully de-differentiated metastatic breast cancer cell line MDA-
MB231. This may link the function of p114RhoGEF to important roles in migration 
and invasion of breast cancer cells during cancer progression. Future experiments 
will need to address the question of how is p114RhoGEF regulating the rate of 
migration? In order in answer this question live cell imaging using FRET based 
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techniques will be required to observe where and when RhoA is spatially active in 
normal and p114RhoGEF depleted cells during cell migration. Traditionally RhoA is 
thought to be active only at the trailing end of migrating cells where it regulates cell 
body contraction and detachment of the trailing end 331. However, recent studies 
demonstrated that RhoA may also be active at the leading edge of migrating cells 
318, although the functional consequences of RhoA activation at the leading edge 
remain unknown. I discovered p114RhoGEF to be localised to the tips of protrusive 
membrane structures of migrating HCE cells during wound healing. It will be 
interesting to investigate several questions: how is p114RhoGEF recruited to these 
structures? Does p114RhoGEF spatially activate RhoA at these membrane tips?  If 
so questions will need to be addressed such as: what are the functional effects of 
RhoA activation? How does it contribute to dynamic coordinated regulation of the 
cytoskeletion during cell migration?  
 
cg10188 the putative p114RhoGEF ortholog in Drosophila melanogaster is 
essential during development.     
I was interested in the evolutionary conservation of p114RhoGEF in different 
species and found it to be conserved in mammals, reptiles, amphibians, fish and 
flies. I explored if cg10188 the putative p114RhoGEF ortholog in the fly Drosophila 
melanogaster had a similar function to p114RhoGEF by using RNAi (Chapter 6). I 
discovered when cg10188 RNAi is performed during development it causes lethality, 
indicating cg10188 is an essential gene. The precise stage at which development 
was arrested remained unknown, however there were no pupal cases that were 
occupied by flies arrested during development indicating developmental lethality 
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occurred before larval pupation. However, the caveat with this result is that the 
observed lethality could be due to an off target effect of the shRNAs used. As 
demonstrated p114RhoGEF is an important regulator of junction formation and a 
regulator of apical membrane constriction in mammalian cells, I observed if loss of 
cg10188 expression by RNAi caused any defects on junctions in imaginal discs 
epithelial structures that require apical constriction to bend and fold to undergo 
morphological changes to form eyes, antennae wings and legs in the adult fly. I 
discovered no defect on cell-cell junctions in cells depleted of cg10188 within the 
imaginal discs (Chapter 6- Figure 6.3). The lack of any phenotype on cell-cell 
junctions could have been a result of inefficient suppression of cg10188 expression. 
However, as the size of clones of GFP negative cells were small, cg10188 RNAi 
could regulate proliferation or induce apoptosis, this will require further 
investigations to confirm this. 
 
It will be important to identify the precise developmental stage affected by the loss of 
cg10188.  Where cg10188 is expressed in the imaginal discs as well as other 
tissues will also be important questions to address. In situ hybridisations will have to 
be performed to observe expression of cg10188 while antibodies against cg10188 
are developed. This will provide additional information of where to observe the 
effects of the loss of cg10188 expression.   
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Final summary  
RhoGTPases are small molecular switch proteins that are important regulators of 
the cytoskeleton and modulators of gene expression. RhoGTPases have thus been 
identified as being major signalling components associated with cell-cell junctions. 
An Important question I asked at the start of this project was how are RhoGTPases 
regulated to control junction formation and gene expression in corneal epithelial 
cells? I have addressed this question by using a siRNA screening approach and 
have identifed a number of candidates that regulate or are downstream effectors of 
RhoGTPase signalling that affected junction formation and NF-κB regulated gene 
expression. I fully characterised one of these candidates p114RhoGEF, a novel TJ 
localised guanine nucleotide exchange factor (GEF) that drives junction formation 
and epithelial cell morphogenesis by spatially restricted activation of RhoA at cell-
cell junctions. I discovered p114RhoGEF to have an important role in cell migration 
and have also started to explore the function of a putative p114RhoGEF ortholog, 
cg10188 in Drosophila melanogaster and shown it to be important in larval 
development.   
 
Future studies will focus on expanding the role of p114RhoGEF in cell migration and 
its putative ortholog, cg10188 in Drosophila melanogaster during development. A 
long-term future aim will be discovering molecular mechanisms by which the other 
identified candidates in the screen regulate RhoGTPases siganlling pathways to 
guide junction formation and modulate gene expression. 
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Appendix 
 
Antibodies 
All antibodies are listed in alphabetical order and state the host species in which 
they were raised and were possible the clone number and the source they were 
obtained from, also shown are dilutions/concentrations if the antibody was used for 
Immunfluoresence (IF), Immunoblotting (IB) and Immunoprecipitation (IP) Zona 
Occludens-1,2 and 3, α Tubulin, VSV, and GEF-H1, anti GST described previously 
212. 
  
Antibody  Host 
Species 
Clone  Source  IF 
Dilution 
IB 
Dilution 
IP 
(µg) 
Alpha Tubulin  Mouse  1A2  Matter Lab  1:10  1:20  ‐ 
Alpha‐Catenin   Rabbit  Poly  Sigma  1:2000  1:4000  ‐ 
ARHGEF18/p1
14RhoGEF 
Goat  Poly  Everest  1:200  1:1000  1.5 
Beta ‐Catenin  Goat  Poly E‐17  Santa Cruz  1:100  1:1000  ‐ 
Cingulin  Rabbit  Poly  Zymed  1:2000  1:5000  1.5 
Cofilin  Mouse  Mono  BD        ‐  1:500  ‐ 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32/Cofilin 
E‐Cadherin  Mouse  Mono  
36/E‐cad 
BD  1:500  1:1000  ‐ 
GEF‐H1  Mouse  B4/7  Matter lab  1:5  1:5  ‐ 
Giantin  Mouse  Mono  Matter lab  1:500  ‐  ‐ 
GST  Rabbit  Poly  Matter lab  ‐  1:2000  ‐ 
Myc  Mouse  Mono 9E10  Matter lab  1:200  1:1000  ‐ 
Myosin IIA  Rabbit  Poly  Sigma  1:2000  1:5000  1.5 
Myosin light 
chain MLC 
Rabbit  Poly  Cell 
signalling 
1:200  1:500   
Myosin light 
chain 
phosphotase  
MYPT1 
Sheep  Poly  Millipore  ‐  1:5000   
Occludin  Mouse  Mono 
OC‐3F10 
Invirogen  1:2000  1:5000  1.5 
p115RhoGEF(L
sc) 
Goat  Poly 
H‐19 
Santa Cruz  ‐  1:1000  1.5 
Phospho  Rabbit  Mono77G2  Cell  ‐  1:500  ‐ 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Cofilin  signalling 
Phospho 
T18,S19 MLC 
Rabbit  Poly  Cell 
signalling 
1:200  1:500  ‐ 
Phospho  T696 
MYPT1 
Sheep  Poly  Millipore  ‐  1:1000  ‐ 
ROCK I  Mouse  Mono  BD  ‐  1:1000  ‐ 
ROCK II  Mouse  Mono  BD  1:200  1:1000  ‐ 
Shroom3  Goat  T‐17  Santa Cruz  ‐  1:1000  ‐ 
VSV  Rabbit  Poly 
4921 
Matter Lab  1:1000  1:2000  ‐ 
ZO‐1  Rabbit  Poly 4913  Matter Lab  1:400  1:1000  1.5 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siRNAs for screens  
Below is a complete list of siRNAs and their target genes used in the RhoGTPase 
siRNA library purchased from Dhamacon. There are four individual siRNA 
sequences per gene used as a pool in the screen and de-convoluted into individuals 
siRNAs for validation.   
 
Catalog 
Number 
Gene 
Symbol 
Locus 
ID 
Accession Sequence 
D-006823-01 INCENP 3619 NM_020238 CCACGAUGCUGACUAAGAA 
D-001206-13 siCONTROL Non-Targeting siRNA Pool 
D-008611-01 ABR 29 NM_001092 GAAGAUCUCUGCCCUCAAG 
D-008611-02 ABR 29 NM_001092 CAACCUGGCUACCGUGUUU 
D-008611-03 ABR 29 NM_001092 GAAGAGAUCUACAUUAACC 
D-008611-04 ABR 29 NM_001092 CAGAGGAACUCAAAGUGAA 
D-008868-05 AKAP13 11214 NM_006738 GGAAGAAGCUUGUACGUGA 
D-008868-01 AKAP13 11214 NM_006738 GAAGACAUAUGGCAAGUUU 
D-008868-02 AKAP13 11214 NM_006738 CGAAACAGCUGGAUUCAGA 
D-008868-03 AKAP13 11214 NM_006738 UCAACAGACUCACUAAAUA 
D-014168-01 ALS2 57679 NM_020919 GAAUUUAGGCUCUGAGGUA 
D-014168-02 ALS2 57679 NM_020919 GGAUAAUGAUCGCGAGGAA 
D-006823-02 INCENP 3619 NM_020238 CAAGAAGACUGCCGAAGAG 
D-001500-01 siTOX Transfection Control 
D-014168-03 ALS2 57679 NM_020919 GCUUAGCCCUUGUACAAUG 
D-014168-04 ALS2 57679 NM_020919 AGAGCCAGGUUAUGUAGUA 
D-008966-01 ARHGAP1 392 NM_004308 GCCAAGUGCUCAAAUAUGA 
D-008966-02 ARHGAP1 392 NM_004308 GGAGACUGUUGCCUACUUA 
D-008966-03 ARHGAP1 392 NM_004308 GGCAGGAGAUGACAAGUAU 
D-008966-04 ARHGAP1 392 NM_004308 GAUCUGACCUUGGAUGACA 
D-009382-01 FLJ20896 79658 NM_024605 GUGAAACACUUAACAAAUG 
D-009382-02 FLJ20896 79658 NM_024605 GAAGUGAAGACAAUAACAA 
D-009382-03 FLJ20896 79658 NM_024605 GGAGAAUUCUGCAGAUUGG 
D-009382-04 FLJ20896 79658 NM_024605 GAAUAUUGUUGUGGAAAUC 
D-006823-03 INCENP 3619 NM_020238 UCUGCAACAUGGAUAAUAA 
D-021122-01 ARHGAP11A 9824 NM_014783 UACAGACUCUUAUCGAUUA 
D-021122-02 ARHGAP11A 9824 NM_014783 GUUCGAAGAUCUCUGCGUU 
D-021122-03 ARHGAP11A 9824 NM_014783 GGUAUCAGUUCACAUCGAU 
D-021122-04 ARHGAP11A 9824 NM_014783 AAGCGUACAUUGCCAGUAG 
D-018019-01 ARHGAP15 55843 NM_018460 GAAAUGAGUUCCUUCUACA 
D-018019-02 ARHGAP15 55843 NM_018460 GAUGCAAUAUAUCGAGUUA 
D-018019-03 ARHGAP15 55843 NM_018460 GAACCUAUAUCCAGACACA 
D-018019-04 ARHGAP15 55843 NM_018460 GCACUGAAUUGCUAAGUCA 
D-008335-01 ARHGAP17 55114 NM_018054 GCAGACAUGUACAACUUUA 
D-008335-02 ARHGAP17 55114 NM_018054 AAACAGAAGUCCUUAGUGA 
D-006823-04 INCENP 3619 NM_020238 GCAAAGAGCCAGAGCUGAU 
D-008335-03 ARHGAP17 55114 NM_018054 GGGAGCAGCUUGCAAGAUU 
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D-008335-04 ARHGAP17 55114 NM_018054 CUGAAGAGGUGGAAUUUAA 
D-015110-01 ARHGAP18 93663 NM_033515 GGAAACAGAAGGCCUCUUA 
D-015110-02 ARHGAP18 93663 NM_033515 UGACAGCGCUAUUAGAACA 
D-015110-03 ARHGAP18 93663 NM_033515 CGAGGCAUCUAACCUUGUU 
D-015110-04 ARHGAP18 93663 NM_033515 CCAUGCACUUAUUGAUUAA 
D-026514-01 ARHGAP20 57569 NM_020809 GCACUCACCUGGACAACUU 
D-026514-02 ARHGAP20 57569 NM_020809 GCUCAUUAAUCAGAGUUUA 
D-026514-03 ARHGAP20 57569 NM_020809 GAAUUGUGCCUACUCUAAA 
D-026514-04 ARHGAP20 57569 NM_020809 CCAUCCGGCUCAUCAGUAA 
D-003317-05 KIF11 3832 NM_004523 GCAGAAAUCUAAGGAUAUA  
D-004775-01 ARHGAP21 57584 NM_020824 UAAAGAAGCUGUCAUCCUA 
D-004775-02 ARHGAP21 57584 NM_020824 GGAGACAGCUCUUCAGUUC 
D-004775-03 ARHGAP21 57584 NM_020824 AAAGGAAACUUCUCAGUAA 
D-004775-04 ARHGAP21 57584 NM_020824 GUAAAUCACUUGCAUCAGA 
D-019080-01 ARHGAP22 58504 NM_021226 CUAGGAAGCUUGACUGUUG 
D-019080-02 ARHGAP22 58504 NM_021226 GGGAUCAGCUUUUCUACUA 
D-019080-03 ARHGAP22 58504 NM_021226 AUUACAACCUGCUCAGAUA 
D-019080-04 ARHGAP22 58504 NM_021226 GGGAUUUAUUUCUCUACAA 
D-023061-01 ARHGAP23 57636 XM_290799 GAAGACGGCCCUGCCCAUA 
D-023061-02 ARHGAP23 57636 XM_290799 GGAACGAGCCGUAUUCUGG 
D-003317-06 KIF11 3832 NM_004523 CAACAAGGAUGAAGUCUAU 
D-023061-03 ARHGAP23 57636 XM_290799 GGGAAAGCGUCAUUGGGAA 
D-023061-04 ARHGAP23 57636 XM_290799 GAAUGGAGGCCGUGGAGGA 
D-014713-01 ARHGAP24 83478 NM_031305 AGAACAAGCUGGAGAGUUA 
D-014713-02 ARHGAP24 83478 NM_031305 GGAGGAUACUGUUCGUUAU 
D-014713-03 ARHGAP24 83478 NM_031305 CGAGAGAGGAAACACAAUA 
D-014713-04 ARHGAP24 83478 NM_031305 GGUCUUUGGUCCUAAUAUC 
D-021175-01 ARHGAP25 9938 XM_376060 GGACUUCCACCUACGAUAA 
D-021175-02 ARHGAP25 9938 XM_376060 GAUCAGAGACCAUGAAGUC 
D-021175-03 ARHGAP25 9938 XM_376060 GCAGGUUCCUACAUGAAAU 
D-021175-04 ARHGAP25 9938 XM_376060 CAAGAGCUACGAAAGGAAA 
D-003317-07 KIF11 3832 NM_004523 CAGCAGAAAUCUAAGGAUA 
D-008426-01 ARHGAP26 23092 NM_015071 GAACAUGACUCAGAACUUU 
D-008426-02 ARHGAP26 23092 NM_015071 CCAAACAGCAUCCUUAAUU 
D-008426-03 ARHGAP26 23092 NM_015071 CAUAGGAGAUGCAGAAACA 
D-008426-04 ARHGAP26 23092 NM_015071 GAAAGAAUCUCAGCUUCAG 
D-027281-01 LOC201176 201176 NM_199282 CCGAGUCGCUGACCAGUUA 
D-027281-02 LOC201176 201176 NM_199282 GAAAGCGGCUCCGGAAGAA 
D-027281-03 LOC201176 201176 NM_199282 GGACUCCUCUGUUCGAUGG 
D-027281-04 LOC201176 201176 NM_199282 GCACUUCCGCCAGUUCAUU 
D-031016-01 ARHGAP28 79822 NM_001010000 GAAGCAAACACUCUGAUUA 
D-031016-03 ARHGAP28 79822 NM_001010000 CCAUUCAACUCAACAAUCA 
D-003317-08 KIF11 3832 NM_004523  
CUAGAUGGCUUUCUCAGUA 
D-031016-05 ARHGAP28 79822 NM_001010000 GAAUAUAUACCUGCCUUCA 
D-031016-06 ARHGAP28 79822 NM_001010000 GUGAAGAACUUGAUGCCAA 
D-003628-05 ARHGAP4 393 NM_001666 CGCAAGAGCUCCCUCAAGA 
D-003628-01 ARHGAP4 393 NM_001666 GCUGAGAUCUGCGUUGAAA 
D-003628-03 ARHGAP4 393 NM_001666 GGAGACAUGGAGAAGUUUA 
D-003628-04 ARHGAP4 393 NM_001666 GACAGACCAUUGAGACAGA 
D-009580-03 ARHGAP5 394 NM_001173 GUACGAAUUUGCAACCAUA 
D-009580-04 ARHGAP5 394 NM_001173 UGAAAGCGCUCGUUCCAAA 
D-009580-01 ARHGAP5 394 NM_001173 GAGAGCAGAUUUCCAGUUA 
D-009580-02 ARHGAP5 394 NM_001173 UGAGAUCACUGCUAAAUUU 
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D-006823-01 INCENP 3619 NM_020238 CCACGAUGCUGACUAAGAA 
D-001206-13 siCONTROL Non-Targeting siRNA Pool 
D-009304-02 ARHGAP6 395 NM_001174 AAACUUAGCCACCAUAUUU 
D-009304-03 ARHGAP6 395 NM_001174 GUACACAGCUUUCAUCAAC 
D-009304-01 ARHGAP6 395 NM_001174 GAAACUGGAUUCACUAGGA 
D-009304-04 ARHGAP6 395 NM_001174 CAUCAUCGCUGUUGUGCAA 
D-009427-01 ARHGAP8 23779 NM_181334 ACAAGGAGUUCGAUAGGAA 
D-009427-02 ARHGAP8 23779 NM_181334 GAUAGGAAGUACAAGAAGA 
D-009427-03 ARHGAP8 23779 NM_181334 GCAUACAAGGAGUUCGAUA 
D-009427-04 ARHGAP8 23779 NM_181334 CCGUGAACUUUGACGACUA 
D-010047-01 ARHGAP9 64333 NM_032496 GAACAAUGAUGUCCUGCAA 
D-010047-02 ARHGAP9 64333 NM_032496 GAAGAGACCGCCCUUACAA 
D-006823-02 INCENP 3619 NM_020238 CAAGAAGACUGCCGAAGAG 
D-001500-01 siTOX Transfection Control 
D-010047-03 ARHGAP9 64333 NM_032496 GAAGGUCGGUUAGAUUUGG 
D-010047-04 ARHGAP9 64333 NM_032496 GGGCCGAAGUUGUUUCAUG 
D-016253-01 ARHGDIA 396 NM_004309 CAGGAAAGGCGUCAAGAUU 
D-016253-02 ARHGDIA 396 NM_004309 GGUGUGGAGUACCGGAUAA 
D-016253-03 ARHGDIA 396 NM_004309 CCGGGUUAACCGAGAGAUA 
D-016253-04 ARHGDIA 396 NM_004309 AGGAUGAGCACUCGGUCAA 
D-010893-05 ARHGDIB 397 NM_001175 GAUGAGAGUCUAAUUAAGU 
D-010893-02 ARHGDIB 397 NM_001175 ACAGCAAGCUCAAUUAUAA 
D-010893-03 ARHGDIB 397 NM_001175 GAAAGUGGAUAAAGCAACA 
D-010893-04 ARHGDIB 397 NM_001175 GGAAGGUUCUGAAUAUAGA 
D-006823-03 INCENP 3619 NM_020238 UCUGCAACAUGGAUAAUAA 
D-012566-01 ARHGDIG 398 NM_001176 GGAAGGUGUUGAUUACAGA 
D-012566-02 ARHGDIG 398 NM_001176 CCAGGAGUAUGAGUUUGUG 
D-012566-03 ARHGDIG 398 NM_001176 UCAGCGGCCUCAAGUGUCU 
D-012566-04 ARHGDIG 398 NM_001176 AUGAGGCUGUGCCCGAGUA 
D-009421-01 ARHGEF1 9138 NM_004706 AGAACGAGCUGGAGACAAA 
D-009421-02 ARHGEF1 9138 NM_004706 CAACGUCGCCUUUGAACUU 
D-009421-03 ARHGEF1 9138 NM_004706 GGUGUGCUCUCAUCACUGA 
D-009421-04 ARHGEF1 9138 NM_004706 UGACGUGGCGGGUGACUAA 
D-013460-01 ARHGEF10 9639 NM_014629 GAACCUUACCUAAAUAAUG 
D-013460-02 ARHGEF10 9639 NM_014629 GAAUACGGAUGGAGUUCGA 
D-006823-04 INCENP 3619 NM_020238 GCAAAGAGCCAGAGCUGAU 
D-013460-03 ARHGEF10 9639 NM_014629 GACGAUGGGAAUCACAUUA 
D-013460-04 ARHGEF10 9639 NM_014629 GACCUAACCCGUUUAAAGG 
D-010360-01 ARHGEF11 9826 NM_014784 GAACCUGCCUGAACUCAUA 
D-010360-02 ARHGEF11 9826 NM_014784 GGAAAGACAUCUGGAAUAU 
D-010360-03 ARHGEF11 9826 NM_014784 GCAAGUGGCUGCACAGUUC 
D-010360-04 ARHGEF11 9826 NM_014784 GAAGAUCCCUGAGAUGCUA 
D-008480-01 ARHGEF12 23365 NM_015313 AGACAGAGAUUUGGGAUUA 
D-008480-02 ARHGEF12 23365 NM_015313 GGAGGAAUGUGAAGUAGAA 
D-008480-03 ARHGEF12 23365 NM_015313 GAGAAGACCUGAGCUCAUU 
D-008480-04 ARHGEF12 23365 NM_015313 GACAGGAAGUGAUUAAUGA 
D-003317-05 KIF11 3832 NM_004523 GCAGAAAUCUAAGGAUAUA  
D-009731-01 ARHGEF15 22899 NM_173728 UGAUGAAGCUCCUCAGAAU 
D-009731-02 ARHGEF15 22899 NM_173728 GCAUGAAGCAGACUGAAGA 
D-009731-03 ARHGEF15 22899 NM_173728 GGUUACAGGUUCUGGACUA 
D-009731-04 ARHGEF15 22899 NM_173728 GAACGGUGCUCCAGAUGCU 
D-010234-01 ARHGEF16 27237 NM_014448 GCGGAGAGCUGUUCUUAGU 
D-010234-02 ARHGEF16 27237 NM_014448 GAUACGCUCUGCCUCAAGA 
D-010234-03 ARHGEF16 27237 NM_014448 CCAACGAGGUCUACCAACA 
D-010234-04 ARHGEF16 27237 NM_014448 GUUCAACGAUGUCCUGGUU 
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D-009751-01 ARHGEF17 9828 NM_014786 GCACCACUCUGAAGCGAAA 
D-009751-02 ARHGEF17 9828 NM_014786 GAGCAAAGCAUGCGUGAGA 
D-003317-06 KIF11 3832 NM_004523 CAACAAGGAUGAAGUCUAU 
D-009751-04 ARHGEF17 9828 NM_014786 GCUACGAGCUUCUGGUGAA 
D-009751-05 ARHGEF17 9828 NM_014786 AGUGAUGGGUUAAAUCUAA 
D-009654-01 ARHGEF18 23370 NM_015318 GCACAGAGCCUCCUAGAGA 
D-009654-02 ARHGEF18 23370 NM_015318 UCAGGGCGCUUGAAAGAUA 
D-009654-03 ARHGEF18 23370 NM_015318 CAAGAGCGGUUGAGCAUGA 
D-009654-04 ARHGEF18 23370 NM_015318 GCACUGAGGACUAUGAAGA 
D-008370-05 ARHGEF19 128272 NM_153213 GGAGUGCAAUGCUAGUGUA 
D-008370-06 ARHGEF19 128272 NM_153213 AAUGGAGGCUCGAAGUGUA 
D-008370-01 ARHGEF19 128272 NM_153213 GAGUCUACCUGCCCUAUGU 
D-008370-03 ARHGEF19 128272 NM_153213 GGACAAGCAGUGGCUGUUU 
D-003317-07 KIF11 3832 NM_004523 CAGCAGAAAUCUAAGGAUA 
D-009883-01 ARHGEF2 9181 NM_004723 GGACAAGCCUUCAGUGGUA 
D-009883-02 ARHGEF2 9181 NM_004723 CAACAUUGCUGGACAUUUC 
D-009883-03 ARHGEF2 9181 NM_004723 GAAUUAAGAUGGAGUUGCA 
D-009883-05 ARHGEF2 9181 NM_004723 GUGCGGAGCAGAUGUGUAA 
D-013243-01 ARHGEF3 50650 NM_019555 CAAACUAGAUCUCUGGAAU 
D-013243-02 ARHGEF3 50650 NM_019555 CGAGGGAUCGUUCCUAAAU 
D-013243-03 ARHGEF3 50650 NM_019555 GUGAAGGCCACGCCAUUAA 
D-013243-04 ARHGEF3 50650 NM_019555 UGGCUUAACUGUAUUCGUC 
D-008235-01 ARHGEF4 50649 NM_015320 GCACAAAGAUGGAGUCAAG 
D-008235-02 ARHGEF4 50649 NM_015320 GAAAGGAGGCUGCACAUAG 
D-003317-08 KIF11 3832 NM_004523  
CUAGAUGGCUUUCUCAGUA 
D-008235-03 ARHGEF4 50649 NM_015320 UCACCAAGCUCAGCAAGUA 
D-008235-04 ARHGEF4 50649 NM_015320 GCUCAGAACUCAUCUACUC 
D-005093-01 ARHGEF5 7984 NM_005435 GCACGGAGACUCAAAGUGA 
D-005093-02 ARHGEF5 7984 NM_005435 GGACAGAGGAGCUAAUCUA 
D-005093-03 ARHGEF5 7984 NM_005435 GCCAGAAGAUUGAGUUUGA 
D-005093-04 ARHGEF5 7984 NM_005435 CAAUGGCUCUUCUCUCGUU 
D-010231-04 ARHGEF6 9459 NM_004840 GAACGGUGGUGACUAGAUU 
D-010231-01 ARHGEF6 9459 NM_004840 GAGGAUGUCUUAUAUCUUA 
D-010231-02 ARHGEF6 9459 NM_004840 GGAAGAAUGUUCAAAGUUU 
D-010231-03 ARHGEF6 9459 NM_004840 GGACGUUCCUCUUCUCUUA 
          
D-006823-01 INCENP 3619 NM_020238 CCACGAUGCUGACUAAGAA 
D-001206-13 siCONTROL Non-Targeting siRNA Pool 
D-009616-01 ARHGEF7 8874 NM_003899 GGAAGAAGAUGCUCAGAUU 
D-009616-02 ARHGEF7 8874 NM_003899 GAAGAGCCCUCCCAAAGGA 
D-009616-03 ARHGEF7 8874 NM_003899 UCAAAGAGCUCGAGAGACA 
D-009616-04 ARHGEF7 8874 NM_003899 GGAGGGCGAUGACAUUAAA 
D-020314-01 ARHGEF9 23229 XM_377014 UGGCUGAGCUCCUAAAGUA 
D-020314-02 ARHGEF9 23229 XM_377014 GAUCUGCAAGUAUCCCUUA 
D-020314-03 ARHGEF9 23229 XM_377014 CAAGCGACGUUUAGAGAAU 
D-020314-04 ARHGEF9 23229 XM_377014 GAGAUUCCAUCGUUAGUGC 
D-003875-02 BCR 613 NM_004327 GUAAAGCUCUCGGUCAAGU 
D-003875-03 BCR 613 NM_004327 GCAUUCCGCUGACCAUCAA 
D-006823-02 INCENP 3619 NM_020238 CAAGAAGACUGCCGAAGAG 
D-001500-01 siTOX Transfection Control 
D-003875-06 BCR 613 NM_004327 CAGGAGCGCUUCCGCAUGA 
D-003875-13 BCR 613 NM_004327 CAGAAGAAGUGUUUCAGAA 
D-015006-01 C9ORF100 84904 NM_032818 CAACAGCCCUGACCAUCAA 
D-015006-02 C9ORF100 84904 NM_032818 GGAGCUCUAUAACCAAUUU 
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D-015006-03 C9ORF100 84904 NM_032818 CGUCGUAGCUUUGGCUGAA 
D-015006-04 C9ORF100 84904 NM_032818 AAAUAAAGGUUUCCGGAGG 
D-005057-01 CDC42 998 NM_001791 GGAGAACCAUAUACUCUUG 
D-005057-02 CDC42 998 NM_001791 GAUUACGACCGCUGAGUUA 
D-005057-03 CDC42 998 NM_001791 GAUGACCCCUCUACUAUUG 
D-005057-04 CDC42 998 NM_001791 CGGAAUAUGUACCGACUGU 
D-006823-03 INCENP 3619 NM_020238 UCUGCAACAUGGAUAAUAA 
D-003814-09 CDC42BPA 8476 NM_003607 CCAUAUAACUUGUGUAAAC 
D-003814-01 CDC42BPA 8476 NM_003607 GGAAACAAAUGGUUAGAAA 
D-003814-04 CDC42BPA 8476 NM_003607 GCGCAAGACUCACCAGUUU 
D-003814-08 CDC42BPA 8476 NM_003607 GAAGAUAGAUUGCCUGAAG 
D-004075-05 CDC42BPB 9578 NM_006035 GAAGUGGGUUGGGAUUCUA 
D-004075-02 CDC42BPB 9578 NM_006035 GAAGAAUACUGAACGAAUU 
D-004075-03 CDC42BPB 9578 NM_006035 GAGAAACACGGAAAUAUUA 
D-004075-04 CDC42BPB 9578 NM_006035 CGAGAAGACUUUGAAAUAA 
D-007691-05 HSMDPKIN 55561 XM_290516 GGAACCAUCCUUUCUUCGA 
D-007691-06 HSMDPKIN 55561 XM_290516 CCACGCAUCUUUAGGGUGA 
D-006823-04 INCENP 3619 NM_020238 GCAAAGAGCCAGAGCUGAU 
D-007691-02 HSMDPKIN 55561 XM_290516 CAAGGACCCUGGCAUCUCA 
D-007691-03 HSMDPKIN 55561 XM_290516 UAUCAAAGGUGAAAGAACU 
D-017551-01 CDC42EP1 11135 NM_007061 GAAAGAGGCGGCUGACUGC 
D-017551-02 CDC42EP1 11135 NM_007061 AUGAUGAGGUCAAGGUGUG 
D-017551-03 CDC42EP1 11135 NM_007061 GGAAAAGCCGCAUGACCGA 
D-017551-04 CDC42EP1 11135 NM_007061 GCCCAGUGGCUGAGGUGAA 
D-012215-03 CDC42EP2 10435 NM_006779 CGCCACACCAUUCAUAUUG 
D-012215-04 CDC42EP2 10435 NM_006779 CCAUCUAUCUGAAGCGUGG 
D-012215-01 CDC42EP2 10435 NM_006779 GCAGUGACAUGUUUGGCGA 
D-012215-02 CDC42EP2 10435 NM_006779 GCAUGCAGAUCCCCACAUA 
D-003317-05 KIF11 3832 NM_004523 GCAGAAAUCUAAGGAUAUA  
D-017358-01 CDC42EP3 10602 NM_006449 GAUGAGGUGCUGAAUGUAA 
D-017358-02 CDC42EP3 10602 NM_006449 CCAAUAACAAGAAAGGAAA 
D-017358-03 CDC42EP3 10602 NM_006449 GCUCUCAUGUUGCCCUUAU 
D-017358-04 CDC42EP3 10602 NM_006449 CGAUGUCUUUGGAGAUAUU 
D-013494-01 CDC42EP4 23580 NM_012121 CCAGUAAGCUGCCCAAGAG 
D-013494-02 CDC42EP4 23580 NM_012121 CAAGACAGCCAGACAAGGA 
D-013494-03 CDC42EP4 23580 NM_012121 GACACCUCCUUCCUCAAUA 
D-013494-04 CDC42EP4 23580 NM_012121 CCCAUGCUCUGGAGGAUGA 
D-017378-01 CDC42EP5 148170 NM_145057 CAAGGUGUGUGCCCGGAAA 
D-017378-02 CDC42EP5 148170 NM_145057 CCACUUCUGUAUACAUAAA 
D-003317-06 KIF11 3832 NM_004523 CAACAAGGAUGAAGUCUAU 
D-017378-03 CDC42EP5 148170 NM_145057 CGUCAUCGGCCUCUAGGUU 
D-017378-04 CDC42EP5 148170 NM_145057 CCAAGAAGCGGCCUGAUCG 
D-013804-01 SPEC1 56882 NM_020239 CAGAUGAGAUCCAAGGGAA 
D-013804-02 SPEC1 56882 NM_020239 GAAGACGGAUUGACCGGAC 
D-013804-03 SPEC1 56882 NM_020239 GGACUUGCCAUGACAGGUG 
D-013804-04 SPEC1 56882 NM_020239 CGAGAUAGGCCAUGGAGCA 
D-020826-01 SPEC2 56990 NM_020240 UCAGUUAGCUCCAUUCAGA 
D-020826-02 SPEC2 56990 NM_020240 CAGAACAGCCUCAGCCUAA 
D-020826-03 SPEC2 56990 NM_020240 UGUUUCAACUGCUGUAUUG 
D-020826-04 SPEC2 56990 NM_020240 GUGCAUACAGCUCAUGUUG 
D-003317-07 KIF11 3832 NM_004523 CAGCAGAAAUCUAAGGAUA 
D-009302-01 CENTD1 116984 NM_015230 GCAAGAAGCUUUAAAUUGA 
D-009302-02 CENTD1 116984 NM_015230 GAACCCGACUGUAGUAUUA 
D-009302-03 CENTD1 116984 NM_015230 GAUGGAAGCAGAAGAAUUA 
D-009302-04 CENTD1 116984 NM_015230 CAAAGAGGACUUCUAUUUA 
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D-009136-01 CENTD2 116985 NM_015242 GAGAAGGAGUGGCCUAUUA 
D-009136-02 CENTD2 116985 NM_015242 GCAGGGAUCUUACAUCUAU 
D-009136-03 CENTD2 116985 NM_015242 GGAGAUCACUGCCAUUGUG 
D-009136-04 CENTD2 116985 NM_015242 ACAAGAAUCUAGAGGAGUA 
D-007052-01 CENTD3 64411 NM_022481 GAACUUGGCUCUGCUGUUU 
D-007052-02 CENTD3 64411 NM_022481 GGAGGAGUCUGAUGUACUU 
D-003317-08 KIF11 3832 NM_004523  
CUAGAUGGCUUUCUCAGUA 
D-007052-03 CENTD3 64411 NM_022481 GGAGAAAUAUAAAGAUGUG 
D-007052-04 CENTD3 64411 NM_022481 CCAGACAGCUCCCAAAUCU 
D-010251-01 CHN1 1123 NM_001822 GAAUAUAGACCUCCUGUUU 
D-010251-02 CHN1 1123 NM_001822 UAUGAGAUCUCCAGAACUA 
D-010251-03 CHN1 1123 NM_001822 CAAUUCCACUCAUUACAUA 
D-010251-04 CHN1 1123 NM_001822 GACCUACACUUUGGCUUUA 
D-003791-01 CHN2 1124 NM_004067 UCAAGAAAGUGUACUGUUG 
D-003791-02 CHN2 1124 NM_004067 GAAGAGGUUUGAGUCGAUU 
D-003791-03 CHN2 1124 NM_004067 UGAUAACACUGUACAUAGA 
D-003791-04 CHN2 1124 NM_004067 CGAUAUAUCUGCCAAUGUC 
          
D-006823-01 INCENP 3619 NM_020238 CCACGAUGCUGACUAAGAA 
D-001206-13 siCONTROL Non-Targeting siRNA Pool 
D-004613-01 CIT 11113 NM_007174 GAUAUUAGAUGCCCUCUUU 
D-004613-02 CIT 11113 NM_007174 GGACCAGUCUUCAGUAUAA 
D-004613-03 CIT 11113 NM_007174 GGACAUCUAUGCUAUGAAA 
D-004613-04 CIT 11113 NM_007174 GGAGCAGUCUUCCAAAUUU 
D-011020-01 CYBA 1535 NM_000101 GAAGAAGGGCUCCACCAUG 
D-011020-02 CYBA 1535 NM_000101 UACCAGGAAUUACUAUGUU 
D-011020-03 CYBA 1535 NM_000101 GGACAGAAGCACAUGACCG 
D-011020-04 CYBA 1535 NM_000101 CCAUGUGGGCCAACGAGCA 
D-011021-01 CYBB 1536 NM_000397 GAAGACAACUGGACAGGAA 
D-011021-02 CYBB 1536 NM_000397 GGAACUGGGCUGUGAAUGA 
D-006823-02 INCENP 3619 NM_020238 CAAGAAGACUGCCGAAGAG 
D-001500-01 siTOX Transfection Control 
D-011021-03 CYBB 1536 NM_000397 GUGAAUGCCCGAGUCAAUA 
D-011021-04 CYBB 1536 NM_000397 GAAACUACCUAAGAUAGCG 
D-017817-01 DEF6 50619 NM_022047 GCAGAGGGCUGACGAGGAU 
D-017817-02 DEF6 50619 NM_022047 GGAGAAGAGUGGCAAAGUC 
D-017817-03 DEF6 50619 NM_022047 GAUAGCAACGGGAACAGUA 
D-017817-04 DEF6 50619 NM_022047 GGAGAUAAGCGUCCGGUCA 
D-013830-01 DEPDC1B 55789 NM_018369 GUACUGGGUUUGUUACAGA 
D-013830-02 DEPDC1B 55789 NM_018369 GGUACAAGCGUCACAGUAU 
D-013830-03 DEPDC1B 55789 NM_018369 GAUCAUAUGGCUCUCAGGA 
D-013830-04 DEPDC1B 55789 NM_018369 AGACAAUCGUCACUUAUAC 
D-006823-03 INCENP 3619 NM_020238 UCUGCAACAUGGAUAAUAA 
D-014602-01 DEPDC2 80243 NM_024870 GAAGCGAAUUUGUGUCAUG 
D-014602-02 DEPDC2 80243 NM_024870 CUGAUAGACUGGUUAAUUG 
D-014602-03 DEPDC2 80243 NM_024870 UAUGAAACAUCGACUUAUG 
D-014602-04 DEPDC2 80243 NM_024870 GAACGGCGGAAAGGUUUAA 
D-014602-01 DEPDC2 80243 NM_024870 GAAGCGAAUUUGUGUCAUG 
D-014602-02 DEPDC2 80243 NM_024870 CUGAUAGACUGGUUAAUUG 
D-014602-03 DEPDC2 80243 NM_024870 UAUGAAACAUCGACUUAUG 
D-014602-04 DEPDC2 80243 NM_024870 GAACGGCGGAAAGGUUUAA 
D-008713-01 DLC1 10395 NM_006094 UUAAGAACCUGGAGGACUA 
D-008713-02 DLC1 10395 NM_006094 GUACGAAAGAGGAGCGUUU 
D-006823-04 INCENP 3619 NM_020238 GCAAAGAGCCAGAGCUGAU 
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D-008713-03 DLC1 10395 NM_006094 UUAAAGAAGUCAAAGAGAA 
D-008713-04 DLC1 10395 NM_006094 GCAUGUACUUAGAGGGCUU 
D-026304-01 DNMBP 23268 NM_015221 GGGAUGAGCUUGAGGGAAC 
D-026304-02 DNMBP 23268 NM_015221 UAGCUGAGGUUAACGGGAA 
D-026304-03 DNMBP 23268 NM_015221 AAGAUAGCCUUAUGGAGAA 
D-026304-04 DNMBP 23268 NM_015221 UCCACAACCUAGCAAGUUA 
D-011253-01 DOCK1 1793 NM_001380 GUACCGAGGUUACACGUUA 
D-011253-02 DOCK1 1793 NM_001380 UAAAUGAGCAGCUGUACAA 
D-011253-03 DOCK1 1793 NM_001380 GAAAUGGUGGGCCCAAUAU 
D-011253-04 DOCK1 1793 NM_001380 GGCCCAAGCCUGACUAUUU 
D-003317-05 KIF11 3832 NM_004523 GCAGAAAUCUAAGGAUAUA  
D-023079-01 DOCK10 55619 XM_371595 CCAGAUAACUCCUACAUUA 
D-023079-02 DOCK10 55619 XM_371595 GCAGUAAGAUCAGUAUUUA 
D-023079-03 DOCK10 55619 XM_371595 GAUAGCAACUCAUUACUAA 
D-023079-04 DOCK10 55619 XM_371595 CAAUAUAGCUACGGAGGUU 
D-015696-01 DOCK11 139818 NM_144658 UAAAUGAGCGGCUAAUUAA 
D-015696-02 DOCK11 139818 NM_144658 GAUCAACACCGACAGUUUA 
D-015696-03 DOCK11 139818 NM_144658 CGACAGAGUUCUACAAGGA 
D-015696-04 DOCK11 139818 NM_144658 CGAAACAGAUCAGGAGUAA 
D-019915-01 DOCK2 1794 NM_004946 GACAUGAGACGGCUAAUUG 
D-019915-02 DOCK2 1794 NM_004946 GACCGGAAAUUUCAGCAUU 
D-003317-06 KIF11 3832 NM_004523 CAACAAGGAUGAAGUCUAU 
D-019915-03 DOCK2 1794 NM_004946 CAACGACACUUUGGGAAUG 
D-019915-04 DOCK2 1794 NM_004946 GAAUGAGUAUCGCUCCGUU 
D-012695-01 DOCK3 1795 NM_004947 GAAGAUAGGCUGCACUGUU 
D-012695-02 DOCK3 1795 NM_004947 CGAGAUCACUGGCGAGUAU 
D-012695-03 DOCK3 1795 NM_004947 UGACGCCCAUUCCAGAUUA 
D-012695-04 DOCK3 1795 NM_004947 GACCUGUGAUGGACACGUA 
D-017968-01 DOCK4 9732 NM_014705 CAAAGGGUCUGGAGCAUUA 
D-017968-02 DOCK4 9732 NM_014705 CCAAAGGACUGGACUGUUA 
D-017968-03 DOCK4 9732 NM_014705 UAAGAGAGCUGAUGCUUGA 
D-017968-04 DOCK4 9732 NM_014705 GGAAAUAGAUGUGAUAGUG 
D-003317-07 KIF11 3832 NM_004523 CAGCAGAAAUCUAAGGAUA 
D-018931-01 DOCK5 80005 NM_024940 AGAACUAUCUAAUUCGUUG 
D-018931-02 DOCK5 80005 NM_024940 GUAACGGGAUGCCCAAGGA 
D-018931-03 DOCK5 80005 NM_024940 GAGUGGCAGUGAUGGAUAU 
D-018931-04 DOCK5 80005 NM_024940 UAUCAUACAUGGGAAGGUG 
D-031950-01 DOCK6 57572 NM_020812 UCACGUAUGUGGAACCGUA 
D-031950-02 DOCK6 57572 NM_020812 CGACAGAACUUCGAGAUCG 
D-031950-03 DOCK6 57572 NM_020812 CGGUGGAGAUGUAUAUUGA 
D-031950-04 DOCK6 57572 NM_020812 CGACGCAGAACUUCAGUGA 
D-031725-01 DOCK7 85440 NM_033407 GAUCGAAGUUGUAAUCGUA 
D-031725-02 DOCK7 85440 NM_033407 GAGGACAGCUCGGUACGUA 
D-003317-08 KIF11 3832 NM_004523  
CUAGAUGGCUUUCUCAGUA 
D-031725-03 DOCK7 85440 NM_033407 GGCAUGAAAUGGGUAGAUA 
D-031725-04 DOCK7 85440 NM_033407 UAACCUAGGUCAAGCAUCU 
D-026106-01 DOCK8 81704 NM_203447 GCAGAGCCCUACACGGUUA 
D-026106-02 DOCK8 81704 NM_203447 GAUCAGAGCCUCAUUAGGA 
D-026106-03 DOCK8 81704 NM_203447 GGAAAUACGUCCAGUACCA 
D-026106-04 DOCK8 81704 NM_203447 CCGCUAAGCUCACAGUAAA 
D-014040-01 DOCK9 23348 NM_015296 GUAAACGAACGUCUGAUUA 
D-014040-02 DOCK9 23348 NM_015296 ACUCAGAAGUUUCGAGAUA 
D-014040-03 DOCK9 23348 NM_015296 CAGCUUGACUACUCAUUAA 
D-014040-04 DOCK9 23348 NM_015296 CGGCAUUGCUUCUCCAUAU 
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D-006823-01 INCENP 3619 NM_020238 CCACGAUGCUGACUAAGAA 
D-001206-13 siCONTROL Non-Targeting siRNA Pool 
D-004068-05 DVL1 1855 NM_004421 GCGAGUUCUUCGUGGACAU 
D-004068-06 DVL1 1855 NM_004421 CGACCAAGGCCUAUACAGU 
D-004068-07 DVL1 1855 NM_004421 CGGCACACGGUCAACAAGA 
D-004068-08 DVL1 1855 NM_004421 GGGAGUCAGCAGAGUGAAG 
D-004069-05 DVL2 1856 NM_004422 CGCUAAACAUGGAGAAGUA 
D-004069-02 DVL2 1856 NM_004422 GACAGAAACCGAGUCAGUA 
D-004069-03 DVL2 1856 NM_004422 UGUGAGAGCUACCUAGUCA 
D-004069-04 DVL2 1856 NM_004422 GAAACCGAGUCAGUAGUGU 
D-006450-01 ECT2 1894 NM_018098 GAUAAAGGAUGAUCUUGAA 
D-006450-02 ECT2 1894 NM_018098 GCACUCACCUUGUAGUUGA 
D-006823-02 INCENP 3619 NM_020238 CAAGAAGACUGCCGAAGAG 
D-001500-01 siTOX Transfection Control 
D-006450-03 ECT2 1894 NM_018098 GAAGGGCUCUUAUGACAUC 
D-006450-04 ECT2 1894 NM_018098 CAGAGGAGAUUAAGACUAU 
D-012851-01 ELMO1 9844 NM_014800 GGAUGAACCAGGAAGAUUU 
D-012851-02 ELMO1 9844 NM_014800 GAAAGGACUGCCCUCAUAU 
D-012851-03 ELMO1 9844 NM_014800 UGAAUGCGCUACUCGGGAA 
D-012851-04 ELMO1 9844 NM_014800 GCAUUACGGAGACUUAGAA 
D-008519-05 FARP1 10160 NM_005766 CAGGAAAACUCGUGUCCAU 
D-008519-01 FARP1 10160 NM_005766 AAGAAGAACUCACAAGGUA 
D-008519-02 FARP1 10160 NM_005766 GCACGUUGUUGUUAAGUUU 
D-008519-03 FARP1 10160 NM_005766 CAGCGCAGCUCUCUUGAUU 
D-006823-03 INCENP 3619 NM_020238 UCUGCAACAUGGAUAAUAA 
D-009237-05 FARP2 9855 NM_014808 GGAUUUGGCUUGAACCUAU 
D-009237-01 FARP2 9855 NM_014808 GAACAUACCUCAAGGAUUU 
D-009237-02 FARP2 9855 NM_014808 CGAAAUUGCUCGAAAGUUG 
D-009237-03 FARP2 9855 NM_014808 GCACUCGGCUGGAGAAAGA 
D-009612-05 FGD1 2245 NM_004463 UCUCAAGGACUAUCUGUUA 
D-009612-01 FGD1 2245 NM_004463 CCAAAGAGCUCAUAAAAGA 
D-009612-02 FGD1 2245 NM_004463 CAAGAUGUAUGGUGAGUAU 
D-009612-03 FGD1 2245 NM_004463 CCAAUGAGCUCCUGCAAAC 
D-008431-01 FGD2 221472 NM_173558 GCUGAUGGAUGCUGAGUUU 
D-008431-02 FGD2 221472 NM_173558 CGACAAGUCUCCACUCUUC 
D-006823-04 INCENP 3619 NM_020238 GCAAAGAGCCAGAGCUGAU 
D-008431-03 FGD2 221472 NM_173558 GGGCCGAACUGAAAUACGA 
D-008431-04 FGD2 221472 NM_173558 AAGCAGCCAUUGACCAAAU 
D-010371-01 FGD3 89846 NM_033086 GCACAUACAUUCAUCAUAA 
D-010371-02 FGD3 89846 NM_033086 GGACGGCUCUCCAGACAUA 
D-010371-03 FGD3 89846 NM_033086 CCAGAAGGCUGACAAGGAU 
D-010371-04 FGD3 89846 NM_033086 GCAUGAUCCUUUACUGUGU 
D-007123-01 FGD4 121512 NM_139241 GAGAAUAUGUGAAAGGAUU 
D-007123-02 FGD4 121512 NM_139241 GGAGAAAGCUGCCACUCUU 
D-007123-03 FGD4 121512 NM_139241 GGUAUGAGAUGCUCCUUAA 
D-007123-04 FGD4 121512 NM_139241 GCAGCAAGCCAUUCUAAUA 
D-003317-05 KIF11 3832 NM_004523 GCAGAAAUCUAAGGAUAUA  
D-028077-02 FGD5 152273 XM_371619 GAAAGGCUGUCAAAUUGGG 
D-028077-03 FGD5 152273 XM_371619 GCUCCUCACAGACUAUUUA 
D-028077-04 FGD5 152273 XM_371619 AAAGUGCCCUACGCUCUAA 
D-028077-01 FGD5 152273 XM_371619 GAACGUGUCUUCCUCUAGG 
D-026895-01 FGD6 55785 XM_370702 GCUCAAAGAUGCCUUAAUA 
D-026895-02 FGD6 55785 XM_370702 GAAGGGACCGGUUUUAUAA 
D-026895-03 FGD6 55785 XM_370702 GAAUUCCGAGUCUAAAGUA 
 259 
D-026895-04 FGD6 55785 XM_370702 GCUCGUCUGUUACGCCAAA 
D-011281-01 GAS8 2622 NM_001481 GAACUCGACUUGCGGAGAA 
D-011281-02 GAS8 2622 NM_001481 UCAAGAACCUCGUGCUAGA 
D-003317-06 KIF11 3832 NM_004523 CAACAAGGAUGAAGUCUAU 
D-011281-03 GAS8 2622 NM_001481 GGGACGAGCUCUAUCGGAA 
D-011281-04 GAS8 2622 NM_001481 ACAGAAAGAGCACCGCAUA 
D-021160-01 GMIP 51291 NM_016573 GAACUGGACUUGCGGCUCA 
D-021160-02 GMIP 51291 NM_016573 GAACGUGACCCUUGAGAUG 
D-021160-03 GMIP 51291 NM_016573 GAAGUGCACGGCUGAGAUA 
D-021160-04 GMIP 51291 NM_016573 CGAGUGUCCUCAAGCGAUU 
D-006729-01 GNE 10020 NM_005476 GGAAAUACAUAUCGAAUGA 
D-006729-02 GNE 10020 NM_005476 AAACUGAACUGCAGAAUUU 
D-006729-03 GNE 10020 NM_005476 CAAGAUGACUUUGACAUUA 
D-006729-04 GNE 10020 NM_005476 UAACAAAACUGGCUCAUUA 
D-003317-07 KIF11 3832 NM_004523 CAGCAGAAAUCUAAGGAUA 
D-004158-05 GRLF1 2909 NM_024342 UCAGCGAGAUCCAAUGUAA 
D-004158-02 GRLF1 2909 NM_024342 GGAGGAAUCUGUAUACAUG 
D-004158-03 GRLF1 2909 NM_024342 GAACAGCGAUUUAAAGCAU 
D-004158-04 GRLF1 2909 NM_024342 GAUGGGCUGUCUUUCAUUA 
D-021811-05 INPP5B 3633 NM_005540 GAAGAGGAUUACACCUAUA 
D-021811-06 INPP5B 3633 NM_005540 GCAUCUGCGUUGUGAAUUC 
D-021811-07 INPP5B 3633 NM_005540 ACUUGGAGCUCUUCGUAAA 
D-021811-08 INPP5B 3633 NM_005540 AACAGGAGCAUGCAGCUUA 
D-008365-01 ITSN1 6453 NM_003024 GGACAUAGUUGUACUGAAA 
D-008365-02 ITSN1 6453 NM_003024 GGAAGGAGCUGAUUAUGUG 
D-003317-08 KIF11 3832 NM_004523  
CUAGAUGGCUUUCUCAGUA 
D-008365-03 ITSN1 6453 NM_003024 GAUAUCAGAUGUCGAUUGA 
D-008365-04 ITSN1 6453 NM_003024 GGCCAUAACUGUAGAGGAA 
D-009841-02 ITSN2 50618 NM_006277 GACAGGAGCUUCUCAAUCA 
D-009841-03 ITSN2 50618 NM_006277 CCAAACAUGUGGGCUAUUA 
D-009841-01 ITSN2 50618 NM_006277 GAUCAAACGUGACAAGUUG 
D-009841-04 ITSN2 50618 NM_006277 AAACUCAGCUGGCUACUAU 
D-010019-02 KALRN 8997 NM_003947 GCAAAGCACUACUUGAUGU 
D-010019-03 KALRN 8997 NM_003947 GACAGGAUCUGCACCAGUA 
D-010019-01 KALRN 8997 NM_003947 GAAGAGGCAUGAUGACUUU 
D-010019-04 KALRN 8997 NM_003947 GGAAACUCGUGACGUAUUU 
          
D-006823-01 INCENP 3619 NM_020238 CCACGAUGCUGACUAAGAA 
D-001206-13 siCONTROL Non-Targeting siRNA Pool 
D-031982-01 LZTFL1 54585 NM_020347 GGAAAAGACUGGCACAAUA 
D-031982-02 LZTFL1 54585 NM_020347 UAUAAAGGCCCAAGACUUA 
D-031982-03 LZTFL1 54585 NM_020347 AAACAGCAGCUUAUCGAAA 
D-031982-04 LZTFL1 54585 NM_020347 GAGAAGUGGUAUCUUAAGC 
D-003577-02 MAP3K11 4296 NM_002419 GCAUGCCACUCGACUUCAA 
D-003577-03 MAP3K11 4296 NM_002419 CUGGAGGACUCAAGCAAUG 
D-003577-05 MAP3K11 4296 NM_002419 GAAGCCAGAAGCCAAAUAA 
D-003577-07 MAP3K11 4296 NM_002419 ACACUACACUGCACAGGAA 
D-003585-02 MAP3K9 4293 NM_033141 GAGCGGAACUGAACACACA 
D-003585-05 MAP3K9 4293 NM_033141 CAAACGAGAUCCUAACCAA 
D-006823-02 INCENP 3619 NM_020238 CAAGAAGACUGCCGAAGAG 
D-001500-01 siTOX Transfection Control 
D-003585-06 MAP3K9 4293 NM_033141 GCACAGAGACGCCCAGCAA 
D-003585-07 MAP3K9 4293 NM_033141 CCUAAGCCCUUUCAUGCUA 
D-003904-05 MCF2 4168 NM_005369 GGUGAUAACCGCAAGUUUG 
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D-003904-01 MCF2 4168 NM_005369 GGUAUCAUCUGUUGAAGAA 
D-003904-02 MCF2 4168 NM_005369 GGAAGAAGUUUAUAUUGUC 
D-003904-04 MCF2 4168 NM_005369 GCAACAGGAUCAAUUAACA 
D-010098-01 MCF2L 23263 NM_024979 AAACAGAGCUGCCCAAUGA 
D-010098-02 MCF2L 23263 NM_024979 CGACAUCGCUUUCAAAUUC 
D-010098-03 MCF2L 23263 NM_024979 UCAAGGAAAUGCUGAAAUA 
D-010098-04 MCF2L 23263 NM_024979 CAACAGGCCUUCACAACAA 
D-006823-03 INCENP 3619 NM_020238 UCUGCAACAUGGAUAAUAA 
D-009313-01 MCF2L2 23101 NM_015078 GCACAUUGCUUUCUCAAGA 
D-009313-02 MCF2L2 23101 NM_015078 GGAAUAGUGUUCUGUAAGA 
D-009313-03 MCF2L2 23101 NM_015078 GGACCAAGCCAGAGACUUA 
D-009313-04 MCF2L2 23101 NM_015078 GAAUGUAACUACCAUGGAA 
D-004063-01 KIAA1804 84451 NM_032435 UGAGAUGGCUCCUACGAAU 
D-004063-02 KIAA1804 84451 NM_032435 GGACAUCGAAUCAGUUUAC 
D-004063-03 KIAA1804 84451 NM_032435 GAGAUGGCUCCUACGAAUA 
D-004063-04 KIAA1804 84451 NM_032435 CGAAUAGUCUGAGUAGAUC 
D-005352-06 MYLK2 85366 NM_033118 GGAGAAAGCCAAACGCUGU 
D-005352-01 MYLK2 85366 NM_033118 GCUCGGAGGUGGCAAGUUU 
D-006823-04 INCENP 3619 NM_020238 GCAAAGAGCCAGAGCUGAU 
D-005352-02 MYLK2 85366 NM_033118 GACCAAAUCUCCGAUAAGA 
D-005352-05 MYLK2 85366 NM_033118 AGACAGACAUGUGGAGUAU 
D-006539-01 MYO9A 4649 NM_006901 GAAAGAAGCUUAGCCCUUA 
D-006539-02 MYO9A 4649 NM_006901 GAUAAUACCUGCUGCAUAA 
D-006539-03 MYO9A 4649 NM_006901 GAACAUACAUUACGGAUAU 
D-006539-04 MYO9A 4649 NM_006901 GAACAAAGGCUAAGAGAAA 
D-003915-05 NET1 10276 NM_005863 GGCAAUAUAUGAAAUGUCC 
D-003915-01 NET1 10276 NM_005863 GAAGUCGCCUAGUCAAAUA 
D-003915-02 NET1 10276 NM_005863 GGAGGAUGCUAUAUUGAUA 
D-003915-03 NET1 10276 NM_005863 UCACGUCCUUGGCAAAUUU 
D-003317-05 KIF11 3832 NM_004523 GCAGAAAUCUAAGGAUAUA  
D-003916-06 NF1 4763 NM_000267 CACCGAGUCUUACAUUUAA 
D-003916-01 NF1 4763 NM_000267 GGAAUAAGAUGGUAGAAUA 
D-003916-02 NF1 4763 NM_000267 GAUAGAAGCUACAGUAAUA 
D-003916-04 NF1 4763 NM_000267 CAACAAAGCUAAUCCUUAA 
D-009354-01 NGEF 25791 NM_019850 GGAGAAACCUCAUUGAACA 
D-009354-02 NGEF 25791 NM_019850 GGACCAAGUUUGUUUCGUU 
D-009354-03 NGEF 25791 NM_019850 GAAAUUCCAUCUUCAAUCG 
D-009354-04 NGEF 25791 NM_019850 UAAAUCGACUCUCCAAGAA 
D-010193-01 NOX1 27035 NM_007052 GCACACCUGUUUAACUUUG 
D-010193-02 NOX1 27035 NM_007052 GCUCUCUGCUUGAAUUUUA 
D-003317-06 KIF11 3832 NM_004523 CAACAAGGAUGAAGUCUAU 
D-010193-03 NOX1 27035 NM_007052 GUGGAUGCCUUCCUGAAAU 
D-010193-04 NOX1 27035 NM_007052 UGAGAAGGCCGACAAAUAC 
D-026087-01 NOXA1 10811 NM_006647 GAUGCCAGGUCCCUAAUCA 
D-026087-02 NOXA1 10811 NM_006647 GGGAGGUGCUACACAAUGU 
D-026087-03 NOXA1 10811 NM_006647 ACUUGGAGCCCGUGGAUUU 
D-026087-04 NOXA1 10811 NM_006647 GGUGGAGCAAGUUGGCAAA 
D-027177-05 OBSCN 84033 NM_052843 GCAGACAGCGACACCUAUA 
D-027177-06 OBSCN 84033 NM_052843 AGACAUACCGCGAAGAUGA 
D-027177-02 OBSCN 84033 NM_052843 GGAAGGACAUACACUCUCA 
D-027177-03 OBSCN 84033 NM_052843 CAGGAGAGAUCCAAUUUGU 
D-003317-07 KIF11 3832 NM_004523 CAGCAGAAAUCUAAGGAUA 
D-010026-01 OCRL 4952 NM_000276 GAAAUUACCUCCCAAGUUG 
D-010026-04 OCRL 4952 NM_000276 UGAAAUCCCUGAUGAGGAA 
D-010026-05 OCRL 4952 NM_000276 UGACAUAGCUUCUAACAGU 
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D-010026-06 OCRL 4952 NM_000276 GAAAGGAUCAGUGUCGAUA 
D-009444-01 OPHN1 4983 NM_002547 GAAAGAAUCUCAGUUACAA 
D-009444-02 OPHN1 4983 NM_002547 GCGAGAGGCUCAAGUGUUA 
D-009444-03 OPHN1 4983 NM_002547 GAACAUAGUGGUGGAAAUA 
D-009444-04 OPHN1 4983 NM_002547 GCUAGUGAUUUGCUGAUUA 
D-003521-01 PAK1 5058 NM_002576 GAAGAAAUAUACACGGUUU 
D-003521-03 PAK1 5058 NM_002576 CAUCAAAUAUCACUAAGUC 
D-003317-08 KIF11 3832 NM_004523  
CUAGAUGGCUUUCUCAGUA 
D-003521-05 PAK1 5058 NM_002576 CAACAAAGAACAAUCACUA 
D-003521-07 PAK1 5058 NM_002576 AGAAAUACCAGCACUAUGA 
D-003597-05 PAK2 5062 NM_002577 AGAAGGAACUGAUCAUUAA 
D-003597-06 PAK2 5062 NM_002577 CUACAGACCUCCAAUAUCA 
D-003597-07 PAK2 5062 NM_002577 GAAACUGGCCAAACCGUUA 
D-003597-09 PAK2 5062 NM_002577 ACAGUGGGCUCGAUUACUA 
D-003614-01 PAK3 5063 NM_002578 GACAAGAGGUGGCCAUAAA 
D-003614-02 PAK3 5063 NM_002578 GGAUGGCUCUGUUAAAUUG 
D-003614-03 PAK3 5063 NM_002578 GAUUAUCGCUGCAAAGGAA 
D-003614-04 PAK3 5063 NM_002578 UUAAAUCGCUGUCUUGAGA 
          
D-006823-01 INCENP 3619 NM_020238 CCACGAUGCUGACUAAGAA 
D-001206-13 siCONTROL Non-Targeting siRNA Pool 
D-003615-07 PAK4 10298 NM_005884 CCAUGAAGAUGAUUCGGGA 
D-003615-03 PAK4 10298 NM_005884 GGAUAAUGGUGAUUGAGAU 
D-003615-05 PAK4 10298 NM_005884 GGGUGAAGCUGUCAGACUU 
D-003615-06 PAK4 10298 NM_005884 AGAAUGUGGUGGAGAUGUA 
D-004338-05 PAK6 56924 NM_020168 CCAAUGGGCUGGCUGCAAA 
D-004338-06 PAK6 56924 NM_020168 GCACCAAUAGGCAUGGAAU 
D-004338-02 PAK6 56924 NM_020168 UCAACGACAUCCAGAAGUU 
D-004338-03 PAK6 56924 NM_020168 GGACAGCUACGUGAAGAUU 
D-003973-09 PAK7 57144 NM_020341 CAAACUCCGUUAUGAUAUA 
D-003973-10 PAK7 57144 NM_020341 GAGCACGGCUUUAAUAAGU 
D-006823-02 INCENP 3619 NM_020238 CAAGAAGACUGCCGAAGAG 
D-001500-01 siTOX Transfection Control 
D-003973-11 PAK7 57144 NM_020341 CAGAAGGACUCAGUACAAA 
D-003973-12 PAK7 57144 NM_020341 AGGGUAACAUGUAGGAUUU 
D-013859-01 PARD6A 50855 NM_016948 GCACAAGCAUGGUUCAGAC 
D-013859-02 PARD6A 50855 NM_016948 CUACUUGGCUAUACGGAUG 
D-013859-03 PARD6A 50855 NM_016948 GCAAAUUUGACGCCGAGUU 
D-013859-04 PARD6A 50855 NM_016948 GAGUCGCAUUCGAGGAGAU 
D-010681-01 PARD6B 84612 XM_030559 GGAAUAAUGUUGUGAGGAA 
D-010681-02 PARD6B 84612 XM_030559 AGACAUCCAUGGAGACUUA 
D-010681-03 PARD6B 84612 XM_030559 CGAAGAAGAUGACAUUAUC 
D-010681-04 PARD6B 84612 XM_030559 GGGUACGUCUUUACAAAUA 
D-006823-03 INCENP 3619 NM_020238 UCUGCAACAUGGAUAAUAA 
D-014909-01 PARD6G 84552 NM_032510 CACCAUAUCUCCAACAGUG 
D-014909-02 PARD6G 84552 NM_032510 GCAAGGCGGUUUCUAGUGC 
D-014909-03 PARD6G 84552 NM_032510 UCAUAAGCCUGGGAAGUUU 
D-014909-04 PARD6G 84552 NM_032510 GAACCGAAGUUUUCACAAG 
D-003020-10 PIK3R1 5295 NM_181504 GAAGUAAAGCAUUGUGUCA 
D-003020-11 PIK3R1 5295 NM_181504 GACGAGAGACCAAUACUUG 
D-003020-12 PIK3R1 5295 NM_181504 GUUGAAGUCUCGAAUCAGU 
D-003020-13 PIK3R1 5295 NM_181504 AGACCUGGAUUUAGAAUAU 
D-003021-05 PIK3R2 5296 NM_005027 GGAAAGGCGGGAACAAUAA 
D-003021-06 PIK3R2 5296 NM_005027 GAUGAAGCGUACUGCAAUU 
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D-006823-04 INCENP 3619 NM_020238 GCAAAGAGCCAGAGCUGAU 
D-003021-07 PIK3R2 5296 NM_005027 GGACAGCGAAUCUCACUAC 
D-003021-08 PIK3R2 5296 NM_005027 GCAAGAUCCGAGACCAGUA 
D-004175-09 PRKCL1 5585 NM_002741 CCUCGAAGAUUUCAAGUUC 
D-004175-10 PRKCL1 5585 NM_002741 ACAGUAAGACCAAGAUUGA 
D-004175-11 PRKCL1 5585 NM_002741 ACAGCGACGUGUUCUCUGA 
D-004175-12 PRKCL1 5585 NM_002741 GAGAAGCAGUUGGCCAUUG 
D-004612-09 PRKCL2 5586 NM_006256 GGAGCGCUCUGAUGGACAA 
D-004612-10 PRKCL2 5586 NM_006256 UAGACAGCCUGAUGUGUGA 
D-004612-11 PRKCL2 5586 NM_006256 GUACGCAUCCCUCAACUAG 
D-004612-03 PRKCL2 5586 NM_006256 GACAGAAGAUCUCAGCAAA 
D-003317-05 KIF11 3832 NM_004523 GCAGAAAUCUAAGGAUAUA  
D-004647-02 PKN3 29941 NM_013355 GAAGCCCACCGCCCUAACA 
D-004647-03 PKN3 29941 NM_013355 GCGCCAAGAACGUGGUGAA 
D-004647-01 PKN3 29941 NM_013355 CCAAGAACGUGGUGAAACU 
D-004647-04 PKN3 29941 NM_013355 GGGCUGCGGUGCCUGGAUA 
D-004201-01 PLCE1 51196 NM_016341 GAAGAGAAAUGGUCCCUUA 
D-004201-02 PLCE1 51196 NM_016341 GAAAUUCCCUGACCAAAGA 
D-004201-03 PLCE1 51196 NM_016341 GCAAAAGGCUCAUCAGUUA 
D-004201-04 PLCE1 51196 NM_016341 GCAUAUACCUGUAAACUGA 
D-009413-01 PLD1 5337 NM_002662 UAACUGAGCUUAUCUAUGU 
D-009413-02 PLD1 5337 NM_002662 GAAGAACAAUUCCUUGGUA 
D-003317-06 KIF11 3832 NM_004523 CAACAAGGAUGAAGUCUAU 
D-009413-03 PLD1 5337 NM_002662 GAAGAUUACUUGACAAAGA 
D-009413-04 PLD1 5337 NM_002662 GGUAAUCAGUGGAUAAAUU 
D-005064-01 PLD2 5338 NM_002663 GGACAACCAAGAAGAAAUA 
D-005064-02 PLD2 5338 NM_002663 GGACCGGCCUUUCGAAGAU 
D-005064-03 PLD2 5338 NM_002663 GACCUGCACUACCGACUGA 
D-005064-04 PLD2 5338 NM_002663 CAGCAUGGCGGGACUAUAU 
D-009659-01 PLD3 23646 NM_012268 GGACAUCGCCUCCUUCUAC 
D-009659-02 PLD3 23646 NM_012268 ACAAGUACAUGGUGACUGA 
D-009659-03 PLD3 23646 NM_012268 CAACUGGUCUGGCAACUAC 
D-009659-04 PLD3 23646 NM_012268 GACAAUGCCCGGAGUUUCA 
D-003317-07 KIF11 3832 NM_004523 CAGCAGAAAUCUAAGGAUA 
D-010295-01 LOC122618 122618 NM_138790 CCACGUGGCUUCAUACUAC 
D-010295-02 LOC122618 122618 NM_138790 CCAACUGGUCGGAGGAUUA 
D-010295-03 LOC122618 122618 NM_138790 CAUCUCACUUCAACCGUUU 
D-010295-04 LOC122618 122618 NM_138790 GCUUGGCGCUGUCAUCUAU 
D-010305-01 FLJ40773 200150 NM_152666 GCACGGGCCUUGUUAUCAA 
D-010305-02 FLJ40773 200150 NM_152666 GGACUGGUAUUCACCGUAU 
D-010305-03 FLJ40773 200150 NM_152666 GGCCUUAACUAUUCAGAAA 
D-010305-04 FLJ40773 200150 NM_152666 GGACAAACAGCACGUGUAU 
D-024745-01 PLEKHG1 57480 XM_027307 GUGAAGAGUUCCACAUUUA 
D-024745-02 PLEKHG1 57480 XM_027307 GAGAUGACACGUUUACAUA 
D-003317-08 KIF11 3832 NM_004523  
CUAGAUGGCUUUCUCAGUA 
D-024745-03 PLEKHG1 57480 XM_027307 CCAGUUGUAUGACCAGAUU 
D-024745-04 PLEKHG1 57480 XM_027307 AGAAACAUCUGGACCGAUC 
D-023690-01 PLEKHG2 64857 NM_022835 UGACAGCGGUUGCCUGGUA 
D-023690-02 PLEKHG2 64857 NM_022835 GGAGAUUUGUUCUGAUUUC 
D-023690-03 PLEKHG2 64857 NM_022835 CCGAAGAGGUGAAGUGUGU 
D-023690-04 PLEKHG2 64857 NM_022835 AGCGAGAGCCCAACCAAUA 
D-022051-01 PLEKHG3 26030 NM_015549 GCCAAGAGUUUGAUAUCUA 
D-022051-02 PLEKHG3 26030 NM_015549 UAGACAAGAUUAAGAGCUA 
D-022051-03 PLEKHG3 26030 NM_015549 GUAAGAAACUCCAUCUCCA 
 263 
D-022051-05 PLEKHG3 26030 NM_015549 CCGCCCAUCUUCAGAAAUU 
          
D-006823-01 INCENP 3619 NM_020238 CCACGAUGCUGACUAAGAA 
D-001206-13 siCONTROL Non-Targeting siRNA Pool 
D-022573-01 PLEKHG4 25894 NM_015432 GGACAAGGCUGACGAGCUA 
D-022573-02 PLEKHG4 25894 NM_015432 GAAUACAGGCCCUAGAGUU 
D-022573-03 PLEKHG4 25894 NM_015432 GAAUAAGCCUCGCUCCGAU 
D-022573-04 PLEKHG4 25894 NM_015432 GAAGUUCGCUCUCGGGCGU 
D-013873-01 KIAA0720 57449 NM_020631 UCAAGUCGGUGCUGAGGAA 
D-013873-02 KIAA0720 57449 NM_020631 UCAAAGGCUUCAAGAUGUU 
D-013873-03 KIAA0720 57449 NM_020631 ACAGCAAGAUGGAUGUGUA 
D-013873-04 KIAA0720 57449 NM_020631 GCCCAGCUCUACCGAAUCA 
D-020318-01 FLJ10665 55200 NM_018173 GCUGAGACCCUGUUUGGAA 
D-020318-02 FLJ10665 55200 NM_018173 GACCAUGGCUUACGCCCGA 
D-006823-02 INCENP 3619 NM_020238 CAAGAAGACUGCCGAAGAG 
D-001500-01 siTOX Transfection Control 
D-020318-03 FLJ10665 55200 NM_018173 GAGGAUACCCUGUGCUGGA 
D-020318-04 FLJ10665 55200 NM_018173 GCGAAGAGCAAGAGAGCUU 
D-016664-01 PLEKHK1 219790 NM_145307 GUGCAAUGCUCGACUAAUG 
D-016664-02 PLEKHK1 219790 NM_145307 GCGAGGAGGUAAACUCUAU 
D-016664-03 PLEKHK1 219790 NM_145307 UCACGACGCUAUGCCAUUU 
D-016664-04 PLEKHK1 219790 NM_145307 CAACAUGUGCUGCCGACUA 
D-031971-05 PLXNA1 5361 NM_032242 GAACGUGCCUGACCUCUCA 
D-031971-06 PLXNA1 5361 NM_032242 GCAGAUCGAUGACGACUUC 
D-031971-07 PLXNA1 5361 NM_032242 GCAGUGAACCGCAUCUAUA 
D-031971-08 PLXNA1 5361 NM_032242 GCACCAACCUGGCCACUGU 
D-006823-03 INCENP 3619 NM_020238 UCUGCAACAUGGAUAAUAA 
D-019590-01 PLXNB1 5364 NM_002673 GAGAGGAGCCGACUACGUA 
D-019590-05 PLXNB1 5364 NM_002673 GCAGAGACCUCACCUUUGA 
D-019590-06 PLXNB1 5364 NM_002673 GCAAACAUCUGAUAACAUG 
D-019590-07 PLXNB1 5364 NM_002673 UCACAGACCUCAUGACUGA 
D-031513-01 PLXNB2 23654 XM_371474 GCAACAAGCUGCUGUACGC 
D-031513-02 PLXNB2 23654 XM_371474 ACCAAUACACGCAGAAGUA 
D-031513-03 PLXNB2 23654 XM_371474 UGAACACCCUCGUGGCACU 
D-031513-04 PLXNB2 23654 XM_371474 CGGCAGAUGGUGCAGGUCA 
D-003168-05 PTK9 5756 NM_002822 GAAGAACUACGACAGAUUA 
D-003168-09 PTK9 5756 NM_002822 GAAGGAGACUAUUUAGAGU 
D-006823-04 INCENP 3619 NM_020238 GCAAAGAGCCAGAGCUGAU 
D-003168-10 PTK9 5756 NM_002822 GAGCGGAUGCUGUAUUCUA 
D-003168-12 PTK9 5756 NM_002822 AGAGGAAUUCGAAGACUAA 
D-003169-05 PTK9L 11344 NM_007284 AGAGAGAGCUCCAGCAGAU 
D-003169-06 PTK9L 11344 NM_007284 UUAACGAGGUGAAGACAGA 
D-003169-07 PTK9L 11344 NM_007284 ACACAGAGCCCACGGAUGU 
D-003169-08 PTK9L 11344 NM_007284 GCUGGGAUCAGGACUAUGA 
D-008650-01 RACGAP1 29127 NM_013277 CAAAUUAUCUCUGAAGUGU 
D-008650-02 RACGAP1 29127 NM_013277 CCACAGACACCAGAUAUUA 
D-008650-03 RACGAP1 29127 NM_013277 GAACAUCAGCUUCUCAAGA 
D-008650-04 RACGAP1 29127 NM_013277 GUAAUCAGGUGGAUGUAGA 
D-003317-05 KIF11 3832 NM_004523 GCAGAAAUCUAAGGAUAUA  
D-017467-01 RAD51L3 5892 NM_002878 GCUCAAACCUGCCCUCGGA 
D-017467-02 RAD51L3 5892 NM_002878 CCACAUAACUCGAGACAGG 
D-017467-03 RAD51L3 5892 NM_002878 AGAAAUGUGGCUUGUCUUA 
D-017467-04 RAD51L3 5892 NM_002878 GCACUCGGAUUCUCCUGGA 
D-009266-01 RALBP1 10928 NM_006788 GAAUGUAACUAUCUUCUGA 
D-009266-02 RALBP1 10928 NM_006788 GAUCAGCCCUACUAAGUUU 
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D-009266-03 RALBP1 10928 NM_006788 GAACGAAGAGCUGGAAAUA 
D-009266-04 RALBP1 10928 NM_006788 GAAGGCAUCUACAGAGUAU 
D-009323-01 RASGRF1 5923 NM_002891 UCAAGAAGAUUCCUUAUGA 
D-009323-02 RASGRF1 5923 NM_002891 GAGAUCACCUCGUCCAUGA 
D-003317-06 KIF11 3832 NM_004523 CAACAAGGAUGAAGUCUAU 
D-009323-03 RASGRF1 5923 NM_002891 CCAACAAGAUUCCAGAUGA 
D-009323-04 RASGRF1 5923 NM_002891 CCACUAAGCACUUCAAUGA 
D-024516-05 RASGRF2 5924 NM_006909 CUGCACACCUAUCGUAUUU 
D-024516-06 RASGRF2 5924 NM_006909 GCACAGUACUUGCUUGACA 
D-024516-01 RASGRF2 5924 NM_006909 CAACAGAGGUGAACAUUUG 
D-024516-04 RASGRF2 5924 NM_006909 GAAGGAACACCAAACUUUA 
D-015163-01 RHPN1 114822 NM_052924 GGACUGCCCUGGUGCAUGU 
D-015163-02 RHPN1 114822 NM_052924 CCUCAUCGCUGCCGUCAUU 
D-015163-03 RHPN1 114822 NM_052924 GCGACUACAUUGUGUCAGU 
D-015163-04 RHPN1 114822 NM_052924 CCAAGUAUGCGGAGCUCGA 
D-003317-07 KIF11 3832 NM_004523 CAGCAGAAAUCUAAGGAUA 
D-016798-01 RHPN2 85415 NM_033103 GAAGAACGACGGCUACUUU 
D-016798-02 RHPN2 85415 NM_033103 GAGGAGGCAUUUACGAUUC 
D-016798-03 RHPN2 85415 NM_033103 GCUUAGCCAUUGAUGAUGA 
D-016798-04 RHPN2 85415 NM_033103 CGGAGUAAAUUGCAGAAUC 
D-003536-05 ROCK1 6093 NM_005406 GCCAAUGACUUACUUAGGA 
D-003536-01 ROCK1 6093 NM_005406 GGACACAGCUGUAAGAUUG 
D-003536-02 ROCK1 6093 NM_005406 GAAGAAACAUUCCCUAUUC 
D-003536-03 ROCK1 6093 NM_005406 GAGAUGAGCAAGUCAAUUA 
D-004610-05 ROCK2 9475 NM_004850 GCAAAUCUGUUAAUACUCG 
D-004610-01 ROCK2 9475 NM_004850 GAGGAAAGCUGAUCAUGAA 
D-003317-08 KIF11 3832 NM_004523  
CUAGAUGGCUUUCUCAGUA 
D-004610-02 ROCK2 9475 NM_004850 GUAGAAACCUUCCCAAUUC 
D-004610-03 ROCK2 9475 NM_004850 GCAACUGGCUCGUUCAAUU 
D-010358-03 RRAS2 22800 NM_012250 GCACGGCAGCUUAAGGUAA 
D-010358-04 RRAS2 22800 NM_012250 CGUGAUGAGUUCCCAAUGA 
D-010358-05 RRAS2 22800 NM_012250 GAACCAACACGGAAAGAAA 
D-010358-06 RRAS2 22800 NM_012250 UAAUAAAGCAGAUCUGGAU 
D-015055-01 RTKN 6242 NM_033046 GCACAAACCUCUUCUGUUA 
D-015055-02 RTKN 6242 NM_033046 GGACGGCCCUUCACCCUAA 
D-015055-03 RTKN 6242 NM_033046 GAAGAGCCGCUGCUUACUA 
D-015055-04 RTKN 6242 NM_033046 GAAGCUAGACCAUGAGAUC 
          
D-006823-01 INCENP 3619 NM_020238 CCACGAUGCUGACUAAGAA 
D-001206-13 siCONTROL Non-Targeting siRNA Pool 
D-015055-01 RTKN 6242 NM_033046 GCACAAACCUCUUCUGUUA 
D-015055-02 RTKN 6242 NM_033046 GGACGGCCCUUCACCCUAA 
D-015055-03 RTKN 6242 NM_033046 GAAGAGCCGCUGCUUACUA 
D-015055-04 RTKN 6242 NM_033046 GAAGCUAGACCAUGAGAUC 
D-009546-01 SH3BP1 23616 NM_018957 GACCUGUACCACUUUGUUA 
D-009546-02 SH3BP1 23616 NM_018957 GAUGACAGCCACCCACUUC 
D-009546-03 SH3BP1 23616 NM_018957 CAUCGAGGCCUGCGUCAUG 
D-009546-04 SH3BP1 23616 NM_018957 GAGCGCAGACACCCUCUUC 
D-007191-01 SMURF1 57154 NM_020429 GCACUAUGAUCUAUAUGUU 
D-007191-02 SMURF1 57154 NM_020429 AAAGAGAUCUAGUCCAGAA 
D-006823-02 INCENP 3619 NM_020238 CAAGAAGACUGCCGAAGAG 
D-001500-01 siTOX Transfection Control 
D-007191-03 SMURF1 57154 NM_020429 GGAAGAAGGUUUGGAUUAC 
D-007191-04 SMURF1 57154 NM_020429 GGACUGCAGAGGACUGUUA 
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D-005194-05 SOS1 6654 NM_005633 GGCAGAAAUUCGACAAUAU 
D-005194-01 SOS1 6654 NM_005633 CAAAGAAGCUGUUCAAUAU 
D-005194-03 SOS1 6654 NM_005633 GAAAUAGCAUGGAGAAGGA 
D-005194-04 SOS1 6654 NM_005633 GAGCACCACUUCUAUGAUU 
D-005195-05 SOS2 6655 NM_006939 UACUCUAGAUCGAAUGUUA 
D-005195-01 SOS2 6655 NM_006939 GGACGAAGCUGUGGAAUUA 
D-005195-02 SOS2 6655 NM_006939 GCACCAACCUCUCCAAAUA 
D-005195-04 SOS2 6655 NM_006939 GCAAACAGCCACCUCGAUU 
D-006823-03 INCENP 3619 NM_020238 UCUGCAACAUGGAUAAUAA 
D-015469-01 SPATA13 221178 NM_153023 GAAGAAACUUGCCAUGUUA 
D-015469-02 SPATA13 221178 NM_153023 GGAGAGCAUCGACAAGAUA 
D-015469-03 SPATA13 221178 NM_153023 GGACCAACGUCAUCCGGGA 
D-015469-04 SPATA13 221178 NM_153023 GCGCAGCUAGCCACUAUUU 
D-009800-01 SRF 6722 NM_003131 GGACUGUGCUGAAGAGUAC 
D-009800-03 SRF 6722 NM_003131 GCACCAGUGUCUGCUAGUG 
D-009800-05 SRF 6722 NM_003131 GCGAGAUGGAGAUCGGUAU 
D-009800-06 SRF 6722 NM_003131 UACACGACCUUCAGCAAGA 
D-026974-01 SRGAP1 57522 NM_020762 CAUGAGGGCUUAGACAUUA 
D-026974-02 SRGAP1 57522 NM_020762 UUAACGAUCUGAUUUCUUG 
D-006823-04 INCENP 3619 NM_020238 GCAAAGAGCCAGAGCUGAU 
D-026974-03 SRGAP1 57522 NM_020762 GACCAGAGUAACCAUGAUA 
D-026974-04 SRGAP1 57522 NM_020762 GCAAUACACGGGCUUCAAU 
D-021531-04 FNBP2 23380 XM_059095 GAGACUACCUCGGUUGAAG 
D-021531-01 FNBP2 23380 XM_059095 GGAAAGGACAGGCUGAGUA 
D-021531-02 FNBP2 23380 XM_059095 CCAAAGAAGGGCCAGAUAA 
D-021531-03 FNBP2 23380 XM_059095 GCGGACAGAUUGCAGUCUA 
D-014175-01 SRGAP2 9901 NM_014850 CCAAUGAGCUCUACACAGU 
D-014175-02 SRGAP2 9901 NM_014850 GCACGGCUCUGCACGAGUU 
D-014175-03 SRGAP2 9901 NM_014850 GAAUAUGAAGCCCAAAUAA 
D-014175-04 SRGAP2 9901 NM_014850 CAGAACUGCUCAUGCGUUA 
D-003317-05 KIF11 3832 NM_004523 GCAGAAAUCUAAGGAUAUA  
D-010256-01 STARD13 90627 NM_052851 GAUGUGAACUUCCAAAGGA 
D-010256-02 STARD13 90627 NM_052851 CCAAGGCACUUUCUAUUGA 
D-010256-03 STARD13 90627 NM_052851 GGGCAACUUUCCACACUUA 
D-010256-04 STARD13 90627 NM_052851 GAAAGUUCCCGACUACAAA 
D-010254-01 STARD8 9754 NM_014725 GAAGAAGGACACUCCAUUU 
D-010254-02 STARD8 9754 NM_014725 CGACGUGGCUGACCUGCUA 
D-010254-03 STARD8 9754 NM_014725 GAACCUGCGUCAAAUGAAU 
D-010254-04 STARD8 9754 NM_014725 GAACCCACCUUUGCCUCUA 
D-012685-01 TRIP10 9322 NM_004240 GAAAGAACGCACCGAAGUG 
D-012685-02 TRIP10 9322 NM_004240 GAACGGCUAGACCAGGAUA 
D-003317-06 KIF11 3832 NM_004523 CAACAAGGAUGAAGUCUAU 
D-012685-03 TRIP10 9322 NM_004240 CGACUCCCACGUCCUUAUA 
D-012685-04 TRIP10 9322 NM_004240 CCAUUUACACGGAGUUUGA 
D-008711-01 TAGAP 117289 NM_054114 UGAAACAGGUUGCAGAUAA 
D-008711-02 TAGAP 117289 NM_054114 GACCAGAGCCUGUCAUUUG 
D-008711-03 TAGAP 117289 NM_054114 ACACUAAACGCCAAUAAUA 
D-008711-04 TAGAP 117289 NM_054114 AGAAGGACCUGAACAACAA 
D-003932-01 TIAM1 7074 NM_003253 GAACCGAAGCUGUAAAGAA 
D-003932-02 TIAM1 7074 NM_003253 GAAAGGAUGCACGCUAUUU 
D-003932-03 TIAM1 7074 NM_003253 AACCGAAGCUGUAAAGAAA 
D-003932-04 TIAM1 7074 NM_003253 GAAGUGGUCUUACCUAACG 
D-003317-07 KIF11 3832 NM_004523 CAGCAGAAAUCUAAGGAUA 
D-008434-05 TIAM2 26230 NM_001010927 GAACUUCAGGCGUCACAUA 
D-008434-06 TIAM2 26230 NM_001010927 CGACCUAAAUUCUGUUCUA 
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D-008434-07 TIAM2 26230 NM_001010927 GUGUAAGGAUCGCCUGGUA 
D-008434-08 TIAM2 26230 NM_001010927 UAAGAGAGCCGUCAUACUG 
D-003102-06 TNK2 10188 NM_005781 GCAAGUCGUGGAUGAGUAA 
D-003102-05 TNK2 10188 NM_005781 AAACGCAAGUCGUGGAUGA 
D-003102-08 TNK2 10188 NM_005781 UCAGCAGCACCCACUAUUA 
D-003102-09 TNK2 10188 NM_005781 GAGAACUACUGGUGGCGUG 
D-005047-01 TRIO 7204 NM_007118 GAUAAGAGGUACAGAGAUU 
D-005047-02 TRIO 7204 NM_007118 GGAAGUCGCUCCUUGACAA 
D-003317-08 KIF11 3832 NM_004523  
CUAGAUGGCUUUCUCAGUA 
D-005047-03 TRIO 7204 NM_007118 CAACGGAGAGUCCAUGUUA 
D-005047-04 TRIO 7204 NM_007118 GAACACCAACUUCAGAUAA 
D-012685-01 TRIP10 9322 NM_004240 GAAAGAACGCACCGAAGUG 
D-012685-02 TRIP10 9322 NM_004240 GAACGGCUAGACCAGGAUA 
D-012685-03 TRIP10 9322 NM_004240 CGACUCCCACGUCCUUAUA 
D-012685-04 TRIP10 9322 NM_004240 CCAUUUACACGGAGUUUGA 
D-003935-05 VAV1 7409 NM_005428 CGACAAAGCUCUACUCAUC 
D-003935-02 VAV1 7409 NM_005428 GCAGCGAGUUCUCAAAUAU 
D-003935-03 VAV1 7409 NM_005428 GCAGAAAUACAUCUACUAA 
D-003935-04 VAV1 7409 NM_005428 GAAGGACUGUACCGGAUCA 
          
D-006823-01 INCENP 3619 NM_020238 CCACGAUGCUGACUAAGAA 
D-001206-13 siCONTROL Non-Targeting siRNA Pool 
D-005199-01 VAV2 7410 NM_003371 GCUGAGCGCUUUGCAAUAA 
D-005199-02 VAV2 7410 NM_003371 CAAGAAGUCUCACGGGAAA 
D-005199-03 VAV2 7410 NM_003371 UCACAGAGGCCAAGAAAUU 
D-005199-04 VAV2 7410 NM_003371 GAAAGUCUGCCACGAUAAA 
D-010178-01 VAV3 10451 NM_006113 UAAUAGAUCUUCAGCAGUA 
D-010178-02 VAV3 10451 NM_006113 GCAGAGACCGAACUUAUUA 
D-010178-04 VAV3 10451 NM_006113 GCAAAGCACAUCAAGAUUU 
D-010178-05 VAV3 10451 NM_006113 AGACCGAACUUAUUAAUAG 
D-005057-01 CDC42 998 NM_001791 GGAGAACCAUAUACUCUUG 
D-005057-02 CDC42 998 NM_001791 GAUUACGACCGCUGAGUUA 
D-006823-02 INCENP 3619 NM_020238 CAAGAAGACUGCCGAAGAG 
D-001500-01 siTOX Transfection Control 
D-005057-03 CDC42 998 NM_001791 GAUGACCCCUCUACUAUUG 
D-005057-04 CDC42 998 NM_001791 CGGAAUAUGUACCGACUGU 
D-003560-09 RAC1 5879 NM_018890 CGGCACCACUGUCCCAACA 
D-003560-05 RAC1 5879 NM_018890 AGACGGAGCUGUAGGUAAA 
D-003560-07 RAC1 5879 NM_018890 UAAGGAGAUUGGUGCUGUA 
D-003560-08 RAC1 5879 NM_018890 UAAAGACACGAUCGAGAAA 
D-007741-01 RAC2 5880 NM_002872 GAGAUGGGGCCGUGGGCAA 
D-007741-02 RAC2 5880 NM_002872 CAGCCAAUGUGAUGGUGGA 
D-007741-03 RAC2 5880 NM_002872 CCAAUGUGAUGGUGGACAG 
D-007741-04 RAC2 5880 NM_002872 ACAAGGACACCAUCGAGAA 
D-006823-03 INCENP 3619 NM_020238 UCUGCAACAUGGAUAAUAA 
D-008836-05 RAC3 5881 NM_005052 AAACUGACGUCUUUCUGAU 
D-008836-01 RAC3 5881 NM_005052 GGAGAUUGGCUCUGUGAAA 
D-008836-02 RAC3 5881 NM_005052 ACGUGAUGGUGGACGGGAA 
D-008836-04 RAC3 5881 NM_005052 CGAGAAUGUUCGUGCCAAG 
D-003860-01 RHOA 387 NM_001664 AUGGAAAGCAGGUAGAGUU 
D-003860-02 RHOA 387 NM_001664 GAACUAUGUGGCAGAUAUC 
D-003860-03 RHOA 387 NM_001664 GAAAGACAUGCUUGCUCAU 
D-003860-04 RHOA 387 NM_001664 GAGAUAUGGCAAACAGGAU 
D-008395-07 RHOB 388 NM_004040 GCAUCCAAGCCUACGACUA 
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D-008395-08 RHOB 388 NM_004040 ACACCGACGUCAUUCUCAU 
D-006823-04 INCENP 3619 NM_020238 GCAAAGAGCCAGAGCUGAU 
D-008395-09 RHOB 388 NM_004040 CAUCCAAGCCUACGACUAC 
D-008395-10 RHOB 388 NM_004040 CAACUGCUGCAAGGUGCUA 
D-009389-01 RHOBTB1 9886 NM_014836 AAAUGAAGCUGCCUGUUUA 
D-009389-02 RHOBTB1 9886 NM_014836 GAACUUGGCUUACCAUACU 
D-009389-03 RHOBTB1 9886 NM_014836 GGACGUGACAUUUAAAUUG 
D-009389-04 RHOBTB1 9886 NM_014836 GAACACCCGUUAUCCUUGU 
D-009252-01 RHOBTB2 23221 NM_015178 UGACAUGGAUUAUGAAAGG 
D-009252-02 RHOBTB2 23221 NM_015178 GACCGUCGCUUUGCUUAUG 
D-009252-03 RHOBTB2 23221 NM_015178 CCCGAGACGUGGUAGAUGA 
D-009252-04 RHOBTB2 23221 NM_015178 GGACAACGCCGUGGGUAAG 
D-003317-05 KIF11 3832 NM_004523 GCAGAAAUCUAAGGAUAUA  
D-020480-05 RHOBTB3 22836 NM_014899 ACAGAUGGCCGUCGAAUAU 
D-020480-02 RHOBTB3 22836 NM_014899 GUAAUUACAUGGAAGCAAA 
D-020480-03 RHOBTB3 22836 NM_014899 CAACCUGGCUACUUCAUUU 
D-020480-04 RHOBTB3 22836 NM_014899 CAACGUUAAUGACAAGUUU 
D-008555-01 RHOC 389 NM_175744 GGAGAGAGCUGGCCAAGAU 
D-008555-02 RHOC 389 NM_175744 AUAAGAAGGACCUGAGGCA 
D-008555-03 RHOC 389 NM_175744 GGAUCAGUGCCUUUGGCUA 
D-008555-04 RHOC 389 NM_175744 GAGAGCUGGCCAAGAUGAA 
D-008940-01 RHOD 29984 NM_014578 UGAACAAGCUCCGAAGAAA 
D-008940-02 RHOD 29984 NM_014578 GAUUGGAGCCUGUGACCUA 
D-003317-06 KIF11 3832 NM_004523 CAACAAGGAUGAAGUCUAU 
D-008940-03 RHOD 29984 NM_014578 CCGAACAGCUUUGACAACA 
D-008940-04 RHOD 29984 NM_014578 AGACGUCGCUGCUGAUGGU 
D-008316-01 RHOF 54509 NM_019034 GGGAGAAUGUGGAGGACGU 
D-008316-02 RHOF 54509 NM_019034 CGGCCGGGCAAGAAGACUA 
D-008316-03 RHOF 54509 NM_019034 AGAUCGUGAUCGUGGGCGA 
D-008316-04 RHOF 54509 NM_019034 ACGACAACGUCCUCAUCAA 
D-008995-01 RHOG 391 NM_001665 CUACACAACUAACGCUUUC 
D-008995-02 RHOG 391 NM_001665 CCAGUCCGCCGUCCUAUGA 
D-008995-03 RHOG 391 NM_001665 GCAACAGGAUGGUGUCAAG 
D-008995-04 RHOG 391 NM_001665 CGUCAUCUGUUUCUCCAUU 
D-003317-07 KIF11 3832 NM_004523 CAGCAGAAAUCUAAGGAUA 
D-008804-01 RHOH 399 NM_004310 CAAGUGGAUUGGUGAAAUU 
D-008804-02 RHOH 399 NM_004310 GAGUACAGCAGGUGUUUGA 
D-008804-03 RHOH 399 NM_004310 GCUCAGCCCUUAGCAAUCG 
D-008804-04 RHOH 399 NM_004310 GGCCAACCAUAACUCAUUC 
D-010367-01 RHOJ 57381 NM_020663 AGAAACCUCUCACUUACGA 
D-010367-02 RHOJ 57381 NM_020663 CCACUGUGUUUGACCACUA 
D-010367-03 RHOJ 57381 NM_020663 UCGUAAACCCUGCCUCUUA 
D-010367-04 RHOJ 57381 NM_020663 CCCGUUUGCUGUAUAUGAA 
D-009943-01 RHOQ 23433 NM_012249 UACCGGAACUUAAGGAAUA 
D-009943-02 RHOQ 23433 NM_012249 AGAAUAGGAUCAAGAUGUA 
D-003317-08 KIF11 3832 NM_004523  
CUAGAUGGCUUUCUCAGUA 
D-009943-03 RHOQ 23433 NM_012249 UAGCAAGACUGAAUGAUAU 
D-009943-04 RHOQ 23433 NM_012249 GAACAAGGACAGAAACUAG 
D-010365-01 RHOT1 55288 NM_018307 GAACUCAACUUCUUUCAGA 
D-010365-02 RHOT1 55288 NM_018307 GAACCAGUAUACAGAAAUA 
D-010365-03 RHOT1 55288 NM_018307 GAACAUAUCAGAGCUCUUU 
D-010365-04 RHOT1 55288 NM_018307 CAGAAUACCUUGCUUAAUC 
D-008340-01 RHOT2 89941 NM_138769 UCUCAGAGCUGUUCUACUA 
D-008340-02 RHOT2 89941 NM_138769 ACGAAGAGCUCAACGCUUU 
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D-008340-03 RHOT2 89941 NM_138769 GGACGUGCGCAUCCUGUUA 
D-008340-04 RHOT2 89941 NM_138769 GAGAAGAUUCGAACUAAGU 
          
D-006823-01 INCENP 3619 NM_020238 CCACGAUGCUGACUAAGAA 
D-001206-13 siCONTROL Non-Targeting siRNA Pool 
D-009882-01 RHOU 58480 NM_021205 GUACUGCUGUUUCGUAUGA 
D-009882-02 RHOU 58480 NM_021205 GAACGUCAGUGAGAAAUGG 
D-009882-03 RHOU 58480 NM_021205 CAGAGAAGAUGUCAAAGUC 
D-009882-04 RHOU 58480 NM_021205 AAGCAGGACUCCAGAUAAA 
D-006374-01 RHOV 171177 NM_133639 GAGGGACGAUGUCAACGUA 
D-006374-02 RHOV 171177 NM_133639 GAAGAAACUGAAUGCCAAA 
D-006374-03 RHOV 171177 NM_133639 GUAUUUGACUCGGCUAUUC 
D-006374-04 RHOV 171177 NM_133639 GCUCAGCCUUGACGCAGAA 
D-008929-01 RND1 27289 NM_014470 CGACUCGGAUGCAGUAUUA 
D-008929-02 RND1 27289 NM_014470 GAACAGAGGGUGGAGCUUA 
D-006823-02 INCENP 3619 NM_020238 CAAGAAGACUGCCGAAGAG 
D-001500-01 siTOX Transfection Control 
D-008929-03 RND1 27289 NM_014470 GCCAAAAGCUGUUCCAUUA 
D-008929-04 RND1 27289 NM_014470 GAACUCAUCUCUUCUACCU 
D-009727-01 ARHN 8153 NM_005440 GAACUACACUGCGAGCUUU 
D-009727-02 ARHN 8153 NM_005440 GACAUUAGCCGACCAGAAA 
D-009727-03 ARHN 8153 NM_005440 ACACAAGGAUCGAGCCAAA 
D-009727-04 ARHN 8153 NM_005440 UCAGGGAUGUCUUCCAUGU 
D-007794-05 ARHE 390 NM_005168 AGAAUUACACGGCCAGUUU 
D-007794-02 ARHE 390 NM_005168 GAACGUGAAAUGCAAGAUA 
D-007794-03 ARHE 390 NM_005168 GAAAUUAUCCAGCAAAUCU 
D-007794-04 ARHE 390 NM_005168 UAGUAGAGCUCUCCAAUCA 
D-006823-03 INCENP 3619 NM_020238 UCUGCAACAUGGAUAAUAA 
D-006823-04 INCENP 3619 NM_020238 GCAAAGAGCCAGAGCUGAU 
D-003317-05 KIF11 3832 NM_004523 GCAGAAAUCUAAGGAUAUA  
D-003317-06 KIF11 3832 NM_004523 CAACAAGGAUGAAGUCUAU 
D-003317-07 KIF11 3832 NM_004523 CAGCAGAAAUCUAAGGAUA 
D-003317-08 KIF11 3832 NM_004523  
CUAGAUGGCUUUCUCAGUA  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Table of indvidual siRNAs that gave reproducible effects during validation  
 Individual siRNAs sequences highlighted in red gave an effect on junction morphology that was reproducible to the pool of all four siRNAs performed in the primary screens.  
Candidates  that had  the  same reproducible effects using 2 or more  individals  siRNAs  were scored as a validated candidate. 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